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1 APPENDICES LITERATURE REVIEW 
1.1 DEFINITION OF TERMS  





Physicians; Physicians, Family; Specialism 
Emtree 




Physicians; General practitioner; Specialist 
 Intervention: oral individual academic detailing 
Mesh 
Education, Medical, Continuing 
Emtree 
Medical education; Academic advisement; Continuing education; Lifelong 
learning; In service training; Learning environment 
Thesaurus psychinfo 
Medical education; professional development; continuing education 
Thesaurus Eric 
Academic advising; Allied health occupations education; Medical education; 
Professional continuing education; Outreach programmes; Intervention 
Key words 
Academic detail*; Educational outreach visit; Face-to-face visit; Educational visit*; 







Education, Medical, Continuing 
Emtree 
Medical education; Academic advisement; Continuing education; Lifelong 
learning; In service training; Learning environment 
Thesaurus psychinfo 
Medical education; professional development; continuing education 
Thesaurus Eric 
Academic advising; Allied health occupations education; Medical education; 
Professional continuing education; Outreach programmes; Intervention 
Key words 
Academic detail*; Educational outreach visit; Face-to-face visit; Educational visit*; 








Education, Medical, Continuing 
Emtree 
Educational model; Continuing education provider 
Thesaurus psychinfo 
Medical education; professional development; continuing education 
Thesaurus Eric 
Teaching methods; Educational strategies 
Key words 
Audit; Feedback; Written information; Social marketing; Collective/group 
outreach visit; Education method; Educational intervention; Information method 
 
OUTCOME: PHYSICIAN’S 




Drug prescription; Drug utilisation; Decision making; Outcome assessment 
(healthcare); Physicians practice patterns; Professional practice; Treatment 
outcome 
Emtree 
General practice; Family practice; Medical practice; Medical decision making; 
Clinical practice; Clinical decision making; Social marketing; Prescription 
Thesaurus psychinfo 
Prescribing (drugs); Prescription drugs; Clinical Practice; Evidence Based 
Practice; Therapeutic Processes/ 
Thesaurus Eric 
Drug therapy; Medical services; Medical care evaluation 
Key words 
Prevention; Prescrib* practice; Prescrib* behavio(u)r; Physician’s level of 
knowledge; Clinical practice 
 
The search strategies are available upon request 
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1.2 QUALITY APPRAISAL OF THE REVIEWS OF REVIEWS AND 
SYSTEMATIC REVIEWS 
1.2.1 REVIEWS OF SYSTEMATIC REVIEWS 
1. BLOOM, 2005 
Bloom BS. Effects of continuing medical education on improving physician clinical care and patient health: a review of 
systematic reviews. International Journal of Technology Assessment in Health Care. 2005;21(3):380-5. 
TITLE:  
Mentions review of systematic reviews 
 
ABSTRACT (structured summary) 
Background YES 
Objectives YES 





Study appraisal and 
synthesis methods NO 




Implications of key 
findings YES 
Systematic review 
registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides a registration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: NO 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: NO 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): YES 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO 
 
RESULTS 
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Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES (but no flow diagram) 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: NO 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: NO 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: YES 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Gives results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): NO 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: NO 
APPRAISAL 
 - The SR presents a substantial number of limitations when assessing the items of the 
PRISMA statement checklist.  
 
2. GRINDROD, 2006 
Grindrod KA, Patel P, Martin JE. What interventions should pharmacists employ to impact health practitioners' 
prescribing practices? Ann Pharmacother. 2006;40(9):1546-57. 
TITLE:  










Study appraisal and 
synthesis methods NO 




Implications of key 
findings YES 
Systematic review 
registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides a registration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
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YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: NO 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): YES 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO META-ANALYSIS 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES, with flow diagram 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: NO 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NO 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: NO 
APPRAISAL 
 - The SR presents a substantial number of limitations when assessing the items of the 
PRISMA statement checklist.  
- A non quantitative summary of the reported results was performed using a vote-
counting method 
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3. LANDRY, 2002 
Landry MD, Sibbald WJ. Changing physician behavior: a review of patient safety in critical care medicine. J Crit Care. 
2002;17(2):138-45. 
TITEL:   









Study appraisal and 
synthesis methods NO 




Implications of key 
findings NO 
Systematic review 
registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides aregistration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
NO 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: NO 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: NO 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): NO 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: NO 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: NO 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): NO 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO 
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: NO 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
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Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: NO 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NO 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): NO 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: NO 
APPRAISAL 
 - The SR presents a substantial number of limitations when assessing the items of the 
PRISMA statement checklist.  
 
4. SATTERLEE, 2008 
Satterlee WG, Eggers RG, Grimes DA. Effective medical education: Insights from the cochrane library. Obstetrical and 
Gynecological Survey. 2008;63(5):329-33. 
TITEL:  









Study appraisal and 
synthesis methods YES 




Implications of key 
findings YES 
Systematic review 
registration number YES 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides aregistration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: YES 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
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and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): YES 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES, no flow diagram 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: NO 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: NO 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NO 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): NO 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: NO 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: NO 
APPRAISAL 
 - The SR presents a limited limitations when assessing the items of the PRISMA 
statement checklist. 
- Only Cochrane database consulted 
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5. SOHN, 2004 
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Study appraisal and 
synthesis methods YES 




Implications of key 
findings YES 
Systematic review 
registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides a registration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: YES 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): NO 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: YES 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES, but no flow diagram 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
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Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: NO 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NO 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: NO 
APPRAISAL 
 - The SR presents a moderate number of limitations when assessing the items of the 
PRISMA statement checklist 
1.2.2 SYSTEMATIC REVIEWS 
1. Arnold, 2005 
Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database 
of Systematic Reviews. 2005;4(4):CD003539. 
TITEL:  









Study appraisal and 
synthesis methods YES 




Implications of key 
findings YES 
Systematic review 
registration number YES 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides aregistration information including registration number: YES 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: YES 
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Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: YES 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): YES 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): YES 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO 
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: YES 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: YES 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NA 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: YES 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: YES 
APPRAISAL 
 - With the exception of a limited number of items, all items are represented as 
required by the PRISMA statement checklist.  
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2. CHAILLET, 2006 
Chaillet N, Dube E, Dugas M, Audibert F, Tourigny C, Fraser WD, et al. Evidence-based strategies for implementing 
guidelines in obstetrics: a systematic review. Obstet Gynecol. 2006;108(5):1234-45. 
 
TITEL:  









Study appraisal and 
synthesis methods YES 




Implications of key 
findings YES 
Systematic review 
registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides a registration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: NO 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: YES 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): NO 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES, but no flow diagram 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within Present data on risk of bias of each study and, if available, any outcome level assessment: YES 
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studies 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: YES 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NA 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NA 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NA 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: NO 
APPRAISAL 
 - The SR presents some limitations when assessing the items of the PRISMA statement 
checklist since e.g. a profile summarising trail flow is not presented.  
 
 
3. FISH, 2002 
Fish A, Watson MC, Bond CM. Practice-based pharmaceutical services: A systematic review. Int. J. Pharm. Pract. 
2002;10(4):225-33. 
TITEL:  









Study appraisal and 
synthesis methods  




Implications of key 
findings  
Systematic review 
registration number  
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides aregistration information including registration number:  
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated:  
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Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis):  
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified:  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot:  
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers):  
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research:  
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: 
APPRAISAL 
 - The SR presents some limitations when assessing the items of the PRISMA statement 
checklist 
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4. GRIMSHAW, 2001 
Grimshaw JM, Shirran L, Thomas R, Mowatt G, Fraser C, Bero L, et al. Changing provider behavior: an overview of 
systematic reviews of interventions. Med Care. 2001;39(8 Suppl 2):II2-45. 
TITEL:  










Study appraisal and 
synthesis methods 
YES 








registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides a registration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: NO 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: NO 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: NO 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): NO 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: YES 
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Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: YES 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NA 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: NO 
APPRAISAL 
 - The SR presents a moderate number of limitations when assessing the items of the 
PRISMA statement checklist  
 
 
5. Grimshaw, 2004 
Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline 
dissemination and implementation strategies. Health Technol Assess. 2004;8(6):iii-iv, 1-72. 
TITEL:  










Study appraisal and 
synthesis methods 
YES 








registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides a registration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow up) and report characteristics 
(e.g., years considered, language, publication status) used as criteria for eligibility, giving 
rationale: YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: YES 
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Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): YES 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta analysis: NA 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NA 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre specified: NO  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: NO, no flow diagram 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: NO 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NA 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: NO 
APPRAISAL 
 - The SR presents a moderate number of limitations when assessing the items of the 
PRISMA statement checklist 
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mental disorders in primary care. Psychosomatics 41:1, 39-52. 
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Study appraisal and 
synthesis methods NO 




Implications of key 
findings NO 
Systematic review 
registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides a registration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: NO 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): NO 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies):NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NA 
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES, but no flow diagram 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
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Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: NO 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NA 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): NO 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: NO 
APPRAISAL 
 - The SR presents a moderate number limitations when assessing the items of the 
PRISMA statement checklist 
 
 
7. LU, 2008 
Lu CY, Ross-Degnan D, Soumerai SB, Pearson S-A. Interventions designed to improve the quality and efficiency of 
medication use in managed care: a critical review of the literature - 2001-2007. BMC Health Services Research. 
2008;8(75). 
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Study appraisal and 
synthesis methods 
YES 








registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides aregistration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: YES 
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Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): YES 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES, no flow diagram 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: NO 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: NO 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NA 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: YES 
APPRAISAL 
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8. MORRISON, 2000  
Morrison A, Wertheimer AI, Berger ML. Interventions to improve antihypertensive drug adherence: A quantitative 
review of trials. Formulary. 2000;35(3):234-45. 
TITEL:  









Study appraisal and 
synthesis methods NO 




Implications of key 
findings NO 
Systematic review 
registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides a registration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: NO 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): NO 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES, No flow diagram 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: NO 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
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Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: NO 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NA 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: NO 
APPRAISAL 
 - The SR presents a moderate number of limitations when assessing the items of the 
PRISMA statement checklist 
 
9. O’BRIEN, 2007 
O'Brien MA, Rogers S, Jamtvedt G, Oxman AD, Odgaard-Jensen J, Kristoffersen DT, et al. Educational outreach visits: 
Effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews. 2007;-(4). 
TITEL:  










Study appraisal and 
synthesis methods 
YES 











The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides aregistration information including registration number:  
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: YES 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
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and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: YES 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): YES 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: YES 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): YES 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: YES  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: YES 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: YES 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: YES 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: YES 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: YES 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: YES 
APPRAISAL 
 - The SR presents very few limitations when assessing the items of the PRISMA 
statement checklist 
 
10. OSTINI, 2009 
Ostini R, Hegney D, Jackson C, Williamson M, Mackson JM, Gurman K, et al. Systematic review of interventions to 
improve prescribing. Ann.Pharmacother. 2009;43(3):502-13. 
TITEL:  










Study appraisal and 
synthesis methods 
YES 
Review methods YES 
Limitations YES 








registration number  
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides aregistration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: NO 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): NO 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: YES 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NO 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: NO 
APPRAISAL 
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 - The SR presents a moderate number of limitations when assessing the items of the 
PRISMA statement checklist. 
 
11. PEARSON, 2003 
Pearson SA, Ross-Degnan D, Payson A, Soumerai SB. Changing medication use in managed care: a critical review of 
the available evidence. Am J Manag Care. 2003;9(11):715-31. 
TITEL:  










Study appraisal and 
synthesis methods 
YES 








registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides a registration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: YES 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: YES 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): YES 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: YES 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
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Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: YES 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NO 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: YES 
APPRAISAL 
 - The SR presents a limited number of limitations when assessing the items of the 
PRISMA statement checklist 
 
12. SKETRIS, 2009 
Sketris IS, Langille Ingram EM, Lummis HL. Strategic opportunities for effective optimal prescribing and medication 














Study appraisal and 
synthesis methods 
YES 








registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides a registration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
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Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: YES 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): NO 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES, but no flow diagram 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: YES 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: YES 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NA 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: YES 
APPRAISAL 
 - The SR presents a limited number of limitations when assessing the items of the 
PRISMA statement checklist  
 
13. TU, 2002 
Tu K, Davis D. Can we alter physician behavior by educational methods? Lessons learned from studies of the 
management and follow-up of hypertension. Journal of Continuing Education in the Health Professions. 2002;22(1):11-
22. 
TITEL:  
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Study appraisal and 
synthesis methods 
YES 








registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides a registration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: NO 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): NO 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: Yes, with flow diagram. 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot:  NO 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NO 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
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implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: YES 
APPRAISAL 
 - The SR presents some limitations when assessing the items of the PRISMA statement 
checklist 
 
14. WEINMANN, 2007 
Weinmann S, Koesters M, Becker T. Effects of implementation of psychiatric guidelines on provider performance and 
patient outcome: systematic review. Acta Psychiat Scnad 2007: 115, 420-433. 
TITEL:  










Study appraisal and 
synthesis methods NO 




Implications of key 
findings NO 
Systematic review 
registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides aregistration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: NO 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: Yes 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): NO 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NA 
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RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES, no flow diagram 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot:  YES 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NO 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: YES 
APPRAISAL 
 - The SR presents a moderate number of limitations when assessing the items of the 
PRISMA statement checklist 
 
15. WILTON, 2002 
Wilton P, Smith R, Coast J, Millar M. Strategies to contain the emergence of antimicrobial resistance: a systematic 
review of effectiveness and cost-effectiveness. J Health Serv Res Policy. 2002;7(2):111-7. 
 
TITEL:  










Study appraisal and 
synthesis methods YES 




Implications of key 
findings NO 
Systematic review 
registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides aregistration information including registration number: NO 
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Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: YES 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: YES 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): YES 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: YES 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): YES 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NA  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES, no flow diagram 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: YES 
Results of individual 
studies 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: YES 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NA 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: YES 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NA 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: NO 
APPRAISAL 
 - The SR presents a limited number of limitations when assessing the items of the 
PRISMA statement checklist 
 
KCE Reports 125 Academic Detailing – Supplement 33 
 
 
16. YEN, 2006  
Yen BM. Engaging physicians to change practice. Journal of Clinical Outcomes Management. 2006;13(2):103-10. 
TITEL:  










Study appraisal and 
synthesis methods 
YES 




Implications of key 
findings NO 
Systematic review 
registration number NO 
INTRODUCTION 
The explicit rationale for the interventions and rationale for the review is provided: YES 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 




Indicates if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provides aregistration information including registration number: NO 
Eligibility criteria Specifies study characteristics (e.g., PICOS, length of follow"up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale: 
YES 
Information sources Describes all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched: YES 
Search Presents full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated: NO 
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta"analysis): YES 
Data collection 
process 
Describes method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators: YES 
Data items Lists and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made: YES 
Risk of bias in 
individual 
studies 
Describes methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be 
used in any data synthesis: NO 
Summary measures States the principal summary measures (e.g., risk ratio, difference in means): NO 
Synthesis of results Describes the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2 ) for each meta"analysis: NO 
Risk of bias across 
studies 
Specifies any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies): NO 
Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre"specified: NO  
RESULTS 
Study selection Gives numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram: YES, but no flow diagram 
Study characteristics For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations: YES 
Risk of bias within 
studies Present data on risk of bias of each study and, if available, any outcome level assessment: NO 
Results of individual For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
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studies data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot: YES 
Synthesis of results Presents results of each meta-analysis done, including confidence intervals and measures of 
consistency: NA 
Risk of bias across 
studies 
Presents results of any assessment of risk of bias across studies: NO 
 
Additional analysis Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression: NO 
DISCUSSION 
Summary of evidence Summarizes the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers): 
YES 
Limitations Discusses limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias): YES 
Conclusions Provides a general interpretation of the results in the context of other evidence, and 
implications for future research: YES 
Funding Describes sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review: YES 
 Summarise key findings, interpret the results in light of totality of available evidence: describe 
potential biases in the review process and suggest a future research agenda: YES 
APPRAISAL 
 - The SR presents a moderate number of limitations when assessing the items of the 
PRISMA statement checklist 
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1.3 PRIMARY STUDIES: EXCLUSION -QUALITY APPRAISAL 
1.3.1 Studies excluded on the basis of full text: reason for exclusion 
Number 
 
Author Reasons for rejection 
1. Bernal-delgado, 2002 
 
This study focuses on group academic detailing only, and not 
on one-to-one academic detailing. 
2. Blanc, 2008 This study provides no description of outcomes, and has a 
retrospective study design that does not allow any 
conclusions on the effectiveness of academic detailing.  
3. Cockburn, 1992 Quality appraisal score of 5/14 
4. Dolovich, 1999 This study focuses on commercially sponsored evidence-
based academic detailing, and is out of scope. 
5. Font, 1991 Out of scope 
6. Freemantle, 1999 This study provides no outcome data since it is a paper that 
documents the rationale and design of the study 
7. Grimshaw, 2001 Overview of systematic reviews--replaced to systematic reviews 
8. Grimshaw, 2004 Duplicate –in list of systematic reviews 
9. Grindrod, 2006 Duplicate –in list of reviews of systematic reviews 
10. Horowitz, 1996 This study provides no outcome data since it describes the 
project design and process of implementing an AD 
intervention. 
11. Joseph, 2004 This study targets hospitals only 
12. Magrini, 2007 This study provides no outcome data since it describes the 
study protocol 
13. May, 2009 This study provides no outcome data since it  describes 
experiences with AD only 
14. Miller, 2004 This study targets hospitals only 
 
15. Morrison, 2000 Review, newly added in listing of reviews 
16. Pearson, 2003  Duplicate –put in list of systematic reviews  
17. Polinski, 2005 This study provides no outcome data since it describes the 
implementation of an AD program only 
18. Pond, 1994 Quality appraisal score of 6/14 
19. Richens, 2004 No reference available 
20. Rosich, 2005 Article in Spanish 
21. Skaer, 1993 Study not included since it is not clear if the intervention is 
directed at hospital physicians or general practitioners 
22. Solomon, 2001 This study targets a US teaching hospital only 
23. Stevens, 2002 This study targets patients with AD and not physicians 
24.  Yeo, 1994 Study not included: describes intervention and process 
evaluation—no evaluation component 
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DESIGN SS STAT 
 
GEN CONF RAND BLIND CLUST DATAP TOTAL 
1. Aspy, 2008 1 1 1 1 1 1 1 1 1 1 1 -1 1 1 13/14 
2. Avorn, 1983 1 -1 1 1 1 1 1 1 1 1 -1 1 0 1 9/14 
3. Benincasa, 1996 1 1 1 0 1 1 1 1 1 -1 0 0 0 1 8/14 
4. Berings, 1994 1 1 1 1 - 1 1 1 1 
 
1 1 -1 0 1 9/14 
5. Bonds, 2009 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 




1 1 1 0 1 1 1 1 1 0 0 0 0 1 9/14 
8. Brown, 2000 1 1 1 1 1 1 1 1 1 -1 1 1 -1 1 12/14 
9. Browner, 1994 1 1 1 1 1 1 1 1 1 -1 1 0 -1 1 11/14 
10. Coenen, 2004 1 1 1 1 1 1 1 1 1 1 1 -1 0 1 11/14 
11. Cranney, 1999 1 1 1 1 1 1 1 1 1 0 1 -1 0 0 9/14 
12. De Burgh, 1995 1 1 1 1 1 1 1 1 1 1 1 -1 0 1 11/14 
13. Dey, 2004 1 1 1 1 1 1 1 1 1 1 1 -1 1 1 12/14 
14.. De Santis, 1994 1 1 1 1 1 1 1 1 1 1 1 -1 0 1 9/14 
15. Eccles, 2007 1 1 1 1 1 1 1 1 1 1 1 -1 0 1 11/14 
16. Epstein, 2008 1 1 1 0 1 1 -1 1 1 0 0 0 0 1 7/14 
17. Etter, 2006 1 1 1 1 1 1 1 1 1 0 1 -1 0 0 9/14 
18. Feder, 1995 1 1 1 1 1 1 1 1 1 1 1 -1 0 1 11/14 
19. Feldstein, 2006 1 1 1 0 1 1 1 1 1 0 0 0 0 1 9/14 
20. Figueiras, 2001 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
21. Figueiras, 2006 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 




1 1 1 1 1 1 1 1 1 1 1 1 0 0 12/14 
24. Fretheim, 2006 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
25. Fretheim, 2006 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
26. Frijling, 2003 1 1 1 1 1 1 1 1 1 1 1 -1 0 1 11/14 
27. Gandjour, 2005 - - - - - - - - - - - - - - 
NA since 
cost study 
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28. Goldberg, 1998 1 1 1 1 1 1 1 1 1 1 1 0 0 1 12/14 
29. Gomel, 1998 1 1 1 1 1 1 1 1 1 0 1 -1 0 1 10/14 
30. Gonzales, 1999 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
31. Graham, 2008 1 1 1 1 1 1 1 1 1 1 0 0 0 1 11/14 
32. Griffiths, 2004 1 1 1 1 1 1 1 1 1 1 1 1 1 1 12/14 
33. Hall, 2001 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
34. Hennessy, 2006 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
35. Horn, 2007 1 1 1 1 1 1 1 1 1 0 0 0 0 1 10/14 
36. Hulsher, 1997 1 1 1 1 1 1 -1 1 1 0 0 1 1 1 11/14 
37. Ilett, 2000 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
38. Jackson, 2004 1 1 1 1 1 1 1 1 1 -1 0 1 0 1 11/14 
39. Kim, 1999 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
40. Lemelin, 2001 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
41. Lin, 1997 1 1 1 0 1 1 1 1 1 0 0 1 0 1 10/14 
42. Lin, 2001 1 1 1 1 1 1 1 1 1 0 1 1 0 1 12/14 
43. Lobo, 2002 1 1 1 1 1 1 1 1 1 0 1 1 0 1 12/14 
44. Lobo, 2002 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
45. Manfredi, 1998 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
46. Mason, 2001 - - - - - - - - - - - - - - 
NA since 
cost study 
47. McDonald, 2003 1 1 1 0 1 1 -1 1 1 0 0 0 0 1 7/14 
48. Midlov, 2006 1 1 1 1 1 1 1 1 1 -1 1 1 0 1 11/14 
49. Mold, 2008 1 1 1 1 1 1 -1 1 1 -1 1 1 0 1 9/14 
50. Meyers, 2004 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
51. Naughton, 2007 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14/14 




1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
54. Nilsson, 2001 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
55. Ofman, 2003 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14/14 
56. Ornstein, 2004 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
57. Paton, 2008 1 1 1 0 1 1 1 1 1 0 0 0 0 1 9/14 
58. Peterson, 1996 1 1 1 1 1 1 -1 1 1 -1 0 1 0 1 8/14 
59. Peterson, 1997 1 1 1 1 1 1 1 1 1 -1 0 1 0 1 10/14 
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60. Pit, 2007 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14/14 
61. Raisch, 1990 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
62. Ray, 1985 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
63. Ray, 1986 1 1 1 1 1 1 1 1 1 -1 -1 1 0 1 9/14 
64. Ricordeau, 2003 1 1 1 1 1 1 1 1 1 -1 0 0 0 1 9/14 
65. Schuster, 2008 1 1 1 1 1 1 1 1 1 1 0 0 0 1 11/14 
66. Schaffner, 1983 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
67. Shanahan, 2006 1 1 1 1 1 1 1 1 1 0 0 0 0 1 10/14 
68. Siegel, 2003 1 1 1 0 1 1 1 1 1 0 1 0 0 1 10/14 
69. Simon, 2005 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14/14 




1 1 1 1 1 1 1 1 1 1 1 -1 0 1 12/14 




- - - - - - - - - - - - - - 
NA since 
cost study 
74. Teng, 2006 1 1 1 1 1 1 -1 1 1 0 0 0 0 1 8/14 
75. Turner, 2000 1 1 1 1 1 1 -1 1 1 -1 1 1 0 1 9/14 




1 1 1 1 1 1 1 1 1 1 1 -1 0 1 12/14 
78 
Van der Wijden, 
1999 
1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
79. Van Eijk, 2001 1 1 1 1 1 1 1 1 1 1 1 -1 0 1 13/14 
80. Walsh, 2005 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
81. Watson, 2001 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
82. Weller, 2003 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
83. Williams, 1994 1 1 1 0 1 1 0 1 1 0 0 0 0 1 8/14 
84. Witt, 2004 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
85. Wong, 2004 1 1 1 1 1 1 1 1 1 -1 1 1 0 1 12/14 
86. Young, 2002 1 1 1 1 1 1 1 1 1 1 1 1 0 1 13/14 
87. Zwar, 2000 1 1 1 1 1 1 1 1 1 1 1 -1 0 1 12/14 
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1.3.3 Elements used to describe the studies on academic detailing  
Item Definition 
1. Country Place were the study was conducted including countries in Europe, U.S., 
Australia and Asia. 
2. Initiator of the program Is the person or organisational entity which has initiated and/or funded the 
programme 
3. Type of research design 
 
The research design refers to RCT, before-after study,.. 
4. Type of objectives 
 
Goals of studies including academic detailing include improvements in processes 
and outcomes of care. 
5. Setting The setting refers to the type of health care setting (physician’s office, primary 
care clinics,….) 
6. Type and number of populations 
targeted 
 
The type of population refers to patients with cancer, heart failure, diabetes, 
neurodegenerative diseases, respiratory diseases,… 
7. Type and number of caregivers targeted 
 
Caregivers targeted refer to individual professionals or groups of care 
providers. 
8. Type of behaviour targeted The behaviour targeted refers to prescription behaviour, adherence to 
guidelines and any other behaviour related to quality/outcomes of care. 
9. Type and number of professionals 
responsible for providing academic 
detailing 
Professionals responsible for academic detailing are individuals who have been 
trained to provide the service 
10. Type, number and intensity of 
interventions 
Interventions refer to all actions that are defined as academic detailing 
11. Academic detailing part of 
multifaceted intervention programme 
A multifaceted intervention programme consists of a least out of one additional 
intervention besides academic detailing. 
12. Type of outcome measures/indicators Outcome measures refer to measurable items of care which focus upon some 
aspects of structure, process (clinical or inter-personal) or outcome and for 
which there is evidence or consensus that it can be used to assess the 
quality of care provided, and hence change it. These include biological 




(Cost)effectiveness is defined in this review as the degree to which the financial 
objectives of a program, care, service or system are achieved.  
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1.4 OVERVIEW OF THE SELECTED PAPERS  
1.4.1 Description of the reviews of reviews 
Number Author, date Main research question Databases (years) Exclusion (E) / inclusion criteria (I) Selected systematic reviews  
1. Bloom, 2005{Bloom, 2005 
#2} 
Effect of continuing medical 
education on physician clinical 
care and patient health 
Medical literature analysis and 
retrieval system on-line, DARE, 
Cochrane, Cinahl, Excerpta Medica 
database, Psychinfo, Canadian 
Medical Association Infobase, 
National Guidelines Clearinghouse, 
evidence-based medicine review, 
American College of Physicians 
Journal Club, HealthSTAR (1/1/1984 
– 30/10/2004) 
(I) English-language peer-reviewed journals 
(I) Formal meta-analysis or other 
structured review 
(E) literature reviews alone 
Morrison et al, 2000 
Thomson O’Brien et al. 2000 
Thomson O’Brien et al. 2001 
2. Grindrod et al, 
2006{Grindrod, 2006 #7} 
Interventions of pharmacists to 
impact health practitioners’ 
prescribing practices 
Medline, Cinahl, Embase, Cochrane 
(! July 2005) 
(I) English-languages SR 
(I) clear report of search strategy, 
inclusion/exclusion criteria, assessment 
criteria and methods for synthesizing or 
summarizing information and references 
Grimshaw al, 2004 
Harvey et al, 2002 
Pearson et al. 2003 
Thomson O’Brien et al. 2000 
Wilton et al., 2002 
3. Landry et al,2002{Landry, 
2002 #9} 
Changing physician behaviour 
(critical safety care medicine) 
Medline, Psychinfo, ABI/INFORM, O-
INSPEC 
(I) controlled observational studies, 
clinical trials and systematic reviews, 
relevant non-health care literature, gray 
literature 
Thomson O’Brien et al. 2000 
4. Satterlee et al, 
2008{Satterlee, 2008 #15} 
Effective medical education Cochrane database of systematic 
review (issue 4 for 2006) 
- Thomson O’Brien et al. 2000 
5. Sohn et al, 2004{Sohn, 2004 
#17} 
Efficacy of educational 
interventions targeting primary 
care provider’s practice 
behaviours (dental care) 
Medline, Cochrane 
(January 1988-March 2003) 
(I) Following a list of interventions 
(I) Outcome measures described 
(I) quality of reporting (QUORUM) 
(I) RCT, CCT, CBA, ITS 
(I) English-language 
Thomson O’Brien et al. 2000 
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1.4.2 Selected systematic reviews and source articles in these reviews 





Selected source articles 
(individual studies) on 
academic detailing / 
outreach visits  
1. Arnold et al, 2005{Arnold, 
2005 #1} 
Interventions to improve antibiotics 
prescribing practices in ambulatory care 
Medline, Embase + 
EPOC search strategy 
(! May 2000) 
(I) RCT, QRCT, CBA,  ITC 
(II) primary care in 
outpatients settings 
(III) professional intervention 
(IV) patient-based 
interventions 
(I) English language articles 
Included Avorn, 1983 







2. Chaillet et al, 2006{Chaillet, 
2006 #3} 
Strategies  for implementing clinical 
practice guidelines in obstetric care 
Cochrane, Medline, 
Embase (January 1990 – 
June 2005) 
(V) RCT, CBA, ITC 
(VI) quality criteria (EPOC) 
(E) non obstetrics, no relation to 
clinical guidelines implementation, 
opinion letters, no patient data, n 




Included Richens, 2004  
 
3. Fish et al, 2002{Fish, 2002 #4} 
 
Practice-based pharmaceutical services Medline, Embase (2001-
2007) 
(I) RCTs, CCTs 
(II) Publication date after 1980 
(III) English language 
Conducted in the UK, 
Australia, Canada, 
Scandinavia or the US 
Included Avorn, 1983 
Braybrook, 1996 










4. Fendrick et al 2001 Effectiveness of benefit based co payment 
 
------ ------ Excluded ----- 
5.  Grimshaw, 2001{Grimshaw, 
2001 #5} 
 
Effectiveness and costs of different 




trial register, Embase, 
Sigle, Cochrane EPOC 
specialised register 
 Included Browner, 1994 
De Burgh, 1995 




42  Academic Detailing – Supplement KCE reports 125 
 





Selected source articles 
(individual studies) on 
academic detailing / 
outreach visits  
Morrison, 1999 I 
Ornstein, 1991 
 
6. Grimshaw al, 2004{Grimshaw, 
2004 #6} 
Effectiveness and costs of different 




trial register, Embase, 
Sigle, Cochrane EPOC 
specialised register 




outcomes: objective measures 
of provider behaviour 
and/or patient outcome 
 
Included  Browner, 1994 
De Burgh, 1995 











Van der Weijden, 1999 
 
7. Harvey et al, 2002 Interventions to improve health 
professionals’ management of obesity 
Medline, psyclit, Embase, 
Sigle, Sociofile, 
dissertation Abstracts, 
Conference Paêrs Index, 
Cochrane  
(I)scope 
(X) RCT, CCT, CBA, ITS 
qualified health 
professionals, overweight and/or 
obese patients 
interventions according to 
EPOC criteria 
(I) outcome measure: provider 
performance or patients 
outcomes 
Excluded No articles selected 




Interventions to improve provider 
diagnosis and treatment of mental 
disorders in primary care 
 (I)scope 
(XIII) RCT, CCT, CBA, ITS 
qualified health professionals, 
overweight and/or obese patients; 
interventions according to EPOC 
criteria 
(I) outcome measure: provider 
performance or patients 
outcomes 
Included Goldberg, 1998 
9. Lu et al, 2008{Lu, 2008 #10} Interventions to improve the quality and 




(I) publication between July 2001 
and January 2007 
(I) related to the research 
Included Simon, 2005 
Soumerai, 1990 
Stevens, 2002 
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Selected source articles 
(individual studies) on 
academic detailing / 
outreach visits  
question  
(E) clinical effectiveness trials, 
cost-effectiveness studies of 
medications, descriptive studies, 
vaccination studies 
(I) RCT, CBA, ITS with at least 20 
subjects in each comparison group 
 
10. Morrison et al, 
2000{Morrison, 2000 #11} 
Effectiveness of interventions to improve 
oral antihypertensive drug adherence 
Medline (1965- February 
1999) + bibliographies 
scrennes 
(I) English-language 
(I) report of parallel-group, RCT, 
QRCT, 
(I) drug adherence= study 
endpoint 
(E) n<10 
Excluded No articles selected 
11.  
 
Thomson O’Brien et al. 2000 
! Update in Doumit, 
2007 
  Out of scope Excluded No articles selected 
12. Thomson O’Brien et al. 2000 
 - update in 2007{O’Brien, 
2007 #124} 
Effects of educational outreach visits on 




Cinahl (March 2007) 
(I) RCT 
(I) healthcare professionals 
responsible for patient care 
(E) students 
(I) outcome: performance in a 
healthcare setting or healthcare 
outcome 
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Selected source articles 
(individual studies) on 
academic detailing / 





Van der Weijden, 1999 
Van Eijk, 2001 







13. O’Brien et al. 2001 
! Update In Forsetlund 
2009 
   Excluded No articles selected 
14. Ostini, 2009 
 
 
Interventions to improve prescribing Pubmed, EMBASE (1974-
2008) 
Experimental and quasi-
experimental research studies 




15. Pearson et al. 2003{Pearson, 
2003 #14} 
Effectiveness of strategies to improve 




Cochrane, Embase, ASI, 
IPA, International 
Network for Rational 
Use of Drugs (INRUD) 
RCT, pre-post studies (with 
statistical test differences 
between groups), ITS 
(I) n>20 
Included Brown, 2000 
 
16. Sketris et al, 2009{Sketris, 
2009 #16} 
Effective optimal prescribing and 
medication management 
PubMed, Cinahl, Embase, 
Ineternational 
pharmaceutical abstract 
(1995-2006) + google, 
google scholar, New 
York Academy of 
Medicine Library Grey 
literature report + 
Cochrane, Canadian 
Agency for Drugs and 
Technologies in Health  
(E) non English language 
(E) behavioural and system change 
theory 














(I) RCT with >50% physician 
involvement, measure of physician 
behaviour change or patient 
Included Goldberg, 1998 
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Selected source articles 
(individual studies) on 
academic detailing / 
outreach visits  
base in continuing 
education (University of 
Toronto) (1966-2000) 
outcomes , physician or patient 
dropout<30%¨+follow-up of 
outcome > 30 days 
18. Weinmann et al, 
2007{Weinmann, 2007 #19} 
 
Effects of implementation of psychiatric 
guidelines on provider performance and 
patient outcome 




19.  Wilton et al., 2002{Wilton, 
2002 #20} 
Strategies to contain the emergence of 





DARE and CRD 
OPAC (1975-2000) 
Cochrane (1990-2000) 
(I) economic evaluations, cost /-
effectiveness studies,  
Included Gonzales, 1999 
Skaer, 1993 
20. Yen et al, 2006{Yen, 2006 
#21} 
Strategies to influence physician 
behaviour 
Medline, Cochrane (?-?) (I) meta-analyses, systematic 
reviews, RCT 




RCT: Randomized Controlled Trials – QRCT: Quasi Randomized Controlled Trials – CCT: Controlled Clinical Trials - CBA: Controlled Before and After studies – ITS: 
Interrupted Time Series – EPOC: Effective Practice and Organisation of Care Group. B: book – D: dissertation – R: report
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YES Process outcomes:  
rates of mammography prescription  
Positive on:  
rates of mammography 
prescription  
RCT US Patients needing cerebral 
and peripheral 





Prescribing of three drug 
groups. 
Pharmacist NO Process outcomes:  
use of three drug groups: cerebral and 
peripheral vasodilators, an oral 
cephalosporin and propoxyphene.  
 
Positive on:  
Significant reductions in the 
number of target drugs in 
intervention group compared to 







Before-after study US 
 
Patients with cancer 
 
CBE and lump-detection 




YES Process outcomes:  
number of lump detections 
Positive on:  
the mean number of  correct lump 
detections increased significantly, 















YES Psycho-social outcomes:  
attitude of physicians about the value 
of oral drug information from an 
industry-independent source 
 
Process outcomes:  
number of benzodiazepines prescribed 
per 100 patient contacts 
Positive on:  
average decrease of 3% in control 
group and of 14% in physicians 
who received written information, 
and 24% in physicians who were 
given oral information + positive 
attitude towards the value of oral 
drug information from an industry-
independent source 
 










Blood pressure control Detailer, not 
specified 
YES Biological outcomes:  
medical comorbidities, blood pressure 
values, recommendations of 
therapeutic life style changes, number 
of blood pressure medications. Key: 
mean SBP and DBP 
 
Process outcomes:  
percent of patients at or below JNC 7 
blood pressure goal; percent of 
patients with undiagnosed 
hypertension, intensification of therapy 
in those not at goal, and appropriate 
No effect on:  
no difference between 2 groups in 
any of the adherence measures. 
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selection of initial therapy in those 









Patients who need 
antibiotics 
 
Antibiotic prescribing Pharmacist 
 
NO Process outcomes:  
antibiotic prescribing indicators (= 
medications) 
 
Economic outcomes:  
Costs 
 
Positive on:  
changes in antibiotic prescribing 
indicators were greater in 
intervention compared to control 






Before after study Australia 
 
People with shoulder pain 
 
Use of diagnostic imaging 
for shoulder complaints in 
general practice and their 
knowledge and confidence 
to manage shoulder pain. 
 
Specialist YES Process outcomes:  
requests for ultrasound imaging, 
knowledge about identifying and 
managing shoulder problems 
Positive on:  
requests for ultrasound imaging 
decreased significantly after six 
months of AD + knowledge and 
confidence 
 
No effect on:  
no effect on the rate of requests 
over time in the control groups 
 






Patients with depression 
 
Management of depression Pharmacist 
 
YES Biological outcomes:  
HSCL-D, receipt of depression 
treatment, score of SF-36  
 
Process outcomes:  
clinician knowledge, attitude and 
practices related to the detection and 
treatment of depression 
 
Economic outcomes:  
dispensing of antidepressant 
medication 
Positive on:  
number of an 
Antidepressants 
 
Negative on:  
deterioration in self-reported 
physical functioning and vitality, 
more depressive cohort patients of 
control physicians improved 









Patients with high serum 
cholesterol levels 
 
Management of high 
serum cholesterol levels  
Detailer, not 
specified 
YES Process outcomes:  
proportion of patients whose 
management complied to the NCEP 
guidelines = Screening for total 
cholesterol, determination of LDL-
cholesterol, treatment of elevated 
LDL-cholesterol level, screening for 
hypercholesterolemia, treatment, 
follow-up for high serum cholesterol 
levels, measurements of HDL-
cholesterol and triglyceride 
No effect on:  
no significant differences in 
screening for high serum 
cholesterol or compliance with 
guidelines between the groups 
receiving CME and the control 
group. There was a trend toward a 
modest benefit from the CME 
interventions. 
 










Patients (adults) who 
need antibiotics for acute 
cough 
 
Prescribing of antibiotics 
for acute cough 
Pharmacist 
 
YES Biological outcomes:  
patients’ symptom resolution due to 
change in antibiotic prescribing 
 
Process outcomes:  
antibiotics prescribing rates + type of 
antibiotics prescribed 
Economic outcomes: medication cost 
per patient from a public perspective 
 
Positive on:  
Less prescribing in intervention 
group + prescribed antibiotics 
more in line with guideline in 
intervention group and less 
expensive from public perspective 
 
No effect on:  








Elderly with hypertension 
 
Management of systolic 
hypertension in the elderly 
(patient aged 70 to 79 
years) 
Researcher YES Process outcomes:  
management of systolic hypertension 
and a specific patient scenario 
 
Positive on:  
significant difference in the stated 
threshold for treating systolic 
hypertension between intervention 
and control + difference in the 
willingness to treat patient (case) 
with mild hypertension 







Patients with anxiety 
 
Precribing of 




NO Process outcomes: benzodiazepine 
prescribing rate, axiety and insomnia 
diagnosis rates 
 
Positive on:  
when comparing the intervention 
arms, benzodiazepine prescribing 
rate, axiety and insomnia diagnosis 
rates declined significantly, also 
initial prescription rates, 
differential downward trend in c 
per insomnia diagnosis, but not to 
a statistical level. 
No effect on: prescribing for 
anxiety diagnosis. 
 






Patients (adults) with low 
back pain 
 
Management of low back 







YES Process outcomes:  
rate of referral for lumbar spine X-
rays, issuing of sickness certification, 
referral to secondary care and 
prescription of muscle relaxants and 
opioid analgesics. 
 
Positive on:  
significant differences between 
study groups for referral to 
physiotherapists or the back pain 
unit 
 
No effect on:  
no significant differences between 
study groups in proportion of 
patients who were referred for X-
ray, issued with a sickness 
certificate, prescribed opioids or 
muscle relaxants, or were referred 
to secondary care. 
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Patients (adults) who 
need antibiotics for 
tonsillitis 
 





YES Process outcomes: 
the percentage of prescriptions of 
antibiotics for tonsillitis complying with 
those recommended in antibiotic 
guidelines 
Positive on:  
when comparing the interventions 
groups, prescriptions consistent 
with recommendations in the 
guidelines increased 
 






Patients who need 
antidepressants for the 




Pharmacist NO Process outcomes:  
prescribing of antidepressant drugs 
during intervention and 12 months 
after intervention. 
 
No effect on:  
When comparing the study groups, 
there was no significant impact of 










Before-after study US 
 





Management of ADHD Physician YES Process outcomes:  
use of guidelines for the assessment 
and treatment of ADHD, use of parent 
and teacher assessment rating scales 
and systematic monitoring of 
responses to medication. 
 
Positive on:  
After intervention, GPs showed 
substantial improvement in the use 
of guidelines for the assessment 
and treatment of ADHD. Use of 
parent and teacher assessment 
rating scales increased significantly. 
Systematic monitoring of 
responses to medication improved. 
 







Adults who smoke 
 






participation at a training 
workshop on tobacco 
dependency treatment 
Nurse NO Process outcomes:  
percentage of patients the physicians 
counselled or treated for tobacco 
dependency and number of physicians 
who took part in a workshop. 
 
Positive on:  
when comparing the intervention 
groups, the proportion of 
physicians who recommended to 
their patients the use of computer-
tailored smoking cessation 
programme increased + the 
proportion of patients who 
received the advice to quit 
smoking increased 
 






Patients (adults) with 
asthma and/or diabetes 
 
Prescribing in asthma, 
review of inhaler 











YES Biological outcomes:  
asthma—peak flow rate, prophylaxis, 
occupation and smoking habit/ 
diabetes: blood glucose concentration 
 
Process outcomes:  
prescribing in asthma, review of inhaler 
technique, review of asthma 
symptoms, glycaemic control, 
funduscopy, feet examination, weight, 
Positive on:  
improvements in all seven diabetes 
variables (see above), improved 
recording of review of inhaler 
technique, smoking habit, and 
review of asthma symptoms, 
quality of prescribing in asthma. 
The use of structured prompts 
was associated with improved 
recording of four of seven 
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size of practice disease registers 
variables on diabetes and all six 
variables on asthma. 
 
No effect on:  













Prescription of Warfarin Physician YES Process outcomes:  
the number of coprescriptions of 
warfarin-interacting medications per 
10000 Warfarin users per month) 
 
Positive on:  
reduction in the rate of Warfarin-
interacting medication prescription 
No effect on:  
group academic detailing did not 






Controlled study Spain 
 





Prescribing of NSAIDs Pharmacist NO Process outcomes:  
number of prescribed units of NSAIDs 
during intervention 
Positive on:  
prescribing behaviour 
improvement in case of one-to-
one education in the 9 months 
after intervention. In the education 
group improvement was also 
noted, but significant more 
improvement in one-to-one 
education group. Reminder 
increased significantly the 










Not specified (not 
applicable) 
 
Reporting of ADRs Detailer, not 
specified 
YES Process outcomes:  
reporting of ADRs 
 
Positive on:  
increase in ADR reporting rates 
attributable to intervention for 
total ADRs, serious ADRs, high 
causality ADRs and unexpected 
ADRs for new drugs-related ADRs 
with the greatest difference to 
occur 4 months after intervention, 
and differences to remain 











immunization aged 12-23 
months 
 
Immunization  Physician + 
team 
YES Biological outcomes: immunization 
rates of children aged 12-23 months 
 
Process outcomes:  
self-reported provider behaviours (11 
items)   
Positive on:  
improvements of self-reported 
provider behaviour 
 
Negative on:  
costs—no favourable cost-benefit 
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aged 12-23 months 
 
Economic outcomes:  
cost of the intervention 
ratio 
 








Adults needing ACE 
inhibitors, raised 
cardiovascular risk 
patients needing aspirin, 
NSAIDs needing patients 
with joint pain, patients 
needing antidepressants. 
 
Adherence to guidelines: 
prescription 
Pharmacist NO Process outcomes:  
prescription of ACE inhibitors with 
loop diuretics to patients suffering 
from heart failure, aspirin, NSAIDs and 
antidepressants. 
 
Positive on:  
AD was associated with a 
significant improvement in 
prescribing practice and an 
increase in the number of patients 















hypertensive drugs  
Pharmacist YES Process outcomes:  
a) proportions of first-time 
prescriptions for hypertension where 
thiazides were prescribed + b) patients 
assessed for cardiovascular risk before 
prescribing antihypertensive or 
cholesterol-lowering drugs, c) patients 
treated for hypertension or 
hypercholesterolemia for 3 months or 
more who had achieved recommended 
treatment goals 
 
Positive on:  
Significant shift in prescribing of 
hypertensive drugs towards the 
use of thiazides,   
No effect on: Little or no 
differences were found for risk 
assessment prior to prescribing 















according to guidelines 
Pharmacist YES Economic outcomes:  
cost-effectiveness of the intervention 
 
Positive on:  
Significant shift in prescribing of 
hypertensive drugs towards the 
use of thiazides, and thus cost-
lowering effects predicted over a 
two year period.  
 













Compliance rates for 12 
evidence-based indicators 











NO Process outcomes:  
assessment of risk factors in patients 
with hypercholesterolemia, angina 
pectoris, hypertension and heart 
failure. 
 
Positive on:  
significant improvement when 
comparing the intervention arms 
was found for: the assessment of 
risk factors in patients with 
hypercholesterolemia and angina 
pectoris, provision of information 
and advice to patients with 
hypercholesterolemia and 
hypertension, checking for clinical 
signs of deterioration in patients 
with heart failure. 
 







Mathematical model Germany 
 
Patients with heart failure: 







NO Economic outcomes: 
 
Positive on:  















Compliance with national 
guidelines for the primary 
care of hypertension and 
depression. 
 
Physician YES Process outcomes:  
percentage of depressives prescribed 
first-generation tricyclics 
 
No effect on:  
CQI-teams and AD in combination 






Patients with hazardous 
alcohol consumption 
 
Management of hazardous 
alcohol consumption 
(screening and counselling 
rates) 
 
Pharmacist YES Process outcomes:  
screening and counselling rates. 
 
Economic outcomes:  
cost-effectiveness 
 
Positive on:  
Update of the intervention package 
and recruitment rates better for 
AD compared to direct mail and 
tele-marketing. Tele-marketing was 
found to be more cost-effective 
than AD and direct mail in 
promoting the update of the 
package to improve screening and 


















YES Process outcomes:  
antibiotic prescription rates, return 
office visits within 30 days of the 
incident visit 
 
Positive on:  
substantial decline in antibiotic 
prescription  rates in intervention 
group, but not at the control and 
limited intervention group.  
 
No effect on:  
Return office visits within 30 days 
of the incident visit for bronchitis 
or pneumonia did not change 















2) inhibitors, as well as 
examine the intervention 
effect on the utilization 
rates of gastroprotective 





NO Biological outcomes:  
patient morbidity and mortality 
 
Process outcomes:  
change in COX-2 utilization rates from 
baseline, office visits rates 
visits/patients, use of protein pump 
inhibitor, mesoprostol and histamine2-
receptor antagonist, GP office visits 
Positive on:  
The osteoarthritis AD intervention 
was associated with a significant 
decrease in COX-2 utilization 
rates in the 3-month period 
immediately following the 
intervention. 
 
No effect on:  
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per patient, specialist office visits per 





measures of patient morbidity and 
















Unscheduled care for 
asthma patients 
 
Nurse YES Biological outcomes:  
rates of attendance for unscheduled 
care, self-management behaviour, 
asthma symptoms 
 
Psycho-social outcomes:  
quality of life 
 
Process outcomes:  
percentage of participants attending 
for unscheduled asthma care and the 
time to first attendance for 
unscheduled asthma care in the year 
after intervention. 
 
Positive on:  
delayed time to first attendance 
when comparing intervention arms 
and reduction in the percentage of 
patients with acute asthma 
 










Pharmacist YES Process outcomes:  
prescription of three drugs 
 
Positive on:  
significant increase in omeprazole 
and metronidazole use 
 
No effect on:  
non-significant change in 














Pharmacist YES Process outcomes:  
proportion of patients achieving blood 
pressure control below 140/90 mmHg 
+ secondary analysis in patients with 
diabetes or kidney disease—controlled 
hypertension: 130/80 mmHg 
 
No effect on:  
no effect or moderate effect 
among patients with hypertension. 









Changes in drug 
utilization following a 
national general practice 
education programme 






YES Process outcomes:  
use of thiazide or thiazide like diuretics 
at first line therapy for hypertension, 
use of low-dose formulations where 
thiazide diuretics were used, use of 
beta-blockers as first line therapy. 
 
 
Positive on:  
increase in low-dose thiazide and 
beta-blocker prescribing. 















Nurse YES Process outcomes:  
prevention of cardiovascular disease 
Positive on:  
Outreach visits were more 
effective than feedback in 
implementing guidelines to 
organise prevention. The increase 
in the number of practices 
adhering to the guidelines was 
significant for six out of 10 
guidelinesNo effect on: the number 
of practices adhering to the 
guideline to make a follow up 
appointment did not reach 
significance 
 






Patients with upper and 
lower respiratory tract 
infections, otitis media 
and urninary tract 
infections. 
 
Antibiotic prescribing Pharmacist NO Process outcomes:  
total number of prescriptions for 
selected individual antibiotics 
 
Positive on:  
when comparing the interventions 
arms, GPs in the intervention 
group prescribed amoxicillin and 
doxycilline (complied to guidelines) 








Controlled study Australia 
 
Patients with atrial 
fibrillation and an elevated 
risk to develop stroke 
 
Reducing the risk of 
stroke through the use of 
antithrombotics 
(Warfarin) in patients 
with atrial fibrillation 
 
Pharmacist NO Process outcomes:  
prescription of Warfarin and aspirin 
Positive on:  
when comparing intervention 
arms: increased use of Warfarin in 
patient at high risk of stroke. 
 










mammography and clinical 
breast examination 
 
Provision of preventive 
care services 
Pharmacist YES Biological outcomes:  
rates of reported mammography 
 
Other:  
number of patients who reported to 
have received preventive care services 
(influenza, pneumococcal, tetanus 
immunization, exercise counselling) 
 
Positive on:  
positive evolution in the number of 
influenza, pneumococcal, and 
tetanus immunization in both 
intervention and control. 
Mammography and clinical breast 
examination worsened in the 
education group only. Patient 
satisfaction scores improved in 
















Nurse YES Process outcomes: 
folic acid supplementation, smoking 
cessation and hypertension treatment 
(index of preventive performance) 
Positive on:  
when comparing intervention and 
control: index of preventive 
performance significantly better in 
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 hypertension treatment  intervention group +proportion of 
patients who received 
recommended preventive services 
 
No effect on:  







Before-after study US 
 






YES Psycho-social outcomes:  
patient satisfaction and depression 
outcomes 
 
Process outcomes:  
physician selection of antidepressant 
medication, adequacy of 
pharmacotherapy, intensity and follow-
up visits during the acute phase of 
depression treatment. 
 
No effect on:  
no improvement in any of the 
outcomes measured. 




Before-after study US 
 






YES Psycho-social outcomes:  
patient satisfaction and depression 
outcomes 
 
Process outcomes:  
new diagnoses per 100 primary care 
visits, new antidepressant medications 
per 100 visits, rate of new diagnosis 
accompanied by a new prescription 
per 100 visits, duration of 
pharmacotherapy 
 
No effect on:  
no difference between intervention 
and control in the rate of new 
depression diagnosis, new 
prescription of antidepressant 
medicines,  
 


















YES Other:  
deficiency score (the difference 
between ideal and actual practice) 
 
Positive on:  
the duration of exposure was 
positively related to the change in 
availability of separate clinics and in 
the amount of teamwork. The 
improvement in instruments and 
materials was positively related to 
the GP’s opnion about the given 
feedback. 
 
No effect on:  
No relations were found between 
key characteristics and changes in 
record-keeping or follow-up 























YES Process outcomes:  
preventive tasks performed by the 
practice assistant (measurements 
taken, history questions asked, advice 
given on), follow-up including making 
an appointment immediately after the 
visit, making an identifiable note, 




availability of instruments and materials 
(e.g. blood pressure meter, glucose 
meter,...), leaflets, adequate ancillary 
staff present, separate room for 
practice assistant, teamwork in the 
practice, record keeping.  
 
Positive on:  
when comparing the intervention 
arms, the difference in change was 
statistically significant for each 
aspect of organizing preventive 
care. The largest absolute 
improvement was found for the 
number of preventive tasks 









Cancer (breast, cervical 
and colorectal cancers) 
 
Screening of cancer 




YES Process outcomes:  
the proportions of patients with a 
chart-documented mammogram, 
clinical breast examination, 
Papanicolauo smear and occult blood 
slide test in 2 years before 
preintervention and postintervention 
chart abstractions. 
 
Positive on:  
between baseline and 
postinterventions, there was a net 
increase in the proportion of 
HMO members in the 
intervention, compared to control 
practices for Papanicolauo smear 
and fecal occult blood slide test. 
There was a net increase in the 
proportion of non-HMO patients 
in the intervention compared with 
the control practices who received 
clinical breast examination and a 
fecal blood slide test. 










medications of ACE 
inhibitors and SSRIs 
(selective serotonin 
reuptake inhibitor) 
Pharmacist YES Economic outcomes:  
cost-effectiveness 
Positive on: 
AD is cost-effective for 
implementation of ACE inhibitors 
+ AD is cost-effective for a 
reduction in use of SSRIs in favour 





Before-after study Australia 
 
Elderly patients with heart 
failure and chronic pain 
associated with 
Prescribing for heart 
failure and chronic pain 
associated with 
Pharmacist NO Psycho-social outcomes: 
satisfaction in physicians and 
pharmacists 
Positive on:  
prescription of NSAID and 
triclyclic antidepressants 










Process outcomes:  
Prescribing of NSAID, angiotensine 





No effect on:  
prescription of angiotensine 
converting enzyme inhibitor 















YES Process outcomes:  
prescribing of medium-and long-acting 
benzodiazepines and total 
benzodiazepines 
 
Positive on:  
significant decreases in prescribing 
of medium-andlong-acting 
benzodiazepines and total 
benzodiazepines 
 
No effect on:  












Preventive services. Principal 
investigator 
YES Process outcomes:  
number of practices who implemented 
one or more of the evidence-based 
processes (selected immunizations and 
preventive services) 
+ the number of total processes 
implemented 
Positive on:  
Intervention practices 
implemented more of the 
processes than control practices 
overall, for adults and for children. 
Intervention practices were also 
more likely to implement at least 
one of the processes for children 
and to implement standing orders. 
Mammography rates increased 
significantly 
 





Patients with an abnormal 
screening result for fecal 
occult blood > 50 years 
 
Management of complete 
diagnostic evaluation 
(CDE) for persons with 
an abnormal screening 
result for fecal occult 
blood. 
 
Nurse YES Process outcomes:  
CDE rates for FOBT 
 
Positive on:  
CDE (complete diagnostic 
evaluation) recommendation and 
performance rates were both 
significantly higher in the 
intervention practices compared to 









Patients with CVD or 
diabetes 
 
Prescribing of CVD 
preventive therapies 
(cardiovascular) in 
patients with CVD or 
diabetes at 3 and 6 
months post intervention 
Researcher YES Psycho-social outcomes: 
satisfaction in GPs 
 
Process outcomes:  
level of antiplatelet prescribing in 
patients with coronary heart disease, 
statin prescribing in patients with CVD 
and, antiplatelet and statin prescribing 
Positive on:  
High level of satisfaction in GPs 
 
No effect on:  
there was a 3% increase in statin 
prescribing in CVD patients at 6 
months post-intervention for both 
groups, but not statistically 
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in patients with diabetes  
 
significant. Same for: statin and 
antiplatelet/warfarin prescribing in 
diabetic patients 
 





Patients with diabetes 
 
Control of hypertension 
and hyperlipidemia in 
patients with diabetes. 
 
Nurse YES Biological outcomes:  
percentage of patients that received 
adequate control= targets for blood 
pressure and lipid management 
 
Process outcomes:  
cholesterol control, blood pressure 
control,  
 
No effect on:  
no improvement in the number of 
patients achieving target after 1 











Patients who need NSAI 
medications 
 
Prescribing to reduce 
costs 
Pharmacist NO Economic outcomes:  
prescribing costs 
 
Positive on:  
there was a decrease in the 
average prescribing cost per 
month in the intervention group 
compared with the reference 
group. 
 




















YES Process outcomes:  
prescribing rates and DDDs per 
prescription in the year before and 
after the intervention 
Positive on:  
significant effect on prescriptions 
for agents acting on the renin-
angiotensin system. 
 
No effect on:  
prescribing rates of proton-pump 
inhibitors and medications for 
depression. 
 





Patients with new 
dyspepsia and chronic 
users of antisecretory 
drugs. 
 




Pharmacist YES Biological outcomes:  




satisfaction with care, health-related 
quality of life 
 
 
Positive on:  
improvements in helicobacter 
pylori testing, use of 
recommended helicobacter pylori 
treatment regimens, and 
discontinuation rates of proton 
pump therapy after treatment.  
 
No effect on:  
Few differences in patient quality 






Patients with (risk for) 





YES Biological outcomes:  
7 outcome measures which reflected 
Positive on:  
positive trends for the percentage 
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n, 2004 #78} 
 










whether patients achieved 
recommended treatment goals. 
 
Process outcomes:  
14 process measures reflecting if 
recommended tests were done, 
appropriate diagnoses made or 
appropriate medication prescribed. 
Percentage of performance targets 
achieved. 
 
of quality indicators at or above 
target, Positive results for 
diagnoses of hypertension and 
blood pressure control in patients 
with hypertension, but no 
differences between intervention 
and control. 














NO Process outcomes: 




Prescribers ‘ knowledge of the 
evidence base and why RLAI is used 
 
Positive on:  
AD was effective in changing 
prescribing practice (Rational 
Prescribing of risperidone long-







Controlled study Australia 
 
Patients with rheumatic 
disorders 
 
Prescribing of NSAIDs 
 
Pharmacist NO Process outcomes:  
(DDD) Daily Dosed Dispensed for 
NSAID compared to paracetamol 
 
Economic outcomes: hospital 
admissions due to gastric ulcers 
 
Positive on:  
Changes in prescribing of NSAIDs 
were evident in both study 
regions, but were significantly 
greater in the intervention area 
compared to the control area. A 
decline in public hospital 






Controlled study Australia 
 
Patients with urinary tract 
infections 
 
Prescribing for antibiotics Pharmacist NO Process outcomes:  
the total DDDs dispensed for the 
recommended first-line agents 
(amoxicillin-potassium clavulanate, 
cephalexin and trimethoprim) 
 
Positive on:  
total DDDs in intervention group 















Prescribing of NSAIDs 
and antihypertensives. 
 
Pharmacist YES Biological outcomes:  
occurrence of falls 
 
Psycho-social outcomes:  
quality of life assessed by SF-12 and 
EQ-5D Scores 
 
Process outcomes: Use of 
benzodiazepines, NSAIDs and thiazide 
Positive on:  
in intervention group; improved 
medication use composite score at 
4-month follow-up (but not after 
12 months), reduction in use of 
NSAIDs, benzodiazepines (not 
significant) and thiazide diuretics, 
lower number of falls and injury 
requiring medical attention. 









Other: use of medication reviews 
 
 
No effect on: Quality of life 
scores 
 




Controlled study US 
 
Patients needing anti-ulcer 
agents 
 
Prescribing of antiulcer 
agents 
Pharmacist NO Process outcomes:  
prescribing of anti-ulcer agents 
(cimetidine, ranitidine and sucralfate) 
 
Positive on:  
no differences in appropriateness 
were found between the two 
intervention groups, but  in the 
first postintervention month the 
mean rate of inappropriate 
prescribing per control 
practitioner was 80% versus > 32% 
for the intervention groups. 
Positive effect on mean cost per 
control practitioner and per 
patient due to appropriate 
prescribing. 
 















NO Process outcomes:  
average change index of contra-
indicated antibiotics (chloramphenicol, 
clindamycin, tetracycline for children 
younger than 8 years) and 
cephalosporins. 
 
Positive on:  
the beneficial effect of the 
physician-counselors persisted 
throughout year 2 with reductions 
in prescribing for both classes of 
drugs and cost savings. 
No effect on: reductions in 












Prescribing of Diazepam  Physician NO Process outcomes:  
prescribing of diazepam 
Other: Receptivity of doctors to 
educational programme 
 
Positive on:  
Lower prescribing of diazepam in 
intervention group and positive 







Time series France 
 
Patients with diabetes 
 
Management of type 2 
diabetes 
Physician NO Process outcomes:  
monthly proportion of the number of 
HbA1c measurements to the total of 
laboratory tests 
 
Positive on:  
the number of HbA1c tests 
(increase) and blood glucose 







Controlled study US 
 






YES Biological outcomes:  
cardiovascular disease risk factors: lipid 
levels, blood pressure and blood 
glucose 
Positive on:  
the number of physicians that 
discussed obesity with their 
patients, reference to obesity 
KCE Reports 125 Academic Detailing – Supplement 61 
  
  
Process outcomes:  
documentation of physician obesity 
management: BMI, weight, record 
height to allow BMI calculation 
Other: Physician knowledge of obesity 
as a CVD factor 
 


















NO Process outcomes:  
Prescription of contraindicated 
antibiotics for use in office practice: 
chloramphenicol, clindamycin and 
tetracycline for children younger than 
8 years and oral cephalosporins. 
 
Positive on:  
when physician educators were 
used, strong attributable 
reductions in prescribing of both 
drug classes were obtained. The 
drug educator had only a modest 
effect. 
 
No effect on:  








Modelling approach Australia 
 
People abusing alcohol 
 




NO Process outcomes:  
screening for alcohol abuse in adults 
 
Positive on:  
achieving a decrease in the number 
of standards drinks consumed by 
risky drinkers. 
 















YES Process outcomes:  
prescription of thiazide diuretics, beta-
blockers and calcium antagonists, 
angiotensine converting enzyme 
inhibitor, angiotensine receptor 
blocker 
 
Positive on:  
prescribing of number of calcium 
antagonists, beta-blockers, thiazide 
diuretics for patients with 
hypertension. For hypertensive 
subjects with diabetes mellitus or 
congestive heart failure, the 
proportion receiving an 
angiotensine converting enzyme 
inhibitor or angiotensin receptor 
blocker increased. Among 
hypertensive subjects with 
coronary artery disease and 
increase in beta-blocker use was 
noted. 
 





Patients with newly 
diagnosed hypertension 
 
Prescription of diuretic or 




NO Process outcomes:  
rates of diuretic or beta-blocker use 
increased in both individual and group 
Positive on: rates of diuretic or 
beta-blocker use increased in both 
individual and group AD practices 
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  AD practices No effect on: neither intervention 
affected blood pressure control 
 









Prescription of diuretic or 





NO Economic outcomes:  
average daily drug cost 
 
Positive on:  
the individual AD resulted in an 
estimated net decrease in average 
daily drug cost per person beyond 
the reductions in the mail group, 
although this finding did not reach 
statistical significance. The 
estimated net reduction 









High risk patients (age > 
65 years, coronary heart 
disease, diabetes and a 
history of splenectomy) 







Physician  YES Process outcomes:  
rates of influenza and pneumoccocal 
vaccination for patients age > 65 years, 
coronary heart disease, diabetes and a 
history of splenectomy 
 
Positive on:  
Improvements in pneumoccocal 
vaccination rates in the 
intervention practices were 
significantly greater compared to 
controls in patients with CHD and 
diabetes but not splenectomy. 
Improvements for influenza 
vaccination were also greater in 
intervention practices but did not 










Patients with cancer 
(colon, rectum, cervix, 
prostate, breast and lung) 
 






YES Process outcomes:  




knowledge of ACS screening guidelines 
for the colon, rectum, cervix, prostate, 
breast and lung 
 
Positive on:  
Identified barriers to practice 
 
No effect on:  
no significant differences in 
knowledge of cancer prevention or 
screening. 
 




Modelling approach Australia 
 
Patients with cancer 
(prostate cancer) 
 
PSA screening  Pharmacist NO Economic outcomes: 
 
Positive on:  
A national programme would 
reduce the burden of disease by 
4.7% of total DALYs due to 
prostate cancer in those aged 70 
and over, with no loss of life and 
an incremental cost effectiveness 
ratio of 16.000/DALY (gross) and 
8.500/DALY (net). 
74. Teng, 2006 Time series Malaysia Patients with respiratory Prescription of antibiotics Physician YES Process outcomes:  Positive on:  









prescription of antibiotics 
 
reductions in the prescription of 
antibiotics for URTI 
 






Patients with congestive 
heart failure 
 
Prescription of ACE 
inhibitors and angiotensin 
2 receptor antagonists for 
the prevention and 
management of CHF. 
Pharmacist NO Process outcomes:  
self-reported use of prescription of 
ACE inhibitors and angiotensin 2 
receptor antagonists for the 
prevention and management of CHF. 
 
No effect on:  
no significant difference in ACE-
inhibitor prescribing between 









Patients with respiratory 
diseases: acute maxillary 
sinusitis 
 
Prescribing of antibiotics 
for maxillary sinusitis  
Physician NO Process outcomes:  
prescribing of antibiotics for acute 
maxillary sinusitis (Amoxicillin), 
proportion of courses of antibiotics 
with recommended duration 
 
Positive on:  
Use of first line drugs (amoxicillin): 
increased 
 
No effect on:  
there were no significant changes 
between AD and problem-based 
learning methods. 
 















Physician NO Psycho-social outcomes: 
job-stress in physicians 




Premises and equipment, service and 
organization, record keeping, 
organisation of quality improvement, 
workload 
Positive on:  
both programmes resulted into 
improvements on many aspects of 
practice management. Practice 
visits by peers resulted into better 
performance for equipment, 
collaboration with colleagues, 
accessibility of patient information 
than after a visit of a non physician 
observer. Visits by non physician 
observers resulted in a higher 
score on extent of use of records, 
outcome assessment and year 
report. 
 

















YES Process outcomes:  
quality of selective case finding (= 
targeting cholesterol testing to patients 
with at least one of the six risk factors 
mentioned in the guideline), and quality 
of diagnostic procedures (= properly 
diagnosed hypercholesterolemia 
requires that average of 3 
measurements to be higher than 6.5 
mmol/l) 
Positive on:  
quantity of cholesterol testing 
Negative on: performance of the 




No effect on:  
quality of selective case finding or 
quality of diagnostic procedures 
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Prescribing of highly 
anticholinergic 
antidepressants in elderly 
people. 
Researcher YES Process outcomes:  
numbers of elderly people with new 
prescriptions of highly anticholinergic 
antidepressants and less anticholinergic 
antidepressants 
 
Positive on:  
in both the intervention arms the 
use of highly anticholinergic 
antidepressants decreased + the 
use of less anticholinergic 
antidepressants increased. 
 






Patients at risk for 




screening (patients aged 
50-79) 
 
Physician YES Process outcomes:  
FOBT in the last 2 years, flexible 
sigmoidoscopy and colonoscopy in the 
previous 5 years, CRC screening 
Positive on:  
patient rates of screening SIG 
(flexible sigmoidoscopy) 
 
No effect on:  























Process outcomes:  
change in the volume prescription 
(DDD) of ibuprofen, diclofenac and 
naproxen (= recommended NSAIDs) 
as a percentage of total NSAID 
prescribing 
 
Economic outcomes:  
cost-benefit analysis 
 
Positive on:  
the proportion of prescribing of 
the five most frequently used 
drugs. 
Negative on: a net increase in 
costs with both interventions 
 
No effect on:  
prescription of ibuprofen, 
diclofenac and naproxen 
 











Pharmacist YES Process outcomes:  





Positive on:  
correct responses to questions 
about prostate cancer treatment 
effectiveness and endorsement of 
PSA testing for prostate cancer by 
professional bodies. 
 
No effect on:  
PSA testing rate lower in AD 














Screening and preventive 
actions on breast, colon-




YES Process outcomes:  
activities in compliance with cancer 
prevention guidelines 
 
Positive on:  
compliance rates + increased 
awareness of resources of ACS 
and in prompting physicians to 
adopt cancer prevention and 
screening procedures, but least 
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effective in making office changes. 
 






Patients with respiratory 
diseases: asthma (children 
< 16 years of age) 
 
Prescription of asthma 
medication (to change 
medication in children to 
more inhaled steroids and 
less B2-aginists, and to 
increase the GPs use of 
peak-flow meters and 
spirometry). 
Researchers YES Process outcomes:  
number of asthma medication 
prescribed (DDD of steroids and B2-
agonists expressed as sales of asthma 
medication by pharmacies). 
 
No effect on:  
prescription of asthma medication 
 








Management of geriatric 
patients: geriatric 
knowledge on cognitive 
impairment, competency, 
urinary incontinence, 





YES Other:  




improvements in geriatric 
knowledge scores 
 






Patients who smoke (age 
18-70 years) 
 
Smoking cassation advice Detailer, not 
specified 
YES Process outcomes:  
recall of GPs advice about nicotine 
replacement patches and gum, patient 
recall of assessment of smoking status 
and GP use of ‘quit dates’, behavioural 
advice and provision of written 
materials 
 
Positive on:  
recall of GPs advice about nicotine 
replacement patches and gum. 
 
No effect on:  
Positive increases but not 
significant for: patient recall of 
assessment of smoking status and 
GP use of ‘quit dates’, behavioural 
advice and provision of written 
materials 
 






Patients (long term users 




Physician YES Process outcomes:  
rate of benzodiazepine prescribing for 
all indications, for anxiety and sleep 
disorders 
Positive on:  
Overall benzodiazepine prescribing 
(in continuing rather than initial 
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1.5 DESCRIPTION OF THE 87 STUDIES SELECTED 





Aspy CB, Enright M, Halstead L, Mold JW. Improving mammography screening using best 
practices and practice enhancement assistants: An Oklahoma Physicians Resource/Research 
Network (OKPRN) study. Journal of the American Board of Family Medicine. 
2008;21(4):326-33. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To apply a multi-component implementation intervention to the problem of 
breast cancer screening within community practices that are members of a 
research based network, with the goal to improve mammography rates. 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Healthy woman age > 50y 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescribing of mammography 
Who does academic detailing # Nurse 
# Physician 




" Not specified 
Interventions " INTERVENTION: 1) audit results and a comparison with a  with a network 
benchmark, 2) academic detailing of exemplar principles and information from the 
medical literature, 3) services from a practice facilitator for 9 months, 4) 
information technology support if requested. 
" CONTROL: no feedback or practice change facilitation 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: rates of mammography prescription 
# Economic outcomes 
# Other: 
 
" Positive on: rates of mammography prescription 
# Negative on:  
# No effect on: 
 
Conclusion: AD is effective on mammography prescription. 
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Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach. A 
randomized controlled trial of academically based "detailing". N Engl J Med. 
1983;308(24):1457-63. 
Quality appraisal score " 9/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate the effectiveness of academic detailing in the reduction of the 
excessive use of three drug groups: cerebral and peripheral vasodilators, an oral 
cephalosporin and propoxyphene.  
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients needing cerebral and peripheral vasodilators, an oral cephalosporin 
and propoxyphene.  
 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Reducing the excessive use of three drug groups: cerebral and peripheral 
vasodilators, an oral cephalosporin and propoxyphene.  
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Interventions " INTERVENTION: face-to-face AD + educational materials  
" INTERVENTION: printed-materials only 
" CONTROL: no intervention 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: use of three drug groups: cerebral and peripheral 
vasodilators, an oral cephalosporin and propoxyphene.  
 
" Economic outcomes: costs 
# Other: 
 
" Positive on: Significant reductions in the number of target drugs in intervention 
group compared to control group + cost reductions 
# Negative on:  
# No effect on: 
 
Conclusion: AD is useful and cost-effective to improve the quality of drug-therapy decisions 
and reduce costs. 
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Benincasa TA, King ES, Rimer BK, Bloom HS, Balshem A, James J, et al. Results of an office-
based training program in clinical breast examination for primary care physicians. Journal of 
Cancer Education. 1996;11(1):25-31. 
Quality appraisal score " 8/14 




# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
" Before-after: one group pretest/posttest design 
# Time series: 
 
Objectives  
To implement an office-based training program in clinical breast examination (CBE) to improve 
lump-detection skills of primary care physicians. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted " Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " CBE and lump-detection skills in physicians. 
 
Who does academic detailing # Nurse 
# Physician 
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# Pharmacist 
" Other: non physician experts in CBE 
Interventions # INTERVENTION: 
# CONTROL:  
" CBE skill training, and didactic discussion + educational package on breast 
cancer screening that included recent journal articles, breast cancer screening 
guidelines, and a complementary silicone breast model + credits for continuing 
medical education 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: number of lump detections 
# Economic outcomes 
# Other: 
 
" Positive on: the mean number of correct lump detections increased 
significantly, and the number of false positives decreased 
# Negative on:  
# No effect on: 
 
Conclusion: The academic detailing model improved the physicians abilities to correctly detect 
lumps in a silicone breast model 
 
72  Academic Detailing – Supplement KCE reports 125 
 
 





Berings D, Blondeel L, Habraken H. The effect of industry-independent drug information on the 
prescribing of benzodiazepines in general practice. Eur J Clin Pharmacol. 1994;46(6):501-5. 
Quality appraisal score " 9/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To measure the effect of industry-independent information on the prescribing 
of benzodiazepines in general practice 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Other: general population 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescription behaviour of benzodiazepines 
Who does academic detailing # Nurse 
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" Physician: GENERAL PRACTITIONER 
# Pharmacist 
# Other 
Interventions " INTERVENTION I:  oral and written  information about the indications and 
limitations of benzodiazepines 
" INTERVENTION II: written information 
" CONTROL: No information at all 
 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
" Psycho-social outcomes: attitude of physicians about the value of oral drug 
information from an industry-independent source 
" Process outcomes: number of benzodiazepines prescribed per 100 patient 
contacts 
# Economic outcomes 
# Other: 
 
" Positive on: average decrease of 3% in control group and of 14% in physicians 
who received written information, and 24% in physicians who were given oral 
information + positive attitude towards the value of oral drug information from an 
industry-independent source 
 
# Negative on:  




74  Academic Detailing – Supplement KCE reports 125 
 
 




Bonds DE, Hogan PE, Bertoni AG, Chen H, Clinch CR, Hiott AE, et al. A multifaceted 
intervention to improve blood pressure control: The Guideline Adherence for Heart 
Health (GLAD) study. American Heart Journal. 2009;157(2):278-84. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective) 
# Before-after: 
# Time series: 
 
Objectives  
" To improve blood pressure control through a multifactorial intervention  
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with hypertension 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Blood pressure control 
Who does academic detailing # Nurse 
# Physician 
# Pharmacist 
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# Other 
" Not specified 
Interventions " INTERVENTION: initial educational session, paper copy of guidelines, four 1 
hour academic detailing sessions every 6 months, educational material for patients 
+ provider material (e.g. automatic blood pressure machines), feedback on the 
preintervention hypertension diagnosis and control levels for the practice 
" CONTROL: intervention to improve compliance to cholesterol, 4 academic 
detailing sessions every 6 months, feedback, educational material for both patients 
and providers about cholesterol management 
 
Multifaceted intervention? " YES 
Outcomes " Biological outcomes: medical co-morbidities, blood pressure values, recommendations 
of therapeutic life style changes, number of blood pressure medications. Key: mean SBP and 
DBP,  
# Psycho-social outcomes 
" Process outcomes: percent of patients at or below JNC 7 blood pressure goal; percent 
of patients with undiagnosed hypertension, intensification of therapy in those not at goal, and 
appropriate selection of initial therapy in those with newly diagnosed hypertension 
# Economic outcomes 
# Other: 
 
# Positive on: 
# Negative on:  
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Braybrook S, Walker R. Influencing prescribing in primary care: a comparison of two different 
prescribing feedback methods. J Clin Pharm Ther. 1996;21(4):247-54. 
Quality appraisal score " 9/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 




To evaluate two different methods of providing practice-based, antibiotic prescribing feedback 
to general practitioners. 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients who need antibiotics 
 
Caregiver targeted " Family physician (= general practitioner): 66 practices 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Antibiotic prescribing 
Who does academic detailing # Nurse 
# Physician 




Interventions " INTERVENTION: face-to-face prescribing discussion visits 
" INTERVENTION II: provision of practice specific prescribing analysis 
workbooks 
" CONTROL: NO INTERVENTION 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: antibiotic prescribing indicators (= medications) 
" Economic outcomes: costs 
# Other: 
 
" Positive on: changes in antibiotic prescribing indicators were greater in 
intervention compared to control group + reduced costs 
# Negative on:  
# No effect on: 
 
Conclusion: face-to-face visits proved most successful to influence GP prescribing, although 
the workbook promoted more change than seen in the control group. 
 
78  Academic Detailing – Supplement KCE reports 125 
 
 





Broadhurst NA, Barton CA, Rowett D, Yelland L, Matin DK, Gialamas A, et al. A before and 
after study of the impact of academic detailing on the use of diagnostic imaging for shoulder 
complaints in general practice. BMC Family Practice. 2007;8(12). 
Quality appraisal score " 9/14 
Country # Europe 
# US 
# Canada 
"  Australia 
# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
" Before-after 
# Time series: 
 
Objectives " To assess the impact of AD on GP’s use of diagnostic imaging for shoulder 
complaints in general practice and their knowledge and confidence to manage 
shoulder pain. 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" People with shoulder pain 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Use of diagnostic imaging for shoulder complaints in general practice and their 
knowledge and confidence to manage shoulder pain. 
Who does academic detailing # Nurse 
# Physician 
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# Pharmacist 
" Other: specialist 
Interventions " INTERVENTION: AD + clinical guidelines + video/DVD on how to examine the 
shoulder, 1 session, lasting 30 to 60 minutes 
# CONTROL: NA 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: requests for ultrasound imaging, knowledge about 
identifying and managing shoulder problems  
" Economic outcomes 
# Other: 
 
" Positive on: requests for ultrasound imaging decreased significantly after six 
months of AD + knowledge and confidence 
# Negative on:  
" No effect on: no effect on the rate of requests over time in the control groups 
 
Conclusion: AD together with education materials and guidelines can improve GPs’ knowledge 
and confidence to manage shoulder problems and reduce the use of imaging, at least in the 
short term. 
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Brown JB, Shye D, McFarland BH, Nichols GA, Mullooly JP, Johnson RE. Controlled trials of 
CQI and academic detailing to implement a clinical practice guideline for depression. Jt 
Comm J Qual Improv. 2000;26(1):39-54. 
Quality appraisal score " 12/14 
Country # Europe 
" US: US (Portland, Oregon) 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To evaluate  the effectiveness of two clinical practice guidelines implementation methods 




Setting  " Physician’s office 
# Primary care clinic 
" Other (specify): HMO 
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with depression: 928 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted # Guideline adherence for the management of depression 
Who does academic detailing # Nurse 





Interventions " INTERVENTION: AD (4 visits) containing three primary messages on the 
management of depression + educational materials + guideline + Continuous 
Quality Improvement Team (CQI)= multidisciplinary team implementing guideline 
on depression 
" CONTROL: usual care 
 
Multifaceted intervention? " YES 
Outcomes " Biological outcomes: HSCL-D, receipt of depression treatment, score of SF-36  
# Psycho-social outcomes 
" Process outcomes: clinician knowledge, attitude and practices related to the 
detection and treatment of depression 
" Economic outcomes: dispensing of antidepressant medication 
# Other: 
 
" Positive on: number of antidepressants 
" Negative on: deterioration in self-reported physical functioning and vitality, 
more depressive cohort patients of control physicians improved compared to 
patients of AD-exposed patients 
" No effect on: no changes in mean depression symptoms 
 
Conclusion: New organizational structures may be necessary before CQI and AD detailing can 
change complex processes such as the primary care of depression. 
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Browner WS, Baron RB, Solkowitz S, Adler LJ, Gullion DS. Physician management of 
hypercholesterolemia. A randomized trial of continuing medical education. West J Med. 
1994;161(6):572-8. 
Quality appraisal score " 11/14 
Country # Europe 
" US: San Francisco 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To determine the effect of continuing medical education (CME) on compliance 
with the recommendations of the National Cholesterol Education Program expert 
Panel on high serum cholesterol levels in adults. 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with high serum cholesterol levels 
 
Caregiver targeted " Family physician (= general practitioner): 174 practices in three groups 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Compliance with recommendations of the National Cholesterol Education 
Program expert Panel on high serum cholesterol levels in adults. 
 
Who does academic detailing # Nurse 





" Not specified 
Interventions " INTERVENTION I: three-hour seminar on high serum cholesterol levels + 
follow-up seminars and free official materials + AD (not specified how many or 
intensity) + follow-up seminars 
" INTERVENTION II: three-hour seminar on high serum cholesterol levels 
" CONTROL: seminar on hypercholesterolemia + educational materials 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: proportion of patients whose management complied to the 
NCEP guidelines = Screening for total cholesterol, determination of LDL-
cholesterol, treatment of elevated LDL-cholesterol level, screening for 
hypercholesterolemia, treatment, follow-up for high serum cholesterol levels, 
measurements of HDL-cholesterol and triglyceride 
# Economic outcomes 
# Other: 
 
# Positive on: 
# Negative on:  
" No effect on: no significant differences in screening for high serum cholesterol 
or compliance with guidelines between the groups receiving CME and the control 
group. There was a trend toward a modest benefit from the CME interventions. 
 
Conclusion: No significant effects measured. 
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Coenen S, Van Royen P, Michiels B, Denekens J. Optimizing antibiotic prescribing for acute 
cough in general practice: a cluster-randomized controlled trial. J Antimicrob Chemother. 
2004;54(3):661-72. 
Quality appraisal score " 11/14 




# Asia (specify) 
 
Initiator "  Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
" Before-after: (clustered –randomized before-after) 
# Time series: 
 
Objectives " To assess the effect of a tailored professional intervention including AD on 
antibiotic prescribing for acute cough 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients (adults) who need antibiotics for acute cough 
 
Caregiver targeted " Family physician (= general practitioner): 85 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Antibiotics prescribing for acute cough 
Who does academic detailing # Nurse 
# Physician 
" Pharmacist  
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# Other 
Interventions " INTERVENTION: booklets and leaflets of a public campaign + a clinical 
practice guideline for the management of acute cough (no specification on duration 
of AD!), an educational outreach visit + materials+ and a postal reminder of the key 
messages 
" CONTROL: no intervention 
 
Multifaceted intervention? " YES 
Outcomes " Biological outcomes: patients’ symptom resolution due to change in antibiotic 
prescribing 
# Psycho-social outcomes 
" Process outcomes: antibiotics prescribing rates + type of antibiotics prescribed 
" Economic outcomes: medication cost per patient from a public perspective 
# Other: 
 
" Positive on: Less prescribing in intervention group + prescribed antibiotics 
more in line with guideline in intervention group and less expensive from public 
perspective 
# Negative on:  
" No effect on: patients’ symptom resolution 
 
Conclusion: A tailored intervention implementing a guideline for acute cough is successful in 
optimizing antibiotic prescribing without affecting patients’ symptom resolution. 
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Cranney M, Barton S, Walley T. Addressing barriers to change: an RCT of practice-based 
education to improve the management of hypertension in the elderly. Br J Gen Pract. 
1999;49(444):522-6. 
Quality appraisal score " 9/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To establish whether an exploration of barriers to change can enhance the 
effectiveness of an educational intervention designed to improve the management 
of hypertension in the elderly 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Elderly with hypertension 
 
Caregiver targeted " Family physician (= general practitioner): 76 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Treating systolic hypertension in the elderly (patient aged 70 to 79 years) 
Who does academic detailing # Nurse 
# Physician 
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# Pharmacist 
" Other: researcher 
Interventions " INTERVENTION: semi-structured vist (one hour) in small groups with 
feedback and audit results, exploration of participants views on the significance of 
the results, discussion of the evidence-base for the treatment of hypertension in the 
elderly, exploration of current practice concerning hypertension management, 
identification of potential barriers to change, creation of a practice action plan to 
address the above issues, discussion on how an audit might be performed 
" CONTROL: all above but without identification of potential barriers to change, 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: management of systolic hypertension and a specific patient 
scenario 
# Economic outcomes 
# Other: 
 
" Positive on: significant difference in the stated threshold for treating systolic 
hypertension between intervention and control + difference in the willingness to 
treat patient (case) with mild hypertension 
# Negative on:  
# No effect on: 
 
Conclusion: The effectiveness of an educational intervention is significantly improved by 
addressing the barriers preventing GPs from implementing findings of research. 
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DE BURG, 1995 
 
de Burgh S, Mant A, Mattick RP, Donnelly N, Hall W, Bridges-Webb C. A controlled trial of 
educational visiting to improve benzodiazepine prescribing in general practice. Aust J Public 
Health. 1995;19(2):142-8. 
Quality appraisal score " 11/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To evaluate the effect of educational practice visiting on benzodiazepine 
prescribing in patients with anxiety 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with anxiety 
 
Caregiver targeted " Family physician (= general practitioner): 286 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Benzodiazepine prescribing in patients with anxiety 
 
#  
Who does academic detailing # Nurse 





Interventions " INTERVENTION: educational visit (20 minutes, receptive educational 
approach) + educational materials= guidelines + a patient review card + access to 
relaxation audio tapes and video series on sleep + a follow-up call 
" CONTROL:  
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: benzodiazepine prescribing rate, axiety and insomnia 
diagnosis rates 
# Economic outcomes 
# Other: 
 
" Positive on: when comparing the intervention arms, benzodiazepine 
prescribing rate, axiety and insomnia diagnosis rates declined significantly, also 
initial prescription rates, differential downward trend in c per insomnia diagnosis, 
but not to a statistical level. 
 
# Negative on:  
" No effect on: prescribing for anxiety diagnosis. 
 
Conclusion: Although positive effects were noted, AD is not justified in an unselected 
population of GP’s. 
 
90  Academic Detailing – Supplement KCE reports 125 
 
 






Dey P, Simpson CW, Collins SI, Hodgson G, Dowrick CF, Simison AJ, et al. Implementation of 
RCGP guidelines for acute low back pain: a cluster randomised controlled trial. Br J Gen 
Pract. 2004;54(498):33-7. 
Quality appraisal score " 12/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To investigate the impact on patient management of an educational strategy 
to promote guidelines for the management of low back pain in primary care 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients (adults) with low back pain 
 
Caregiver targeted " Family physician (= general practitioner): 54 general practices 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Medical management of low back pain in adults= rate of referral for lumbar 
spine X-rays, issuing of sickness certification, referral to secondary care and 
prescription of muscle relaxants and opioid analgesics. 
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Who does academic detailing # Nurse 
# Physician 
# Pharmacist 
" Other: senior representatives, health authority 
Interventions " INTERVENTION: outreach visits to promote national guidelines + access to 
fast-track physiotherapy and to a triage service for patients with persistent 
symptoms. Ad included raising awareness on guidelines, emphasise key messages in 
guidelines, identify potential barriers to implementation and suggesting strategies 
to overcome barriers identified + posters  
# CONTROL: no visit from guidelines team and no direct access to the back clinic 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: rate of referral for lumbar spine X-rays, issuing of sickness 
certification, referral to secondary care and prescription of muscle relaxants and 
opioid analgesics. 
# Economic outcomes 
# Other: 
 
" Positive on: significant differences between study groups for referral to 
physiotherapists or the back pain unit 
# Negative on:  
" No effect on: no significant differences between study groups in proportion of 
patients who were referred for X-ray, issued with a sickness certificate, prescribed 
opioids or muscle relaxants, or were referred to secondary care. 
 
 
Conclusion: Management of low back pain mostly unchanged by AD, but an increase in referral 
to physiotherapy and back pain unit. 
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DE SANTIS, 1994 
 
De Santis G, Harvey KJ, Howard D, Mashford ML, Moulds RF. Improving the quality of antibiotic 
prescription patterns in general practice. The role of educational intervention. Med J Aust. 
1994;160(8):502-5. 
Quality appraisal score " 9/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To assess the quality of antibiotic prescribing by GPs and the effectiveness of 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients (adults) who need antibiotics for tonsillitis 
 
Caregiver targeted " Family physician (= general practitioner): 182 (104 intervention, 78 control) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Improving prescribing of antibiotics for tonsillitis. 
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Interventions " INTERVENTION: 3-month educational mailing campaign (brochure) + five 
mailings) + AD by pharmacist (intensity not specified!) 
# CONTROL: no intervention 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: the percentage of prescriptions of antibiotics for tonsillitis 
complying with those recommended in antibiotic guidelines 
# Economic outcomes 
# Other: 
 
" Positive on: when comparing the interventions groups, prescriptions consistent 
with recommendations in the guidelines increased 
# Negative on:  
# No effect on: 
 
Conclusion: The educational campaign significantly improved the prescribing of appropriate 
antibiotics for tonsillitis by GPs 
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Eccles MP, Steen IN, Whitty PM, Hall L. Is untargeted educational outreach visiting delivered by 
pharmaceutical advisers effective in primary care? A pragmatic randomized controlled trial. 
Implement Sci. 2007;2:23. 
Quality appraisal score " 11/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (pragmatic cluster randomized controlled trial) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate the effectiveness of routine outreach on the prescription of cost-
effective antidepressants in primary care. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients who need antidepressants for the treatment of depression 
 
Caregiver targeted " Family physician (= general practitioner): 73 practices—36 intervention, 37 
control. 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescription of cost-effective antidepressants in primary care. 
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Who does academic detailing # Nurse 
# Physician 
" Pharmacist (trained in educational outreach) 
# Other 
Interventions " INTERVENTION: AD (two visits), and GPs from the same practice were seen 
together) including use of guidelines, exploration of knowledge and patterns of 
current activity, offering clear behavioural objectives, acknowledged areas of 
controversy + educational materials including key messages from guidelines.  
" CONTROL: Distribution of guidelines through courier or postal system 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: prescribing of antidepressant drugs during intervention and 
12 months after intervention. 
# Economic outcomes 
# Other: 
 
# Positive on: 
# Negative on:  
" No effect on: When comparing the study groups, there was no significant 
impact of the intervention on usage of antidepressants. 
 
Conclusion: Untargeted educational outreach may not be a worthwhile strategy. 
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Epstein JN, Langberg JM, Lichtenstein PK, Mainwaring BA, Luzader CP, Stark LJ. Community-
wide intervention to improve the attention-deficit/hyperactivity disorder assessment and 
treatment practices of community physicians. Pediatrics. 2008;122(1):19-27. 
Quality appraisal score " 7/14 
Country # Europe 
" US (Cincinnati) 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
" Before-after: 
# Time series: 
 
Objectives  
" To implement and test a quality-improvement intervention aimed at 
improving community-based primary care providers’ adherence to the American 
Academy of Pediatrics, evidence-based diagnostic and treatment guidelines for 
attention-deficit/hyperactivity disorder (ADHD) 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 




Caregiver targeted " Family physician (= general practitioner): 55 practices and 202 GPs. 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Improving community-based primary care providers’ adherence to the 
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American Academy of Pediatrics, evidence-based diagnostic and treatment 
guidelines for attention-deficit/hyperactivity disorder (ADHD) 
 




Interventions " INTERVENTION: Four post-graduate sessions + AD (1-hour) including: 
incorporation of evidence-based guidelines + feedback + performance improvement 
techniques including small tests of change or plan-do-study-act cycles + tools 
including ADHD rating scales, practices were thaught to use a patient log to track 
progress of patient, a written care management plan, scripts for assessing 
medication responses during telephone interviews with parents + parent handouts 
describing ADHD/treatment + algorithm for making ADHD referrals to 
behavioural health specialists. 
# CONTROL: NA 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: use of guidelines for the assessment and treatment of 
ADHD, use of parent and teacher assessment rating scales and systematic 
monitoring of responses to medication. 
# Economic outcomes 
# Other: 
 
" Positive on: After intervention, GPs showed substantial improvement in the 
use of guidelines for the assessment and treatment of ADHD. Use of parent and 
teacher assessment rating scales increased significantly. Systematic monitoring of 
responses to medication improved. 
# Negative on:  
# No effect on: 
 
Conclusion: Multifaceted QI intervention effective on quality of care for children with ADHD. 
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Etter J-F. Impact of educational outreach visits on smoking cessation activities performed by 
specialist physicians: a randomized trial. EDUC HEALTH. 2006;19(2):155-65. 
Quality appraisal score " 9/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (post-test only) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To examine of educational visits by a nurse to specialist physicians improved 
the self-reporting of smoking cessation activities, whether these visits increased the 
percentage of physicians who were aware of and recommended a computer-
tailored smoking cessation program and who participated in a training workshop on 
tobacco dependency treatment. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Adults who smoke 
 
Caregiver targeted " Family physician (= general practitioner) ---523 physicians in total with 261 
intervention and 262 control. 
" Specialists: internists, cardiologists, pneumologists and surgeons  
# Type of physician not specified 
 
KCE Reports 125 Academic Detailing – Supplement 99 
 
Behavior targeted " Self-reporting of smoking cessation activities, recommending a computer-
tailored smoking cessation program and participation at a training workshop on 
tobacco dependency treatment 




Interventions " INTERVENTION: One 40-minute visit by nurse (former medical sales 
representative) including: guidelines and answering questions from physicians + 
presentation of computer-based smoking cessation program. 
# CONTROL: no intervention 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: percentage of patients the physicans counselled or treated 
for tobacco dependency and number of physicians who took part in a workshop. 
# Economic outcomes 
# Other: 
 
" Positive on: when comparing the intervention groups, the proportion of 
physicians who recommended to their patients the use of computer-tailored 
smoking cessation program increased + the proportion of patients who received 
the advice to quit smoking increased 
# Negative on:  
" No effect on: The intervention had no impact on the physicians’ participation in 
the workshop. 
 
Conclusion: AD positively influences the number of recommendations to use computer 
smoking cessation program + advice to quit smoking. 
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Feder G, Griffiths C, Highton C, Eldridge S, Spence M, Southgate L. Do clinical guidelines 
introduced with practice based education improve care of asthmatic and diabetic patients? 
A randomised controlled trial in general practices in east London. BMJ. 
1995;311(7018):1473-8. 
Quality appraisal score " 11/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (cross-over design) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To determine whether locally developed guidelines on asthma and diabetes 
disseminated through practice based education improve quality of care in non-
training general practices. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients (adults) with asthma and/or diabetes 
 
Caregiver targeted " Family physician (= general practitioner): 27 practices 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescribing in asthma, review of inhaler technique, review of asthma 
symptoms, glycaemic control, funduscopy, feet examination, weight, smoking habit, 
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use of structured consultation ‘prompts’ 
 




Interventions " INTERVENTION: AD: 3 post-graduate education sessions +  guideline 
discussion + practice protocol for implementing guidelines + prompts + practical 
discussion on home urine monitoring or peak flow measurement + inhaler 
technique + audit + analysis of coping with implementing guidelines 
# CONTROL: (cross-over design) 
 
Multifaceted intervention? " YES 
Outcomes " Biological outcomes: asthma—peak flow rate, prophylaxis, occupation and 
smoking habit/ diabetes: blood glucose concentration 
# Psycho-social outcomes 
" Process outcomes: prescribing in asthma, review of inhaler technique, review 
of asthma symptoms, glycaemic control, funduscopy, feet examination, weight, 
smoking habit, use of structured consultation ‘prompts’ 
" Economic outcomes 
" Other: size of practice disease registers 
 
" Positive on: improvements in all seven diabetes variables (see above), 
improved recording of review of inhaler technique, smoking habit, and review of 
asthma symptoms, quality of prescribing in asthma. The use of structured prompts 
was associated with improved recording of four of seven variables on diabetes and 
all six variables on asthma. 
# Negative on:  
" No effect on: sizes of disease registers were unchanged 
 
Conclusion: Practice-based education on the use of guidelines improves the management of 
diabetes and asthma in non training practices. The use of prompts may enhance this 
improvement. 
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Feldstein AC, Smith DH, Perrin N, Yang X, Simon SR, Krall M, et al. Reducing warfarin 
medication interactions: an interrupted time series evaluation. Arch Intern Med. 
2006;166(9):1009-15. 
Quality appraisal " 9/14 




# Asia (specify) 
 
Initiator " Nonprofit group model HMO 
Design # RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
" Time series 
 
Objectives  
To measure the effectiveness of electronic medical record alerts and group academic detailing 
to reduce the coprescribing of Warfarin and interacting medications. 
 
 
Setting  # Physician’s office 
" Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients taking WARFARIN 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescription of Warfarin 
Who does academic detailing # Nurse 





Interventions " INTERVENTION: electronic medical record alerts and group academic 
detailing (8 clinics) 
" CONTROL: group academic detailing (7clinics) 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: the number of coprescriptions of warfarin-interacting 
medications per 10000 Warfarin users per month) 
# Economic outcomes 
# Other: 
 
" Positive on: reduction in the rate of Warfarin-interacting medication 
prescription 
# Negative on:  
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Figueiras A, Sastre I, Tato F, Rodriguez C, Lado E, Caamano F, et al. One-to-one versus group 
sessions to improve prescription in primary care: a pragmatic randomized controlled trial. 
Med Care. 2001;39(2):158-67. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
" Controlled study (prospective/retrospective): pragmatic controlled trial 
# Before-after: 
# Time series: 
 
Objectives  
"  To evaluate the effectiveness of two educational strategies aimed at 
improving prescribing standards on NSAID in primary care 
  
 
Setting  "  Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
"  Patients (adults) with osteoarthrosis with inflammation signs needing NSAIDs 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescribing standards on NSAID 
Who does academic detailing # Nurse 
# Physician 
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" Pharmacist (doctoral level) 
# Other 
Interventions " INTERVENTION I: AD (20 minutes): one-to-one education group (n= 98): 
relevant articles + reminder 
" INTERVENTION II: a by-group education group (n= 92): 45 minutes by-group 
education 
" CONTROL: n= 405 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: number of prescribed units of NSAIDs during intervention 
# Economic outcomes 
# Other: 
 
" Positive on: prescribing behaviour improvement in case of one-to-one 
education in the 9 months after intervention. In the education group improvement 
was also noted, but significant more improvement in one-to-one education group. 
Reminder increased significantly the effectiveness of the one-to-one intervention. 
# Negative on:  
# No effect on: 
 
Conclusion: proscribing standards can be improved through educational sessions with one-to-
one education to be most effective. 
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Figueiras A, Herdeiro MT, Polonia J, Gestal-Otero JJ. An educational 
intervention to improve physician reporting of adverse drug reactions: a 
cluster-randomized controlled trial. JAMA. 2006;296(9):1086-93. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (cluster randomized trial) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate the effectiveness of educational outreach visits for improving 
adverse drug reaction (ADR) reporting in physicians. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Not specified (not applicable) 
 
Caregiver targeted " Family physician (= general practitioner): 1388 intervention (4 clusters); 5063 
control (11 clusters) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Adequate reporting of ADRs 
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Interventions " INTERVENTION: 1 hour and 2-part session =AD (outreach visit) + reminder 
card + report form---but provided in groups of 10 to 20 physicians! Special focus on 
attitudes associated with underreporting + educational materials (essential 
messages on ADRs) 
# CONTROL:  
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: reporting of ADRs 
# Economic outcomes 
# Other: 
 
" Positive on: increase in ADR reporting rates attributable to intervention for 
total ADRs, serious ADRs, high causality ADRs and unexpected ADRs for new 
drugs-related ADRs with the greatest difference to occur 4 months after 
intervention, and differences to remain statistically significant for 12 months. 
# Negative on:  
# No effect on: 
 
Conclusion: A targeted outreach program may improve high-quality reporting of ADRs among 
physicians. 
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Franzini L, Boom J, Nelson C. Cost-effectiveness analysis of a practice-based 
immunization education intervention. Ambul Pediatr. 2007;7(2):167-75. 
Quality appraisal score " 7/14 
Country # Europe 
" US: Houston 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Not specified 
Design " RCT—pre-intervention/post-intervention study 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To improve immunization coverage in communities through the 





Setting  " Physician’s office 
# Primary care clinic 
# Other 
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Children needing immunization aged 12-23 months 
 
Caregiver targeted " Family physician (= general practitioner): 189 practices 
" Specialist (paediatric) 
# Type of physician not specified 
 
Behavior targeted " Improving immunization coverage 
Who does academic detailing # Nurse 
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" Physician + team 
# Pharmacist 
# Other 
Interventions " INTERVENTION: Peer-based  (1-hour) educational lunch presentation (not-
one-to-one) with three topics + educational materials + recinforcements every 
months (during six months) 
# CONTROL:  
 
Multifaceted intervention? " YES 
Outcomes " Biological outcomes: immunization rates of children aged 12-23 months 
# Psycho-social outcomes 
" Process outcomes: self-reported provider behaviours (11 items)   
aged 12-23 months 
" Economic outcomes: cost of the intervention 
# Other: 
 
" Positive on: improvements of self-reported provider behavior 
" Negative on: costs—no favourable cost-benefit ratio 
" No effect on: Immunization rates 
 
Conclusion: the costs for one child with up-to-date immunization status are higher than 
potential societal savings. 
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Freemantle N, Nazareth I, Eccles M, Wood J, Haines A, Evidence-based 
OutReach t. A randomised controlled trial of the effect of educational 
outreach by community pharmacists on prescribing in UK general 
practice. Br J Gen Pract. 2002;52(477):290-5. 
Quality appraisal score " 12/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT: cross-over block design 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate the effectiveness of AD in primary care practices in implementing 
4 evidence-based guidelines. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Adults needing ACE inhibitors, raised cardiovascular risk patients needing 
aspirin, NSAIDs needing patients with joint pain, patients needing antidepressants. 
 
Caregiver targeted " Family physician (= general practitioner): four practices 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Adherence to guidelines: prescription 
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Interventions " INTERVENTION: AD (4 practice visits) including role-play and practice 
orientation, guideline discussion, investigation of potential barriers to change + 
incentive= audit at the end of project. 
# CONTROL:  
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: prescription of ACE inhibitors with loop diuretics to 
patients suffering from heart failure, aspirin, NSAIDs and antidepressants. 
# Economic outcomes 
# Other: 
 
" Positive on: AD was associated with a significant improvement in prescribing 
practice and an increase in the number of patients treated within the guideline 
recommendations. 
# Negative on:  
# No effect on: 
 
Conclusion: There is good evidence to support the use of educational outreach in small 
practices. 
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Fretheim A, Oxman AD, Havelsrud K, Treweek S, Kristoffersen DT, Bjorndal 
A. Rational prescribing in primary care (RaPP): a cluster randomized trial 
of a tailored intervention. PLoS Med. 2006;3(6):e134. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients needing antihypertensive medication (only those patients were 
included in the cost-effectiveness study) 
 
Caregiver targeted " Family physician (= general practitioner): intervention= 69 practices and 244 
physicians; Control= 70 practices and 257 physicians. 
# Specialist 
# Type of physician not specified 
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Behavior targeted " Prescription of hypertensive drugs according to guidelines 




Interventions " INTERVENTION: AD + audit+ feedback + computerized reminders linked to 
the medical record system 
# CONTROL:  
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: a) proportions of first-time prescriptions for hypertension 
where thiazides were prescribed + b) patients assessed for cardiovascular risk 
before prescribing antihypertensive or cholesterol-lowering drugs, c) patients 
treated for hypertension or hypercholesterolemia for 3 months or more who had 
achieved recommended treatment goals. 
# Other: 
 
" Positive on: Significant shift in prescribing of hypertensive drugs towards the 
use of thiazides,   
# Negative on:  
" No effect on: Little or no differences were found for risk assessment prior to 
prescribing and for achievement of treatment goal. 
 
Conclusion: intervention had a significant impact on prescribing hypertensive drugs, but was 
ineffective in improving the quality of other aspects of managing hypertension and 
hypercholesterolemia in primary care. 
114 Academic Detailing – Supplement KCE reports 125 
 
 







Fretheim A, Aaserud M, Oxman AD. Rational prescribing in primary care 
(RaPP): economic evaluation of an intervention to improve professional 
practice. PLoS Med. 2006;3(6):e216. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  




Setting  # Physician’s office 
# Primary care clinic 
# Other (specify):  
Not applicable 
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients needing antihypertensive medication (only those patients were 
included in the cost-effectiveness study) 
 
Caregiver targeted " Family physician (= general practitioner): intervention= 69 practices and 244 
physicians; Control= 70 practices and 257 physicians. 
# Specialist 
# Type of physician not specified 
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Behavior targeted " Prescription of hypertensive drugs according to guidelines 




Interventions " INTERVENTION: AD + audit+ feedback + computerized reminders 
# CONTROL:  
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
# Process outcomes 
" Economic outcomes: cost-effectiveness of the intervention 
# Other: 
 
" Positive on: Significant shift in prescribing of hypertensive drugs towards the 
use of thiazides, and thus cost-lowering effects predicted over a two year period.  
# Negative on:  
# No effect on: 
 
Conclusion: The cost of the intervention was more than twice the savings within the time 
frame of the study. Modest savings were predicted. 
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Frijling BD, Lobo CM, Hulscher ME, Akkermans RP, van Drenth BB, Prins A, et 
al. Intensive support to improve clinical decision making in cardiovascular 
care: a randomised controlled trial in general practice. Qual Saf Health 
Care. 2003;12(3):181-7. 
Quality appraisal score " 11/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To evaluate the effects of outreach visits combined with feedback reports on 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
" Heart failure + hypertension, hypercholesterolemia and angina pectoris 
# Neurodegenerative diseases 
# Respiratory diseases 
 
 
Caregiver targeted " Family physician (= general practitioner): 124 practices 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Compliance rates for 12 evidence-based indicators for the management of 
patients with hypertension, hypercholesterolemia, angina pectoris or heart failure. 
Who does academic detailing # Nurse 




" Other: non physicians not specified 
Interventions " INTERVENTION: outreach visits (7) including discussion of feedback reports, 
selection of clinical issues for improvement, selection of methods to achieve 
change, provision of materials and advice, provision of a reminder and evaluation. 
" CONTROL: no intervention 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: assessment of risk factors in patients with 
hypercholesterolemia, angina pectoris, hypertension and heart failure. 
# Economic outcomes 
# Other: 
 
" Positive on: significant improvement when comparing the intervention arms 
was found for: the assessment of risk factors in patients with hypercholesterolemia 
and angina pectoris, provision of information and advice to patients with 
hypercholesterolemia and hypertension, checking for clinical signs of deterioration 
in patients with heart failure. 
# Negative on:  
# No effect on: 
 
Conclusion: Intensive support from trained non-physicians can alter certain aspects of the 
clinical decision making of GPs in cardiovascular care, although the effect is small. 
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Gandjour A, Lauterbach KW. How much does it cost to change the behavior 
of health professionals? A mathematical model and an application to 
academic detailing. Medical Decision Making. 2005;25(3):341-7. 
 
 
Quality appraisal score # Not applicable 




# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
" Other: mathematical model 
 
Objectives " To portray the mathematical relationship between the proportion of patients 
who lack appropriate care due to non-compliance of health professionals and the 




Setting  # Physician’s office 
# Primary care clinic 
" Other (specify): NA 
 
Population targeted # Cancer 
" Heart failure: coronary heart failure (hypertension) 
# Neurodegenerative diseases 




Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
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Behavior targeted " Prescription of antihypertensive drugs 
Who does academic detailing # Nurse 
# Physician 
# Pharmacist 
" Other: not specified 
Interventions " INTERVENTION: outreach visits to improve prescription 
# CONTROL:  
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
# Process outcomes 
" Economic outcomes 
# Other: 
 
# Positive on: 
# Negative on:  
# No effect on: 
 
Conclusion: Marginal implementation costs are directly proportional to the natural logarithm 
of the size of the current quality deficit. If outreach educators were to visit all primary care 
physicians in Germany to improve the prescription of hypertensive drugs, the annual 
implementation cost would total 238 EUR million, or 0,2% of the health insurance total budget 
(same goes for coronary heart disease).  Implementation costs may not have a critical impact on 
the cost-effectiveness ratio of preventive services through AD. 
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Goldberg HI, Wagner EH, Fihn SD, Martin DP, Horowitz CR, Christensen DB, 
et al. A randomized controlled trial of CQI teams and academic detailing: 
can they alter compliance with guidelines? Jt Comm J Qual Improv. 
1998;24(3):130-42. 
Quality appraisal score " 12/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To determine the effectiveness of AD techniques and continuous quality 
improvement teams in increasing compliance with national guidelines for the 




Setting  # Physician’s office 
" Primary care clinic (four primary care clinics) 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with hypertension and depression 
 
Caregiver targeted " Family physician (= general practitioner): 15 small group practices 
# Specialist 
# Type of physician not specified 
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#  




Interventions " INTERVENTION: AD (15 minutes) by physician + educational materials + 
follow-up sessions by pharmacists during which computer-generated profiles 
comparing provider prescribing patterns 
" INTERVENTION: AD  +  CQI teams 
" CONTROL:  usual care 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: percentage of depressives prescribed first-generation 
tricyclics 
# Economic outcomes 
# Other: 
 
" Positive on: percentage of depressives prescribed first-generation tricyclics 
increased 
# Negative on:  
" No effect on: CQI-teams and AD in combination 
 
Conclusion: The AD techniques and the CQI teams evaluated were generally 
ineffective in improving guideline compliance and clinical outcomes regarding the 
primarycare of hypertension and depression. 
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Gomel MK, Wutzke SE, Hardcastle DM, Lapsley H, Reznik RB. Cost-effectiveness of 
strategies to market and train primary health care physicians in brief intervention 
techniques for hazardous alcohol use. Soc Sci Med. 1998;47(2):203-11. 
Quality appraisal score " 10/14 
Country # Europe 
# US 
# Canada 
" Australia: Sydney 
# Asia (specify) 
 
Initiator "  Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives "  To evaluate the cost-effectiveness of an intervention targeting GPs in 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" People with hazardous alcohol consumption 
 
Caregiver targeted " Family physician (= general practitioner): 127 + 34 control 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Management of hazardous alcohol consumption (screening and counselling 
rates) 
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Interventions " INTERVENTION: Training and no support for uptake of the “Drink-less 
package” (direct mail): 35 
" INTERVENTION: Training and minimal support for uptake of the “Drink-less 
package”  (tele-marketing): 45 + reminders 
" INTERVENTION: Training and maximal support for uptake of the “Drink-less 
package” –practice visits every two weeks (AD): 40 
" CONTROL: 42 (no training or support) 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: screening and counselling rates. 
" Economic outcomes: cost-effectiveness 
# Other: 
 
" Positive on: Update of the intervention package and recruitment rates better 
for AD compared to direct mail and tele-marketing. Tele-marketing was found to 
be more cost-effective than AD and direct mail in promoting the update of the 
package to improve screening and counselling for hazardous alcohol consumption. 
# Negative on:  
# No effect on: 
 
Conclusion: Tele-marketing was found to be more cost-effective than AD and 
direct mail in promoting the update of the package to improve screening and 
counselling for hazardous alcohol consumption. 
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Gonzales R, Steiner JF, Lum A, Barrett PH, Jr. Decreasing antibiotic use in 
ambulatory practice: impact of a multidimensional intervention on the 
treatment of uncomplicated acute bronchitis in adults. JAMA. 
1999;281(16):1512-9. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
" Controlled study (prospective) but non-randomized 
# Before-after 
# Time series: 
 
Objectives " To decrease total antibiotic use for uncomplicated acute bronchitis in adults 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with uncomplicated acute bronchitis 
 
Caregiver targeted " Family physician (= general practitioner): 56 physicians+ 2462 adults 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescription of antibiotics 
Who does academic detailing # Nurse 
# Physician 
# Pharmacist 
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" Not specified 
Interventions " INTERVENTION: AD (not clearly described) + household and office-based 
patient educational materials, education, practice profiling 
" INTERVENTION LIMITED: 
" CONTROL: office-based educational materials 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: antibiotic prescription rates, return office visits within 30 
days of the incident visit 
# Economic outcomes 
# Other: 
 
" Positive on: substantial decline in antibiotic prescription  rates in intervention 
group, but not at the control and limited intervention group.  
# Negative on:  
" No effect on: Return office visits within 30 days of the incident visit for 
bronchitis or pneumonia did not change significantly for any of the sites 
 
 
Conclusion: Antibiotic treatment of adults diagnosed with uncomplicated bronchitis can be 
reduced using a combination of patient and clinician interventions 
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Graham SD, Hartzema AG, Sketris IS, Winterstein AG. Effect of an academic 
detailing intervention on the utilization rate of cyclooxygenase-2 
inhibitors in the elderly. Ann Pharmacother. 2008;42(6):749-56. 
Quality appraisal score " 11/14 




# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
" Before-after: Retrospective cohort, before/after design 
# Time series: 
 
Objectives  
" To evaluate the effect of a GP targeted osteoarthritis AD intervention on a 
reduction in the prescribing of cyclooxygenase-2 (COX-2) inhibitors, as well as 
examine the intervention effect on the utilization rates of gastroprotective agents 
and medical services. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with osteoarthritis 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Reduction in the prescribing of cyclooxygenase-2 (COX-2) inhibitors, as well as 
examine the intervention effect on the utilization rates of gastroprotective agents 
and medical services. 
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Who does academic detailing " Nurse (1) 
# Physician 
" Pharmacist (3) 
# Other 
 
Interventions " INTERVENTION: AD (interactive) 
# CONTROL: usual care 
 
Multifaceted intervention? " NO 
Outcomes " Biological outcomes: patient morbidity and mortality 
# Psycho-social outcomes 
" Process outcomes: change in COX-2 utilization rates from baseline, office visits 
rates visits/patients, use of protein pump inhibitor, mesoprostol and histamine2-
receptor antagonist, GP office visits per patient, specialist office visits per patient 
and death rates per GP due to gastrointestinal complications 
# Economic outcomes 
# Other: 
 
" Positive on: The osteoarthritis AD intervention was associated with a 
significant decrease in COX-2 utilization rates in the 3-month period immediately 
following the intervention. 
# Negative on:  
" No effect on: measures of patient morbidity and mortality due to 
gastrointestinal complications 
 
Conclusion: AD yield both positive outcomes and no outcomes. 
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Griffiths C, Foster G, Barnes N, Eldridge S, Tate H, Begum S, et al. Specialist 
nurse intervention to reduce unscheduled asthma care in a deprived 
multiethnic area: the east London randomised controlled trial for high risk 
asthma (ELECTRA). BMJ. 2004;328(7432):144. 
Quality appraisal score " 12/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (cluster RCT) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To determine whether asthma specialist nurses using a liaison model of care 
reduce unscheduled care in a deprived multiethnic area. 
 
 
Setting  " Physician’s office 
" Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
" Respiratory diseases: asthma 
 
Caregiver targeted " Family physician (= general practitioner): 44 practices 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Unscheduled care for asthma patients 
Who does academic detailing " Nurse (asthma specialist nurses) 
# Physician 




Interventions " INTERVENTION: patient review in a nurse-led clinic and liaison with GPs 
comprising: educational outreach (= AD, not well described), promotion of 
guidelines, and ongoing clinical support. 
" CONTROL: a visit promoting standard asthma guidelines, and control patients 
where checked for inhaler technique. 
 
Multifaceted intervention? " YES 
Outcomes " Biological outcomes: rates of attendance for unscheduled care, self-
management behaviour, asthma symptoms 
" Psycho-social outcomes: quality of life 
" Process outcomes: percentage of participants attending for unscheduled 
asthma care and the time to first attendance for unscheduled asthma care in the 
year after intervention. 
# Economic outcomes 
# Other: 
 
" Positive on: delayed time to first attendance when comparing intervention 
arms and reduction in the percentage of patients with acute asthma 
# Negative on:  
" No effect on: quality of life and self-management behaviour and asthma 
symptoms 
 
Conclusion: Asthma specialist nurses using a liaison model of care reduced unscheduled care 
for asthma. 
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Hall L, Eccles M, Barton R, Steen N, Campbell M. Is untargeted outreach 
visiting in primary care effective? A pragmatic randomized controlled 
trial. J Public Health Med. 2001;23(2):109-13. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To evaluate the effectiveness of untargeted outreach visiting in addition to 
postal distribution of educational materials. 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with helicobacter pylori 
 
Caregiver targeted " Family physician (= general practitioner): 38 practices 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Management of helicobacter pylori 
Who does academic detailing # Nurse 
# Physician 




Interventions " INTERVENTION: guidelines + AD (exploration of knowledge and patterns of 
current activity, behavioural objectives, acknowledged areas of controversy + 
educational materials + audit  
# CONTROL:  
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: prescription of three drugs 
# Economic outcomes 
# Other: 
 
" Positive on: significant increase in omeprazole and metronidazole use 
# Negative on:  
" No effect on: non-significant change in prescribing of dose units 
  
Conclusion: the routine use of untargeted outreach visiting is probably not a worthwhile 
strategy. 
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Hennessy S, Leonard CE, Yang W, Kimmel SE, Townsend RR, Wasserstein 
AG, et al. Effectiveness of a two-part educational intervention to improve 
hypertension control: a cluster-randomized trial. Pharmacotherapy. 
2006;26(9):1342-7 
Quality appraisal score "  13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT cluster randomized trial) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To measure the effectiveness of a multifaceted educational intervention to 
improve ambulatory hypertension control. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with hypertension 
 
Caregiver targeted " Family physician (= general practitioner); 39 intervention group, and 54 control 
group. 
# Specialist 
# Type of physician not specified 
 
Behavior targeted "  Ambulatory hypertension control. 
 
KCE Reports 125 Academic Detailing – Supplement 133 
 
Who does academic detailing # Nurse 
# Physician 
"  Pharmacist 
# Other 
Interventions "  INTERVENTION: AD (20-30 minutes session) + provider-specific audits= 
provider specific data about hypertension control, educational materials to the 
provider and the patient. 
"  CONTROL: no intervention 
 
Multifaceted intervention? "  YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
"  Process outcomes: proportion of patients achieving blood pressure control 
below 140/90 mmHg + secondary analysis in patients with diabetes or kidney 
disease—controlled hypertension: 130/80 mmHg 
# Economic outcomes 
# Other: 
 
# Positive on: 
# Negative on:  
"  No effect on: no effect or moderate effect among patients with hypertension. 
 
Conclusion: AD yield very little or no positive effects in this study. 
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Horn FE, Mandryk JA, Mackson JM, Wutzke SE, Weekes LM, Hyndman RJ. 
Measurement of changes in antihypertensive drug utilisation following 
primary care educational interventions. Pharmacoepidemiol Drug Saf. 
2007;16(3):297-308. 
Quality appraisal score #  
Country # Europe 
# US 
# Canada 
"  Australia: 
# Asia (specify) 
 
Initiator "   Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
"  Time series: with intervention implemented over a period of 6 to 8 months. 
 
Objectives " To measure changes in drug utilization following a national general practice education 




Setting  "   Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
"   Patients with hypertension 
 
Caregiver targeted "  Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Changes in drug utilization following a national general practice education 
program aimed at improving prescribing for hypertension. 
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Who does academic detailing # Nurse 
# Physician 
# Pharmacist 
" Not specified 
Interventions " INTERVENTION: newsletters+ prescribing feed-back, AD, clinical audit with 
feedback and case studies (paper-based and peer group discussion) over an 6 to 8 
months period. 
# CONTROL:  
# NA 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: use of thiazide or thiazide like diuretics at first line therapy 
for hypertension, use of low-dose formulations where thiazide diuretics were used, 
use of beta-blockers as first line therapy. 
# Economic outcomes 
# Other: 
 
" Positive on: increase in low-dose thiazide and beta-blocker prescribing.  
# Negative on:  
# No effect on: 
 
Conclusion: A national education program aimed at GPs is successful in improving prescribing 
for hypertension. 
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Hulscher ME, van Drenth BB, van der Wouden JC, Mokkink HG, van Weel C, 
Grol RP. Changing preventive practice: a controlled trial on the effects of 
outreach visits to organise prevention of cardiovascular disease. Qual 
Health Care. 1997;6(1):19-24. 
Quality appraisal score " 11/14 




# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
" Controlled study (prospective/retrospective): non randomized controlled trial 
# Before-after: 
# Time series: 
 
Objectives  
" To assess the effects of outreach visits by trained nurse facilitators on the 
organization of services used to prevent cardiovascular disease. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with cardiovascular disease 
 
Caregiver targeted " Family physician (= general practitioner): 95 general practices 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prevention of cardiovascular disease 
Who does academic detailing " Nurse 





Interventions " INTERVENTION: Outreach visits (multiple visits with a total of 30 hours with 
25 practice visits over an 18-month period; duration of one visit= 73 minutes) + 
practice feedback report + action plan for improvement + educational tools +  
" CONTROL: feedback 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: prevention of cardiovascular disease 
# Economic outcomes 
# Other: 
 
" Positive on: Outreach visits were more effective than feedback in 
implementing guidelines to organise prevention. The increase in the number of 
practices adhering to the guidelines was significant for six out of 10 guidelines 
# Negative on:  
" No effect on: the number of practices adhering to the guideline to make a 
follow up appointment did not reach significance 
 
Conclusion: Outreach visits by trained nurse facilitators proved to be effective in 
implementing guidelines within general practices. 
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Ilett KF, Johnson S, Greenhill G, Mullen L, Brockis J, Golledge CL, et al. 
Modification of general practitioner prescribing of antibiotics by use of a 
therapeutics adviser (academic detailer). Br J Clin Pharmacol. 
2000;49(2):168-73. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with upper and lower respiratory tract infections, otitis media and 
urninary tract infections. 
 
Caregiver targeted " Family physician (= general practitioner): 112; 56 intervention; 56 control 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Antibiotic prescribing by general practitioners 
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Interventions " INTERVENTION: AD (10-15 minutes) + educational materials (including 
guidelines) 
# CONTROL: usual care 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: total number of prescriptions for selected individual 
antibiotics 
" Economic outcomes: costs 
# Other: 
 
" Positive on: when comparing the interventions arms, GPs in the intervention 
group prescribed amoxicillin and doxycilline (complied to guidelines) + positive 
effect on total costs of antibiotics 
# Negative on:  
# No effect on: 
 
Conclusion: AD is successful in modifying prescribing patterns, and it also decreased 
prescription numbers and costs. 
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Jackson SL, Peterson GM, Vial JH. A community-based educational 
intervention to improve antithrombotic drug use in atrial fibrillation. Ann 
Pharmacother. 2004;38(11):1794-9. 
Quality appraisal score " 11/14 




# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
" Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To assess the effectiveness of AD in reducing the risk of stroke through the use 
of antithombotics in patients with atrial fibrillation 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with atrial fibrillation and an elevated risk to develop stroke 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Reducing the risk of stroke through the use of antithrombotics (Warfarin) in 
patients with atrial fibrillation 
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Interventions " INTERVENTION: AD + educational materials (guidelines) 
# CONTROL:  
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: prescription of Warfarin and aspirin 
# Economic outcomes 
# Other: 
 
" Positive on: when comparing intervention arms: increased use of Warfarin in 
patient at high risk of stroke. 
# Negative on:  
# No effect on: 
 
Conclusion: the educational program led to a significant increase in the prescribing of 
Warfarin for stroke prevention in patients with AF 
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Kim CS, Kristopaitis RJ, Stone E, Pelter M, Sandhu M, Weingarten SR. 
Physician education and report cards: do they make the grade? results 
from a randomized controlled trial. Am J Med. 1999;107(6):556-60. 
Quality appraisal score " 13/14 
Country # Europe 
" US (California) 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Kaiser Permanente woodland Hills 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To evaluate the effectiveness of a comprehensive QI program on the provision 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients needing immunization, mammography and clinical breast 
examination 
 
Caregiver targeted " Family physician (= general practitioner): 48 physicians 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Provision of preventive care services 
Who does academic detailing # Nurse 





Interventions " INTERVENTION: comprehensive intervention: educational reminders, peer-
comparison feedback + AD (= at beginning of study and after 6 and 12 months, 
duration of 15 minutes) 
" CONTROL: education only= mailed educational materials 
 
Multifaceted intervention? " YES 
Outcomes " Biological outcomes: rates of reported mammography 
# Psycho-social outcomes 
" Process outcomes 
# Economic outcomes 
" Other: number of patients who reported to have received preventive care 
services (influenza, pneumococcal, tetanus immunization, exercise counselling) 
 
" Positive on: positive evolution in the number of influenza, pneumococcal, and 
tetanus immunization in both intervention and control. Mammography and clinical 
breast examination worsened in the education group only. Patient satisfaction 
scores improved in intervention group, but no significant result 
# Negative on:  
# No effect on: 
 
Conclusion: multifaceted intervention has modest effects on patient satisfaction and possibly 
on the offering of selected preventive care services. 
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Lemelin J, Hogg W, Baskerville N. Evidence to action: a tailored multifaceted 
approach to changing family physician practice patterns and improving 
preventive care. CMAJ. 2001;164(6):757-63. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To evaluate the effectiveness of a multifaceted intervention on preventive 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients needing preventive actions 
 
Caregiver targeted " Family physician (= general practitioner): 23 practices intervention/ 23 
practices control 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Improved prevention: folic acid supplementation, smoking cessation and 
hypertension treatment 
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Interventions " INTERVENTION: guidelines + AD (21-50 times) with average visit length of 1 
hour and 45 minutes + audit and ongoing feedback + consensus building+ opnion 
leaders and network + reminders systems + patient-mediated activities + patient 
educational materials. 
" CONTROL: no intervention 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: folic acid supplementation, smoking cessation and 
hypertension treatment (index of preventive performance) 
# Economic outcomes 
# Other: 
 
" Positive on: when comparing intervention and control: index of preventive 
performance significantly better in intervention group +proportion of patients who 
received recommended preventive services 
# Negative on:  
" No effect on: index of preventive performance 
 
Conclusion: Multifaceted intervention delivered by nurse facilitators effective on 
modifying physician practice patterns and preventive performance. 
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Lin EH, Katon WJ, Simon GE, Von Korff M, Bush TM, Rutter CM, et al. 
Achieving guidelines for the treatment of depression in primary care: is 
physician education enough? Med Care. 1997;35(8):831-42. 
Quality appraisal score " 10/14 
Country # Europe 
" US (Washington) 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
" Before-after: quasi-experimental and before/after comparisons 
# Time series: 
 





Setting  " Physician’s office 
" Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with depression 
 
Caregiver targeted " Family physician (= general practitioner): 22 
" Specialist: general internists 
# Type of physician not specified 
 
Behavior targeted " Management of depression 
Who does academic detailing # Nurse 





" Not specified 
Interventions " INTERVENTION: AD + guidelines, role-play of improved practices, review of 
patient education pamphlets and videotapes, use of a reference handbook on 
depression) + reorganizing of services + criteria for urgent psychiatric referrals and 
case reviews with psychiatric consultants. 
# CONTROL: NA  
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
" Psycho-social outcomes: patient satisfaction and depression outcomes 
" Process outcomes: physician selection of antidepressant medication, adequacy 
of pharmacotherapy, intensity and follow-up visits during the acute phase of 
depression treatment. 
# Economic outcomes 
# Other: 
 
# Positive on: 
# Negative on:  
" No effect on: no improvement in any of the outcomes measured.  
 
Conclusion: No effect of multifaceted intervention including AD 
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Lin EH, Simon GE, Katzelnick DJ, Pearson SD. Does physician education on 
depression management improve treatment in primary care? Journal of 
General Internal Medicine. 2001;16(9):614-9. 
Quality appraisal score " 12/14 
Country # Europe 
" US  
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
" Before-after: before/after comparisons 
# Time series: 
 




Setting  " Physician’s office 
" Primary care clinic: 15 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with depression 
 
Caregiver targeted " Family physician (= general practitioner): 109 
" Specialist: general internists 
# Type of physician not specified 
 
Behavior targeted " Management of depression 
Who does academic detailing # Nurse 
# Physician 




" Not specified 
Interventions " INTERVENTION: Small group interactive discussions+ expert demonstrations 
+ role-play, AD of pharmacotherapy + criteria for urgent psychiatric referrals and 
case reviews with psychiatric consultants + case based feedback 
# CONTROL: usual care 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
" Psycho-social outcomes:  
" Process outcomes: new diagnoses per 100 primary care visits, new 
antidepressant medications per 100 visits, rate of new diagnosis accompanied by a 
new prescription per 100 visits, duration of pharmacotherapy 
# Economic outcomes 
# Other: 
 
# Positive on: 
# Negative on:  
" No effect on: no difference between intervention and control in the rate of new 
depression diagnosis, new prescription of antidepressant medicines 
 
Conclusion: No effect of multifaceted intervention including AD on depression diagnosis or 
phamacotherapy 
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Lobo CM, Frijling BD, Hulscher MEJL, Braspenning JC, Grol RPTM, Prins A, et 
al. Organizing cardiovascular preventive care in general practice: 
determinants of a successful intervention.[see comment]. Prev Med. 
2002;35(5):430-6. 
Quality appraisal score " 12/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To determine determinants of success of outreach visiting to optimizing 
cardiovascular preventive care. 
 
 
Setting  # Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients needing cardiovascular preventive care 
 
Caregiver targeted " Family physician (= general practitioner): 62 intervention, 62 control 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Cardiovascular preventive care. 
 
#  
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Who does academic detailing # Nurse 
# Physician 
# Pharmacist 
" Other: project team member 
Interventions " INTERVENTION: Outreach visits--15 (practice organization and clinical 
decision making, goal-setting) 
" CONTROL: no intervention 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
# Process outcomes 
# Economic outcomes 
" Other: deficiency score (the difference between ideal and actual practice) 
 
" Positive on: the duration of exposure was positively related to the change in 
availability of separate clinics and in the amount of teamwork. The improvement in 
instruments and materials was positively related to the GP’s opnion about the 
given feedback. 
# Negative on:  
" No effect on: No relations were found between key characteristics and changes 
in record-keeping or follow-up routines. 
 
Conclusion: Disentagling the ‘black box’ of an outreach visit intervention is difficult. 
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Lobo CM, Frijling BD, Hulscher MEJL, Bernsen RMD, Braspenning JC, Grol 
RPTM, et al. Improving quality of organizing cardiovascular preventive 
care in general practice by outreach visitors: a randomized controlled 
trial.[see comment]. Prev Med. 2002;35(5):422-9. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To determine determinants of success of outreach visiting to optimizing 
cardiovascular preventive care. 
 
 
Setting  # Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients needing cardiovascular preventive care 
 
Caregiver targeted " Family physician (= general practitioner): 62 intervention, 62 control 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Cardiovascular preventive care. 
 
#  
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Who does academic detailing # Nurse 
# Physician 
# Pharmacist 
" Other: project team member  
Interventions " INTERVENTION: Outreach visits—15 over 21-month period (practice 
organization and clinical decision making, goal-setting) 
" CONTROL: no intervention 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: preventive tasks performed by the practice assistant 
(measurements taken, history questions asked, advice given on), follow-up including 
making an appointment immediately after the visit, making an identifiable note, 
providing an appointment car for patients. 
# Economic outcomes 
" Other: availability of instruments and materials (e.g. blood pressure meter, 
glucose meter,...), leaflets, adequate ancillary staff present, separate room for 
practice assistant, teamwork in the practice, record keeping.  
 
" Positive on: when comparing the intervention arms, the difference in change 
was statistically significant for each aspect of organizing preventive care. The 
largest absolute improvement was found for the number of preventive tasks 
performed by the practice assistant. 
# Negative on: 
# No effect on:  
 
 
Conclusion: AD is effective in improving organization of cardiovascular preventive 
care. 
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Manfredi C, Czaja R, Freels S, Trubitt M, Warnecke R, Lacey L. Prescribe for 
health. Improving cancer screening in physician practices serving low-
income and minority populations. Arch Fam Med. 1998;7(4):329-37. 
Quality appraisal score " 13/14  
Country # Europe 
" US: Chicago 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " HMO 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate the effectiveness of a Health Maintenance Organization (HMO)-
sponsored intervention to improve cancer screening in private physician practices 
serving low-income, minority populations. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted " Cancer (breast, cervical and colorectal cancers) 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
 
Caregiver targeted " Family physician (= general practitioner): 87 intervention;  
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Screening of cancer (breast, cervical and colorectal cancers) 
Who does academic detailing # Nurse 
# Physician 
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# Pharmacist 
" Not specified 
Interventions " INTERVENTION: Outreach visits (2; within 2 months of initial training) + chart 
reminder system to identify patients in need of cancer screening + guidelines + 
patient educational materials + awareness materials + on-site training of staff + 
CME seminars for physicians + feedback 
" CONTROL:  
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: the proportions of patients with a chart-documented 
mammogram, clinical breast examination, Papanicolauo smear and occult blood 
slide test in 2 years before preintervention and postintervention chart abstractions. 
# Economic outcomes 
# Other: 
 
" Positive on: between baseline and postinterventions, there was a net increase 
in the proportion of HMO members in the intervention, compared to control 
practices for Papanicolauo smear and fecal occult blood slide test. There was a net 
increase in the proportion of non-HMO patients in the intervention compared with 
the control practices who received clinical breast examination and a fecal blood 
slide test. 
# Negative on:  
# No effect on: 
 
Conclusion: Multifaceted intervention, including outreach visits affective on 
improving cancer screening 
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Mason J, Freemantle N, Nazareth I, Eccles M, Haines A, Drummond M. When 
is it cost-effective to change the behavior of health professionals? JAMA. 
2001;286(23):2988-92. 
Quality appraisal score # NA 




# Asia (specify) 
 
Initiator " Not specified 
Design " Cost modelling study ---(based on RCT study of Freemantle) 
# Controlled study (prospective/retrospective): 
# Before-after: 




" Providing a framework for exploring the economics of influencing physician 
behaviour (underlying study the one of Freemantle) 
 
 
Setting  # Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
" Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Depression 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Changes in prescribing medications of ACE inhibitors and SSRIs (selective 
serotonin reuptake inhibitor) 
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Interventions # INTERVENTION: 
# CONTROL:  
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
# Process outcomes 
"  Economic outcomes: cost-effectiveness 
# Other: 
 
"  Positive on: AD is cost-effective for implementation of ACE inhibitors + AD is 
cost-effective for a reduction in use of SSRIs in favour of triclyclic antidepressants in 
small practices 
# Negative on:  
# No effect on: 
 
Conclusion: AD is cost-effective for implementation of ACE inhibitors + AD is cost-effective 
for a reduction in use of SSRIs in favour of triclyclic antidepressants in small practices 
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McDonald PK, Winkle CA, Askew D. Evaluation of academic detailing within a 
coordinated care trial. Journal of Pharmacy Practice and Research. 
2003;33(2):114-6. 
Quality appraisal score " 7/14 




# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
" Before-after: quasi-experimental design 
# Time series: 
 
Objectives  
" To evaluate the effectiveness of AD on general practitioners’ prescribing for 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Elderly patients with heart failure and chronic pain associated with 
osteoarthritis 
 
Caregiver targeted " Family physician (= general practitioner): 115 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescribing for heart failure and chronic pain associated with osteoarthritis in 
an elderly population. 
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Who does academic detailing # Nurse 
# Physician 
" Pharmacist (teaching-hospital clinical pharmacists) 
# Other 
Interventions " INTERVENTION: AD visits focusing on key messages (2 visits: 30-minute, 
followed by 15-minute visit to reinforce messages) + educational materials 
# CONTROL:  
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
" Psycho-social outcomes: satisfaction in physicians and pharmacists 
" Process outcomes: Prescribing of NSAID, angiotensine converting enzyme 
inhibitor and triclyclic antidepressants 
# Economic outcomes 
# Other: 
 
" Positive on: prescription of NSAID and triclyclic antidepressants 
# Negative on:  
" No effect on: prescription of angiotensine converting enzyme inhibitor 
 
Conclusion: AD was partly successful in changing prescribing practices for heart failure and 
pain management of osteoarthritis 
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Study number 48. Study included 
 
 
MIDLOV ET AL. 2005 
 
Effects of educational outreach visits on prescribing of bezodiazepines and antipsychotic drugs 
to elderly patients in primary health care in Southern Sweden. 
Quality appraisal score " 11/14 




# Asia (specify) 
 
Initiator " University 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate if educational outreach visits to GP practices can affect the 
prescribing of benzodiazepines and antipsychotic drugs to the elderly and evaluate 
the opinions of the participating GPs on such education. 
 
 
Setting of AD " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Elderly needing: benzodiazepines and antipsychotic drugs 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescribing of benzodiazepines and antipsychotic drugs 
Who does academic detailing # Nurse 





Interventions " INTERVENTION: group education programmes (2 sessions) and outreach visit 
(2 visits): 8 practices and 23 physicians  
" CONTROL: education after study period: 7 practices and 31 physicians 
 
Multifaceted intervention? " YES 
# NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: prescribing of medium-and long-acting benzodiazepines and total 
benzodiazepines 
# Economic outcomes 
# Other: 
 
" Positive on: significant decreases in prescribing of medium-and long-acting 
benzodiazepines and total benzodiazepines 
# Negative on:  
" No effect on: decreases in prescribing of antipsychotic drugs 
 
Conclusion: Educational outreach visits are effective in modifying GPs prescribing habits 
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Mold JW, Aspy CA, Nagykaldi Z. Implementation of evidence-based 
preventive services delivery processes in primary care: An Oklahoma 
Physicians Resource/Research Network (OKPRN) study. Journal of the 
American Board of Family Medicine. 2008;21(4):334-44. 
Quality appraisal score " 9/14 




# Asia (specify) 
 
Initiator # Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients needing selected immunizations and preventive services 
 
Caregiver targeted " Family physician + staff of practice (= general practitioner): 12 intervention; 12 
control 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Improvement of preventive services. 
Who does academic detailing # Nurse 




" Other: principal investigator, practice facilitator and IT-professional 
Interventions " INTERVENTION: AD (3 evidence based processes; 90-minute session)  + 
feedback (report listing the GPs rates of delivery of preventive services--including 
DTaPX4, measles/mumps/rubella, HepB for 3 to 3 year olds, pneumonia 
vaccination, colorectal cancer screening and mammography for 50-75 year olds + 
benchmarking + educational materials + assistance to practices (e.g. training staff + 
IT-support)  
" CONTROL: Feedback and benchmarking 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: number of practices who implemented one or more of the 
evidence-based processes (selected immunizations and preventive services) 
+ the number of total processes implemented 
# Economic outcomes 
# Other: 
 
" Positive on: Intervention practices implemented more of the processes than 
control practices overall, for adults and for children. Intervention practices were 
also more likely to implement at least one of the processes for children and to 
implement standing orders. Mammography rates increased significantly 
# Negative on:  
# No effect on:  
 
Conclusion: A multicomponent implementation strategy consisting of AD, feedback, 
benchmarking, facilitation and IT support increased the implementation of evidence-based 
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Myers RE, Turner B, Weinberg D, Hyslop T, Hauck WW, Brigham T, et al. 
Impact of a physician-oriented intervention on follow-up in colorectal 
cancer screening. Prev Med. 2004;38(4):375-81. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate the effectiveness of a program directed at improved management 
of complete diagnostic evaluation (CDE) for persons with an abnormal screening 
result for fecal occult blood. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Persons with an abnormal screening result for fecal occult blood > 50 years 
 
 
Caregiver targeted " Family physician (= general practitioner): 470 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Improved management of complete diagnostic evaluation (CDE) for persons 
with an abnormal screening result for fecal occult blood. 
 
KCE Reports 125 Academic Detailing – Supplement 165 
 




Interventions " INTERVENTION: screening program + intervention: CDE-reminders + CDE 
feedback report + two AD visits (including tailored letter and phone call + 
discussion on colorectal cancer screening + educational materials + barriers to CDE 
" CONTROL: only screening program + CDE reminders 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: CDE rates for FOBT 
# Economic outcomes 
# Other: 
 
" Positive on: CDE (complete diagnostic evaluation) recommendation and 
performance rates were both significantly higher in the intervention practices 
compared to the control practices 
# Negative on:  
# No effect on: 
 
Conclusion: the reminder-feedback plus educational outreach intervention significantly 
increased CDE recommendation and performance  
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Naughton C, Feely J, Bennett K. A clustered randomized trial of the effects of 
feedback using academic detailing compared to postal bulletin on 
prescribing of preventative cardiovascular therapy. Fam Pract. 
2007;24(5):475-80. 
Quality appraisal score " 14/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT: cluster randomized trial 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate the effect of of prescribing feedback on GP practice using AD 
compared to postal bulletin on prescribing of CVD preventive therapies in patients 
with CVD or diabtetes at 3 and 6 months post intervention, and to evaluate the 
intervention from the GP perspective 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with CVD or diabetes 
 
Caregiver targeted " Family physician (= general practitioner): 48 intervention; 50 control 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescribing of CVD preventive therapies (cardiovascular) in patients with CVD 
or diabetes at 3 and 6 months post intervention 
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Who does academic detailing # Nurse 
# Physician 
# Pharmacist 
" Other: researcher 
Interventions " INTERVENTION: individualized prescribing feedback via AD (= postal bulletin 
+ outreach visit). Interactive AD= 15 to 30 minutes + educational materials 
" CONTROL: postal bulletin including prescribing feedback 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
" Psycho-social outcomes: satisfaction in GPs 
" Process outcomes: level of antiplatelet prescribing in patients with coronary 
heart disease, statin prescribing in patients with CVD and, antiplatelet and statin 
prescribing in patients with diabetes  
# Economic outcomes 
# Other: 
 
" Positive on: High level of satisfaction in GPs 
# Negative on:  
" No effect on: there was a 3% increase in statin prescribing in CVD patients at 6 
months post-intervention for both groups, but not statistically significant. Same for: 
statin and antiplatelet/warfarin prescribing in diabetic patients 
 
Conclusion: Prescribing preventive therapies increased in both randomized groups, but AD did 
not have an additional effect on changing prescribing over the postal bulletin alone. 
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New JP, Mason JM, Freemantle N, Teasdale S, Wong L, Bruce NJ, et al. 
Educational outreach in diabetes to encourage practice nurses to use 
primary care hypertension and hyperlipidaemia guidelines (EDEN): a 
randomized controlled trial. Diabet Med. 2004;21(6):599-603. 
Quality appraisal score " 14/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT—practice–level randomized controlled trial. 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To determine the effectiveness of specialist nurse delivered education in 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with diabetes 
 
Caregiver targeted " Family physician (= general practitioner): 44 practices (10.303 subjects) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Control of hypertension and hyperlipidemia in patients with diabetes. 
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Interventions " INTERVENTION: AD (intervention targets, measurement methods and work 
through case examples) + guidelines + list of patients that were above target + 
every three month visits visit to provide support and encouragement to continue 
intervening as patients returned for annual reviews. 
" CONTROL: -- 
 
Multifaceted intervention? " YES 
Outcomes " Biological outcomes: percentage of patients that received adequate control= 
targets for blood pressure and lipid management 
# Psycho-social outcomes 
" Process outcomes: cholesterol control, blood pressure control 
# Economic outcomes 
# Other: 
 
# Positive on: 
# Negative on:  
" No effect on: no improvement in the number of patients achieving target after 
1 year; same for hyperlipidemia and hypertension. 
 
Conclusion: specialist nurses to perform educational outreach does not improve target 
adherence to patients with diabetes care. 
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Newton-Syms FA, Dawson PH, Cooke J, Feely M, Booth TG, Jerwood D, et al. 
The influence of an academic representative on prescribing by general 
practitioners. Br J Clin Pharmacol. 1992;33(1):69-73. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To analyse the effect of providing information about NSAI medicines by a short 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients who need NSAI medications 
 
Caregiver targeted " Family physician (= general practitioner): 101 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Rational and economic prescribing of NSAIs to reduce costs 
Who does academic detailing # Nurse 





Interventions " INTERVENTION: AD-one visit (educational messages) + educational materials 
+ educational materials for patients (posters)  
# CONTROL:  
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
# Process outcomes 
" Economic outcomes: prescribing costs 
# Other: 
 
" Positive on: there was a decrease in the average prescribing cost per month in 
the intervention group compared with the reference group. 
# Negative on:  
# No effect on: 
 
Conclusion: AD positively affects cost-effective prescribing. 
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Nilsson G, Hjemdahl P, Hassler A, Vitols S, Wallen NH, Krakau I. Feedback on 
prescribing rate combined with problem-oriented pharmacotherapy 
education as a model to improve prescribing behaviour among general 
practitioners. Eur J Clin Pharmacol. 2001;56(11):843-8. 
Quality appraisal score #  




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate the effectiveness of a problem-oriented pharmacotherapy 
education model on prescribing rates of medications for hypertension, peptic 
ulcer/dyspepsia and depression. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with hypertension, peptic ulcer/dyspepsia and depression 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescribing rates of medications for hypertension, peptic ulcer/dyspepsia and 
depression. 
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Interventions " INTERVENTION: AD operationalized as a pharmacotherapy education group 
consisting of four teacher-physicians, hospitals specialists and clinical pharmacists. 
The group provided medical education + educational materials on hypertension, 
peptic ulcer/dyspepsia and depression. Three visits were organized + feedback 
" CONTROL: intervention groups acted as each others control 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: prescribing rates and DDDs per prescription in the year 
before and after the intervention 
# Economic outcomes 
# Other: 
 
" Positive on: significant effect on prescriptions for agents acting on the renin-
angiotensin system. 
# Negative on:  
" No effect on: prescribing rates of proton-pump inhibitors and medications for 
depression. 
 
Conclusion: Mixed results for a model taregtting prescription behaviour of GPs. 
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Ofman JJ, Segal R, Russell WL, Cook DJ, Sandhu M, Maue SK, et al. A 
randomized trial of an acid-peptic disease management program in a 
managed care environment. Am J Manag Care. 2003;9(6):425-33. 
Quality appraisal score " 14/14 
Country # Europe 
" US (Orlando) 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (cluster randomized clinical trial) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate the effectiveness of a disease management program on processes 
of care for patients with acid-related disorders. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with new dyspepsia and chronic users of antisecretory drugs. 
 
Caregiver targeted " Family physician (= general practitioner): 35 physicians (200 patients) in 
intervention; 48 control (206 patients) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Processes of care for patients with acid-related disorders. 
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Interventions " INTERVENTION: guidelines + single group meeting with alocal physician 
champion + AD + 3 follow-up group meetings + nursing & pharmacist education + 
on-site H pylori serology testing + education of patients on h pylori and the 
management of side effects + follow up by phone of patients by nurse.  
" CONTROL: usual care 
 
Multifaceted intervention? " YES 
Outcomes " Biological outcomes: symptoms (epigastric pain, heartburn,..) 
" Psycho-social outcomes: satisfaction with care, health-related quality of life 
" Process outcomes: H.pylori testing 
# Economic outcomes 
# Other: 
 
" Positive on: improvements in helicobacter pylori testing, use of recommended 
helicobacter pylori treatment regimens, and discontinuation rates of proton pump 
therapy after treatment. Few differences in patient quality of life and symptoms. 
# Negative on:  
" No effect on: Few differences in patient quality of life and symptoms. 
 
 
Conclusion: The disease management program for patients with acid-related disorders led to 
improvements in processes of care. 
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Ornstein S, Jenkins RG, Nietert PJ, Feifer C, Roylance LF, Nemeth L, et al. A 
multimethod quality improvement intervention to improve preventive 
cardiovascular care: a cluster randomized trial. Ann Intern Med. 
2004;141(7):523-32. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To determine whether a multimethod quality improvement program was 
more effective than a less intensive intervention for improving adherence to 21 





Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with (risk for) cardiovascular disease and (risk for )stroke 
 
Caregiver targeted " Family physician (= general practitioner): 20 community based practices or 
general internal medicine practices in 14 states. 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prevention of cardiovascular disease and stroke. 




Who does academic detailing # Nurse 
" Physician 
" Pharmacist 
" Other: persons with experience in quality improvement 
Interventions " INTERVENTION: guidelines + quarterly performance reports (= feedback) 
documenting the practice’s adherence to each of the 21 study indicators + practice 
site visits (6-7 visits with an elapse time of one or two days every three months) + 
network meetings + instructions for the use of quality improvement tools available 
in the electronic medical record 
" CONTROL: performance reports 
 
Multifaceted intervention? " YES 
Outcomes " Biological outcomes: 7 outcome measures which reflected whether patients 
achieved recommended treatment goals. 
# Psycho-social outcomes 
" Process outcomes: 14 process measures reflecting if recommended tests were 
done, appropriate diagnoses made or appropriate medication prescribed. 
Percentage of performance targets achieved. 
# Economic outcomes 
# Other: 
 
" Positive on: positive trends for the percentage of quality indicators at or above 
target, but no differences between intervention and control. Positive results for 
diagnoses of hypertension and blood pressure control in patients with hypertension. 
# Negative on:  
" No effect on: no differences between intervention and control. 
 
Conclusion: Mixed results of DM-program on prevention of cardiovascular disease and stroke. 
A multi-method QI improvement program is only marginally more effective than performance 
reports alone for improving adherence to 21 quality indicators for primary and secondary 
prevention of cardiovascular disease and stroke in primary care practices. 
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Paton C. The use of academic detailing to improve evidence based 
prescribing of risperidone long acting injection. Int. J. Psychiatry Clin. Pract. 
2008, 12 (3): 210-214. 
 
Quality appraisal score " 9/14 
Country " Europe: UK 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Not specified 
Design " Time series 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To evaluate the effectiveness of AD on Rational Prescribing of risperidone 
long-acting injection (RLAI) 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with schizophrenia 
 
Caregiver targeted # Family physician 
 " Specialist: psychiatrists 
# Type of physician not specified 
 
Behavior targeted " Rational Prescribing of risperidone long-acting injection (RLAI) 
 
Who does academic detailing # Nurse 
# Physician 
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# Pharmacist 
" Other: trained detailer, not specified 
 
Interventions " INTERVENTION: Ad visits + guidelines (summaries) 
 
Multifaceted intervention? " NO 
Outcomes Biological outcomes:  
Psycho-social outcomes 
" Process outcomes: prescribing of risperidone long-acting injection (RLAI) 
 
Economic outcomes 
" Other: Prescribers ‘ knowledge of the evidence base and why RLAI is used 
 
" Positive on: AD was effective in changing prescribing practice (Rational 
Prescribing of risperidone long-acting injection (RLAI) 
 
Negative on:  
No effect on: 
 
Conclusion: AD was effective in changing prescribing practice + improving 
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Peterson GM, Bergin JK, Nelson BJ, Stanton LA. Improving drug use in 
rheumatic disorders. J Clin Pharm Ther. 1996;21(4):215-20. 
Quality appraisal score #  
Country # Europe 
# US 
# Canada 
" Australia (Southern Tasmania) 
# Asia (specify) 
 
Initiator "  Not specified 
Design # RCT 
" Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 





Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with rheumatic disorders 
 
Caregiver targeted " Family physician (= general practitioner): 177 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Rational prescribing of NSAIDs 
 
Who does academic detailing # Nurse 





Interventions " INTERVENTION: AD—20 session (interactive discussion + educational 
materials) 
# CONTROL:  
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: (DDD) Daily Dosed Dispensed for NSAID compared to 
paracetamol 
" Economic outcomes: hospital admissions due to gastric ulcers 
# Other: 
 
" Positive on: Changes in prescribing of NSAIDs were evident in both study 
regions, but were significantly greater in the intervention area compared to the 
control area. A decline in public hospital admissions was noted too. 
# Negative on:  
# No effect on: 
 
Conclusion: This study shows that an educational programme utilizing AD by pharmacists can 
modify prescribing practices within the community. AD session well received by GPs. 
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Peterson GM, Stanton LA, Bergin JK, Chapman GA. Improving the prescribing 
of antibiotics for urinary tract infection. J Clin Pharm Ther. 
1997;22(2):147-53. 
Quality appraisal score " 10/14 
Country # Europe 
# US 
# Canada 
" Australia (South Tasmania) 
# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
" Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To examine whether AD performed by a pharmacist could modify prescribing 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with urinary tract infections 
 
Caregiver targeted " Family physician (= general practitioner): 169 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescribing for antibiotics used in the treatment of Urinary Tract Infections 
(UTI) in the community setting. 
Who does academic detailing # Nurse 





Interventions " INTERVENTION: AD—20 session (interactive discussion + educational 
materials) 
 
# CONTROL:  
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: the total DDDs dispensed for the recommended first-line 
agents (amoxicillin-potassium clavulanate, cephalexin and trimethoprim) 
# Economic outcomes 
# Other: 
 
" Positive on: total DDDs in intervention group 
# Negative on:  
# No effect on: 
 
Conclusion: This study shows that an educational programme utilizing AD by pharmacists can 
modify prescribing practices for antibiotics within the community. AD session well received by 
GPs. 
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Pit SW, Byles JE, Henry DA, Holt L, Hansen V, Bowman DA. A Quality Use of 
Medicines program for general practitioners and older people: a cluster 
randomised controlled trial. Med J Aust. 2007;187(1):23-30. 
Quality appraisal score " 14/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (cluster randomized trial) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To investigate the effectiveness of an educational Quality Use of Medicines 
program, delivered at the level of general practice, on medicines use, falls and 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Elderly people taking benzodiazepines, NSAIDs/COX-2 inhibitors and 
antihypertensives. 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Rational prescribing 
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Interventions " INTERVENTION: AD + provision of prescribing information and feedback + 
medication risk assessment + facilitation of medication review + financial incentives. 
" CONTROL: clinical audit (feedback) 
 
Multifaceted intervention? " YES 
Outcomes " Biological outcomes: occurrence of falls 
" Psycho-social outcomes: quality of life assessed by SF-12 and EQ-5D Scores. 
" Process outcomes: Use of benzodiazepines, NSAIDs and thiazide diuretics 
# Economic outcomes 
" Other: use of medication reviews 
 
" Positive on: in intervention group; improved medication use composite score 
at 4-month follow-up (but not after 12 months), reduction in use of NSAIDs, 
benzodiazepines (not significant) and thiazide diuretics, lower number of falls and 
injury requiring medical attention. 
# Negative on:  
" No effect on: Quality of life scores 
 
Conclusion: Education and systems for medication review conducted by GPs can be used to 
improve use of medicines. These interventions are associated with a reduction in falls among 
older people, without adverse effects on quality of life. 
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Raisch DW, Bootman JL, Larson LN, McGhan WF. Improving antiulcer agent 
prescribing in a health maintenance organization. Am J Hosp Pharm. 
1990;47(8):1766-73. 
Quality appraisal score " 13/14 
Country # Europe 
" US (Arizona) 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " HMO 
Design # RCT 
" Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate the effect of one-to-one educational meetings between physicians 
and pharmacists on the prescribing of anti-ulcer agents for outpatients. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients needing anti-ulcer agents 
 
Caregiver targeted " Family physician (= general practitioner): intervention (16), control (8). 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescribing of antiulcer agents. 
Who does academic detailing # Nurse 





Interventions " INTERVENTION: AD (10 minutes presentations) using case studies (= ‘vivid 
interventions’)   
" CONTROL: statistical data (=‘nonvivid interventions’) 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: prescribing of anti-ulcer agents (cimetidine, ranitidine and 
sucralfate) 
" Economic outcomes: cost per precription 
# Other: 
 
" Positive on: no differences in appropriateness were found between the two 
intervention groups, but  in the first postintervention month the mean rate of 
inappropriate prescribing per control practitioner was 80% versus > 32% for the 
intervention groups. Positive effect on mean cost per control practitioner and per 
patient due to appropriate prescribing. 
# Negative on:  
" No effect on:  
 
Conclusion: One-to-one educational meetings between physicians and a pharmacist improved 
the prescribing of anti-ulcer agents for outpatients. 
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Ray WA, Schaffner W, Federspiel CF. Persistence of improvement in 
antibiotic prescribing in office practice. JAMA. 1985;253(12):1774-6. 
Quality appraisal score " 13/14 
Country # Europe 
" US (Tennessee) 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Tennessee Medical Association 
Design # RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
" Time series 
 
Objectives  
" To evaluate whether the improvement in antibiotic prescribing produced by 
the physician-counselor vists persisted for a second year, and if the improvement 
persisted, whether the effect was attenuated and what the estimated reducation 
was in expenditures produced by the educational program. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients needing antibiotics 
 
Caregiver targeted " Family physician (= general practitioner): 332 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescription of contra-indicated antibiotics and cephalosporins. 
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Interventions " INTERVENTION: AD by physician/pharmacist, but in separate regions of the 
state (interactive discussion—poor explanation in article) 
" CONTROL: usual care 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: average change index of contra-indicated antibiotics 
(chloramphenicol, clindamycin, tetracycline for children younger than 8 years) and 
cephalosporins. 
# Economic outcomes 
# Other: 
 
" Positive on: the beneficial effect of the physician-counselors persisted 
throughout year 2 with reductions in prescribing for both classes of drugs and cost 
savings. 
# Negative on:  
" No effect on: reductions in prescribing in the group of pharmacist-counselors 
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Ray WA, Blazer DG, 2nd, Schaffner W, Federspiel CF, Fink R. Reducing long-
term diazepam prescribing in office practice. A controlled trial of 
educational visits. JAMA. 1986;256(18):2536-9. 
Quality appraisal score " 9/14 
Country # Europe 
"  US 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Tennessee Medical Association 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" This study tested the efficacy of positive, educational methods in the reduction 
of diazepam prescribing in office practice 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients needing benzodiazepine anxiolytic drug 
 
Caregiver targeted " Family physician (= general practitioner): 44 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Reduction of diazepam prescribing in office practice 
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Who does academic detailing # Nurse 
"  Physician 
# Pharmacist 
# Other 
Interventions " INTERVENTION: AD + educational materials  
" CONTROL: usual care 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: prescribing of diazepam 
# Economic outcomes 
" Other: Receptivity of doctors to educational program 
 
" Positive on: Lower prescribing of diazepam in intervention group and positive 
receptivity of doctors to educational program 
# Negative on:  
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Ricordeau P, Durieux P, Weill A, Chatellier G, Vallier N, Bissery A, et al. Effect 
of a nationwide program of educational outreach visits to improve the 
processes of care for patients with type 2 diabetes. International Journal 
of Technology Assessment in Health Care. 2003;19(4):705-10. 
Quality appraisal score " 9/14 




# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
" Time series: 
 
Objectives " To evaluate the effectiveness of physician to physician AD on the management 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with diabetes 
 
Caregiver targeted " Family physician (= general practitioner)—22.940 
" Specialist: endocrinologists 
# Type of physician not specified 
 
Behavior targeted " Management of type 2 diabetes 
Who does academic detailing # Nurse 





Interventions " INTERVENTION: AD (outreach or phone consultation) + guidelines  
# CONTROL: --- 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: monthly proportion of the number of HbA1c 
measurements to the total of laboratory tests 
# Economic outcomes 
# Other: 
 
" Positive on: the number of HbA1c tests (increase) and blood glucose 
measurements and urine microalbumin 
# Negative on:  
# No effect on: 
 
" Conclusion: Physician to physician outreach visits can be effective to improve processes 
of care for diabetes and to routinize nationwide use of practice guidelines. 
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Schuster RJ, Tasosa J, Terwoord NA. Translational research - Implementation 
of NHLBI obesity guidelines in a primary care community setting: The 
physician obesity awareness project. Journal of Nutrition, Health and 
Aging. 2008;12(10 SUPPL.):764S-9S. 
Quality appraisal score 
 " 11/14 
Country # Europe 
" US: Dayton, Ohio 
# Canada 
# Australia 
# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
" Controlled study (prospective/retrospective): 
# Before-after: 
# Time series 
 
Objectives  
" To increase involvement in translating proven research into practice to 
improve physician awareness and improve outcomes of overweight/obesity 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with obesity 
 
Caregiver targeted " Family physician (= general practitioner): 21 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Management of obesity  
Who does academic detailing # Nurse 





" Not specified 
Interventions " INTERVENTION: physician obesity education through AD 
" (enhanced intervention): physician obesity education 
 
Multifaceted intervention? " YES 
Outcomes " Biological outcomes: cardiovascular disease risk factors: lipid levels, blood 
pressure and blood glucose 
# Psycho-social outcomes 
" Process outcomes: documentation of physician obesity management: BMI, 
weight, record height to allow BMI calculation 
# Economic outcomes 
" Other: Physician knowledge of obesity as a CVD factor 
 
" Positive on: the number of physicians that discussed obesity with their patients, 
reference to obesity management increased, BMI and cardio-vascular co-
morbidities improved. 
# Negative on:  
# No effect on: 
 
Conclusion: A combination of AD and presentation of outcomes to physicians improves 
awareness and result in improved outcomes. 
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Schaffner W, Ray WA, Federspiel CF, Miller WO. Improving antibiotic 
prescribing in office practice. A controlled trial of three educational 
methods. JAMA. 1983;250(13):1728-32. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " A consortium of State’s medical societies 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To improve antibiotic prescribing in office practice 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Children needing antibiotics 
 
Caregiver targeted " Family physician (= general practitioner): 372 (1087 patients) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Elimination of prescription of contraindicated antibiotics for use in office 
practice: chloramphenicol, clindamycin and tetracycline for children younger than 8 
years) and reduction of oral cephalosporins. 
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Interventions " INTERVENTION: AD (15 minutes) + educational materials 
" CONTROL: usual care 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: Prescription of contraindicated antibiotics for use in office 
practice: chloramphenicol, clindamycin and tetracycline for children younger than 8 
years and oral cephalosporins. 
# Economic outcomes 
# Other: 
 
" Positive on: when physician educators were used, strong attributable 
reductions in prescribing of both drug classes were obtained. The drug educator 
had only a modest effect. 
# Negative on:  
" No effect on: The mailed brochure had no detectable effect. 
 
Conclusion: AD by physicians if effective on the prescription of contracindicated antibiotics 
and a reduction in the prescribing of cephalosporines. 
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Shanahan M, Shakeshaft A, Mattick RP. Modelling the costs and outcomes of 
changing rates of screening for alcohol misuse by GPs in the Australian 
context. Applied Health Economics and Health Policy. 2006;5(3):155-66. 
Quality appraisal score " 10/14 




# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
" A modelling approach 
 
Objectives  
" To assess the relative cost effectiveness of four strategies (academic detailing, 
computerised reminder systems, target payments and interactive continuing 
medical education) of screening for alcohol misuse. 
 
 
Setting  # Physician’s office 
# Primary care clinic 
# Other (specify):  
" Not specified 
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
# Elderly 
" Alcohol abuse 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
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Behavior targeted " Screening of alcohol abuse 




" Not specified 
Interventions # INTERVENTION: NA 
# CONTROL: NA 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: screening for alcohol abuse in adults 
# Economic outcomes 
# Other: 
 
" Positive on: achieving a decrease in the number of standards drinks consumed 
by risky drinkers. 
# Negative on:  
# No effect on: 
 
Conclusion: Targeted payments are the least efficient of four commonly used strategies to 
increase GPs provision of care to reduce alcohol consumption among their patients. Academic 
detailing and computerised reminder system appear most effective in achieving a decrease in the 
number of standards drinks consumed by risky drinkers. 
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Siegel D, Lopez J, Meier J, Goldstein MK, Lee S, Brazill BJ, et al. Academic 
detailing to improve antihypertensive prescribing patterns. American 
Journal of Hypertension. 2003;16(6):508-11. 
 
Quality appraisal score " 10/14 




# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
" Before-after 
# Time series: 
 





Setting  " Physician’s office (community outpatient centers and academic medical clinics) 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with hypertension, diabetes mellitus and heart failure 
 
Caregiver targeted " Family physician (= general practitioner): 308 patients 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Compliance with antihypertensive treatment guidelines 
 
Who does academic detailing # Nurse 





" Not specified 
Interventions " INTERVENTION: face-to face (10-15 minutes) and group AD + 4 hour training 
sessions (effective communication techniques, discussion on normal 
antihypertensive recommendations, use of computer programs to extract and 
format data) + teleconference + educational materials + feedback (provider 
profiling of prescribing patterns) 
# CONTROL:  
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: prescription of thiazide diuretics, beta-blockers and calcium 
antagonists, angiotensine converting enzyme inhibitor, angiotensine receptor 
blocker 
# Economic outcomes 
# Other: 
 
" Positive on: prescribing of number of calcium antagonists, beta-blockers, 
thiazide diuretics for patients with hypertension. For hypertensive subjects with 
diabetes mellitus or congestive heart failure, the proportion receiving an 
angiotensine converting enzyme inhibitor or angiotensin receptor blocker 
increased. Among hypertensive subjects with coronary artery disease and increase 
in beta-blocker use was noted. 
# Negative on:  
# No effect on: 
 
Conclusion: Multifaceted intervention including AD effective on prescribing patterns compliant 
to national guidelines 
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Simon SR, Majumdar SR, Prosser LA, Salem-Schatz S, Warner C, Kleinman 
K, et al. Group versus individual academic detailing to improve the use of 
antihypertensive medications in primary care: a cluster-randomized 
controlled trial. Am J Med. 2005;118(5):521-8. 
Quality appraisal score " 14/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (cluster randomized controlled trial) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To compare group versus individual academic detailing to increase diuretic of 
beta-blocker use in hypertension. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with newly diagnosed hypertension 
 
Caregiver targeted " Family physician (= general practitioner): 9 practices randomized to 3 
intervention arms (physicians: 75; patients: 1066 individual AD; physicians: 87; 
patients: 1007 group AD; 1619 in mail intervention sites) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Diuretic of beta-blocker use in hypertension 
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" Not specified ‘trained detailer’ 
Interventions " INTERVENTION: individual AD (15-30 minutes) 
" INTERVENTION: group AD (45 small group session: 7-8 physicians 
attendance) 
" CONTROL: mail intervention  
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: rates of diuretic or beta-blocker use 
# Economic outcomes: intervention costs and medication costs 
# Other: 
 
" Positive on: rates of diuretic or beta-blocker use increased in both individual 
and group AD practices 
# Negative on:  
" No effect on: neither intervention affected blood pressure control 
 
Conclusion: both individual and group AD imrpved antihypertensive prescribing above and 
over usual care. Individual AD had a more persistent effect two years after intervention 
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Simon SR, Rodriguez HP, Majumdar SR, Kleinman K, Warner C, Salem-
Schatz S, et al. Economic analysis of a randomized trial of academic 
detailing interventions to improve use of antihypertensive medications. J 
Clin Hypertens (Greenwich). 2007;9(1):15-20. 
Quality appraisal score " 14/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " Retrospective cost-analysis of a RCT (cluster randomized controlled trial) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " Estimating the costs and cost savings (perspective of the payer) of 
implementing a program of mailed practice guidelines, single-visits individual and 




Setting  " Physician’s office (NA) 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with hypertension 
 
Caregiver targeted " Family physician (= general practitioner): 9 practices randomized to 3 
intervention arms (patients: 1066 individual AD; 1007 group AD; 1619 in mail 
intervention sites) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Diuretic of beta-blocker use in hypertension 
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" Not specified ‘trained detailer’ 
Interventions " INTERVENTION: individual AD (15-30 minutes) 
" INTERVENTION: group AD (45 small group session: 7-8 physicians 
attendance) 
" CONTROL: mail intervention 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
# Process outcomes:  
" Economic outcomes: average daily drug cost 
# Other: 
 
" Positive on: the individual AD resulted in an estimated net decrease in average 
daily drug cost per person beyond the reductions in the mail group, although this 
finding did not reach statistical significance. The estimated net reduction 
corresponded to savings.  
# Negative on:  
" No effect on: The group AD resulted in no change in the average daily cost of 
antihypertensive agents. 
 
Conclusion: Mixed results on cost-savings, but individual AD demonstrated better cost savings 
compared to group and mailing intervention 
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Siriwardena AN, Rashid A, Johnson MR, Dewey ME. Cluster randomised 
controlled trial of an educational outreach visit to improve influenza and 
pneumococcal immunisation rates in primary care. Br J Gen Pract. 
2002;52(482):735-40. 
Quality appraisal score " 12/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (cluster randomized controlled trial) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 





Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" High risk patients (age > 65 years, coronary heart disease, diabetes and a 
history of splenectomy) needing influenza and pneumoccocal vaccinations. 
 
Caregiver targeted " Family physician (= general practitioner): 30 (15 intervention; 15 control) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Influenza and pneumoccocal vaccinations 
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Who does academic detailing # Nurse 
" Physician (general practitioner) 
# Pharmacist 
# Other 
Interventions " INTERVENTION: AD (+/- one hour; often during primary health care team 
meeting, exploring barriers to vaccination + information) + audit + feedback of 
practice vaccination rates 
" CONTROL: written feed-back on vaccination rates 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: rates of influenza and pneumoccocal vaccination for 
patients age > 65 years, coronary heart disease, diabetes and a history of 
splenectomy 
# Economic outcomes 
# Other: 
 
" Positive on: Improvements in pneumoccocal vaccination rates in the 
intervention practices were significantly greater compared to controls in patients 
with CHD and diabetes but not splenectomy. Improvements for influenza 
vaccination were also greater in intervention practices but did not reach statistical 
significance. 
# Negative on:  
# No effect on: 
 
Conclusion: AD is effective on the uptake pneumococcal vaccination in high risk groups, but 
not for influenza vaccination. 
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Sheinfeld Gorin S, Gemson D, Ashford A, Bloch S, Lantigua R, Ahsan H, et al. 
Cancer education among primary care physicians in an underserved 
community. Am J Prev Med. 2000;19(1):53-8. 
Quality appraisal score " 10/14 
Country # Europe 
" US  
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
" Before-after design 
# Time series: 
 
Objectives  
" To evaluate the effectiveness of a QI program on cancer screening and 
prevention in an underserved community 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted " Cancer (colon, rectum, cervix, prostate, breast and lung) 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
 
Caregiver targeted " Family physician (= general practitioner): 84 intervention; 38 control. 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Cancer prevention and screening practices 
Who does academic detailing # Nurse 
# Physician 
# Pharmacist 
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# Other 
" Not specified (bachelors, masters and public health professionals) 
Interventions " INTERVENTION: AD (+/- 2-3 visits; practice visits and contacts over the 
phone, information) + educational materials + perceived barriers to 
implementation + educational materials for patients + dinner seminars about 
cancer prevention and screening 
# CONTROL:  
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: self-reported cancer prevention and screening practices 
# Economic outcomes 
" Other: knowledge of ACS screening guidelines for the colon, rectum, cervix, 
prostate, breast and lung 
 
" Positive on: Identified barriers to practice 
# Negative on:  
" No effect on: no significant differences in knowledge of cancer prevention or 
screening. 
 
Conclusion: Educational visits did not seem to alter cancer screening and prevention practices. 
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Stone CA, May FW, Pinnock CB, Elwood M, Rowett DS. Prostate cancer, the 
PSA test and academic detailing in Australian general practice: an 
economic evaluation. Aust N Z J Public Health. 2005;29(4):349-57. 
Quality appraisal score " NA 




# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
" Modelling scenario 
 
Objectives  
" To evaluate whether introduction of a national education program for GPS to 
improve decision making relating to the use of prostate specific antigen (PSA) 




Setting  # Physician’s office 
# Primary care clinic 
# Other (specify):  
" NA 
 
Population targeted " Cancer (prostate cancer) 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
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Behavior targeted " PSA screening  




Interventions # INTERVENTION: 
# CONTROL:  
" NA 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
# Process outcomes 
" Economic outcomes 
# Other: 
 
" Positive on: A national program would reduce the burden of disease by 4.7% of 
total DALYs due to prostate cancer in those aged 70 and over, with no loss of life 
and an incremental cost effectiveness ratio of 16.000/DALY (gross) and 8.500/DALY 
(net). 
# Negative on:  
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Teng CL, Achike FI, Phua KL, Nurjahan MI, Mastura I, Asiah HN, et al. 
Modifying antibiotic prescribing: the effectiveness of academic detailing 
plus information leaflet in a Malaysian primary care setting.[see 
comment]. Med J Malaysia. 2006;61(3):323-31. 
Quality appraisal score " 8/14 




" Asia (specify): Malaysia 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
" Time series: Interrupted time series design 
 
Objectives  
" To evaluate the effectiveness of AD on prescribing of antibiotics for URTI 
 
 
Setting  # Physician’s office 
" Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
" Respiratory diseases (Upper respiratory Tract Infections) 
 
 
Caregiver targeted " Family physician (= general practitioner): 29 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescription of antibiotics 
Who does academic detailing # Nurse 
" Physician (family care specialist) 




Interventions " INTERVENTION: AD (20 minute one-to-one meeting + guidelines  
(summarized on one page leaflet) + poster (leaflet) 
# CONTROL:  
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: prescription of antibiotics 
# Economic outcomes 
# Other: 
 
" Positive on: reductions in the prescription of antibiotics for URTI 
# Negative on:  
# No effect on: 
 
Conclusion: AD is effective on a reduction in the prescription of antibiotics for URTI . 
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Turner CJ, Parfrey P, Ryan K, Miller R, Brown A. Community pharmacist 
outreach program directed at physicians treating congestive heart failure. 
American Journal of Health-System Pharmacy. 2000;57(8):747-52. 
Quality appraisal score " 9/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate the ability of a pharmacist outreach program to address 
underutilization of ACE inhibitors among patients receiving treatment for CHF 
(congestive heart failure) 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
" Heart failure (congestive heart failure) 
# Neurodegenerative diseases 
# Respiratory diseases 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
" Pharmacist 
 
Behavior targeted " Prescription of ACE inhibitors and angiotensin 2 receptor antagonists for the 
prevention and management of CHF. 
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Interventions " INTERVENTION: AD + guidelines  
" CONTROL: AD 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: self-reported use of prescription of ACE inhibitors and 
angiotensin 2 receptor antagonists for the prevention and management of CHF. 
# Economic outcomes 
# Other: 
 
# Positive on: 
# Negative on:  
" No effect on: no significant difference in ACE-inhibitor prescribing between 
intervention and control group 
 
Conclusion: A pharmacist outreach program involving AD did not affect prescribing or 
dosages of ACE inhibitors but demonstrated value as a quality assurance tool. 
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Varonen H, Rautakorpi U-M, Nyberg S, Honkanen PO, Klaukka T, Palva E, et 
al. Implementing guidelines on acute maxillary sinusitis in general 
practice--a randomized controlled trial. Fam Pract. 2007;24(2):201-6. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (multi-centre RCT conducted in 30 health centers). 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To study whether a nationwide guidelines implementation programme has an 
effect on the management of acute maxillary sinusitis (antibiotics prescribing) 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
" Respiratory diseases: acute maxillary sinusitis 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Management of acute maxillary sinusitis (antibiotics prescribing) 
Who does academic detailing # Nurse 
" Physician 




# Not specified (‘external experts’) 
Interventions " INTERVENTION: AD (information sources, feedback, and visits) by local 
general practitioner 
" CONTROL: problem-based learning 
 
Multifaceted intervention? " NO 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: prescribing of antibiotics for acute maxillary sinusitis 
(Amoxicillin), proportion of courses of antibiotics with recommended duration 
# Economic outcomes 
# Other: 
 
" Positive on: Use of first line drugs (amoxicillin): increased 
# Negative on:  
" No effect on: there were no significant changes between AD and problem-
based learning methods. 
 
Conclusion: The program produced modest changes in the management of AMS, but AD was 
not more effective compared to other educational techniques. 
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Study number 77. Study included 
 
 
VAN DEN HOMBERG, 1999 
 
Van den Hombergh, P, Grol R, et al. Practice visits as a tool in quality 
improvement: mutual visits and feedback by peers compared with visits 
and feedback by non-physician observers. Qual Health Care 8, 1999 (3): 
161-6 
Quality appraisal score " 14/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (prospective, randomised intervention study, with follow-up after one 
year). 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate and compare the effects of two programs of assessment of 
practice management in a practice visit on functioning of GP practices 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Not applicable 
 
Caregiver targeted " Family physician (= general practitioner): 14 local groups with 109 GPs 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Global Practice functioning 
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Who does academic detailing # Nurse 
" Physician 
# Pharmacist 
" Other: non-physician observers 
 
Interventions " INTERVENTION: Practice visits by peers (physicians) 
" INTERVENTION: Practice visit by non physician observers 
 
Multifaceted intervention " NO 
Outcomes # Biological outcomes 
" Psycho-social outcomes: job-stress in physicians 
" Process outcomes: delegation and collaboration 
# Economic outcomes 
" Other: Premises and equipment, service and organization, record keeping, 
organisation of quality improvement, workload 
 
" Positive on: both programmes resulted into improvements on many aspects of 
practice management. Practice visits by peers resulted into better performance for 
equipment, collaboration with colleagues, accessibility of patient information than 
after a visit of a non physician observer. Visits by non physician observers resulted 
in a higher score on extent of use of records, outcome assessment and year report. 
# Negative on:  
# No effect on: 
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Study number 78. Study included 
 
 
VAN DER WEIJDEN, 1999 
 
van der Weijden T, Grol RP, Knottnerus JA. Feasibility of a national 
cholesterol guideline in daily practice. A randomized controlled trial in 20 
general practices. Int J Qual Health Care. 1999;11(2):131-7. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate the feasibility and implementation needs of a cholesterol guideline 
by assessing the effectiveness of simple dissemination as well as extensive 
implementation of this guideline on actual performance of GPs. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients with abnormal cholesterol levels 
 
Caregiver targeted " physician (= general practitioner): 32 GPs in 20 practices, 3950 patient records 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Management of cholesterol 
Who does academic detailing # Nurse 




" Other: scientific collaborator 
Interventions " INTERVENTION: extensive implementation of guideline= guideline+ 
educational materials + 3h educational session by local opinion leader + feedback + 
2 outreach visits with face-to-face instruction + barriers to change 
" CONTROL: simple implementation of guideline= postal distribution of the 
guideline with scientific background materials 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: quality of selective case finding (= targeting cholesterol 
testing to patients with at least one of the six risk factors mentioned in the 
guideline), and quality of diagnostic procedures (= properly diagnosed 
hypercholesterolemia requires that average of 3 measurements to be higher than 
6.5 mmol/l) 
# Economic outcomes 
# Other: 
 
" Positive on: quantity of cholesterol testing 
" Negative on: performance of the procedure necessary to diagnose 
hypercholesterolemia even deteriorated 
" No effect on: quality of selective case finding or quality of diagnostic 
procedures 
 
Conclusion: Mixed results from multifaceted intervention on management of cholesterol. 
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Study number 79. Study included 
 
 
VAN EIJK, 2001 
 
van Eijk ME, Avorn J, Porsius AJ, de Boer A. Reducing prescribing of highly 
anticholinergic antidepressants for elderly people: randomised trial of 
group versus individual academic detailing. BMJ. 2001;322(7287):654-7. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (with 3 intervention arms) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To compare the effect of individual educational visits versus group visits using 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Elderly patients (> 60) needing anticholinergic antidepressants 
 
Caregiver targeted " Family physician (= general practitioner): 37 practices – 190 GPs 
" Pharmacists 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescribing of highly anticholinergic antidepressants in elderly people. 
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Who does academic detailing # Nurse 
# Physician 
# Pharmacist 
" Other: researcher 
Interventions " INTERVENTION: individual academic detailing (two 20 minute visits) + educational 
materials + feedback on practice performance  
" INTERVENTION: group academic detailing (two visits) 
" CONTROL: no intervention 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: numbers of elderly people with new prescriptions of highly 
anticholinergic antidepressants and less anticholinergic antidepressants 
# Economic outcomes 
# Other: 
 
" Positive on: in both the intervention arms the use of highly anticholinergic 
antidepressants decreased + the use of less anticholinergic antidepressants 
increased. 
# Negative on:  
# No effect on: 
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Walsh JM, Salazar R, Terdiman JP, Gildengorin G, Perez-Stable EJ. Promoting 
use of colorectal cancer screening tests. Can we change physician 
behavior? J Gen Intern Med. 2005;20(12):1097-101. 
Quality appraisal score " 13/14 
Country # Europe 
" US (San Francisco) 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To assess the effect of an intervention targeting physicians and their patients 
on rates of colorectal cancer screening (CRC). 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted " Cancer: patients at risk for development of colorectal cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
 
Caregiver targeted " Family physician (= general practitioner) or internal medicine: 94; 9652 
patients enrolled for 2 years and 3732 patients were enrolled for 5 years. 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Colorectal cancer screening (patients aged 50-79) 
 
Who does academic detailing # Nurse 
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" Physician: opinion leaders 
# Pharmacist 
# Other 
Interventions " INTERVENTION: AD + educational sessions + guidelines + identification of 
barriers + patient intervention: letter, brochure, and a Fecal Occult Blood test 
cards 
" CONTROL: --- 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: FOBT in the last 2 years, flexible sigmoidoscopy and 
colonoscopy in the previous 5 years, CRC screening. 
# Economic outcomes 
# Other: 
 
" Positive on: patient rates of screening SIG (flexible sigmoidoscopy) 
# Negative on:  
" No effect on: rates of CRC screening. 
 
Conclusion: Mixed results from study applying academic detailing.  
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Watson M, Gunnell D, Peters T, Brookes S, Sharp D. Guidelines and 
educational outreach visits from community pharmacists to improve 
prescribing in general practice: a randomised controlled trial. J Health 
Serv Res Policy. 2001;6(4):207-13. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (cluster randomized trial) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To evaluate the effectiveness of guidelines with or without ont-to-one 
educational oureach visits in improving general practice prescribing for non-
steroidal anti-inflammatory drugs (NSAIDs). 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients needing non-steroidal anti-inflammatory drugs (NSAIDs). 
 
 
Caregiver targeted " Family physician (= general practitioner): 20 practices;  
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescribing for non-steroidal anti-inflammatory drugs (NSAIDs). 
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Who does academic detailing # Nurse 
# Physician 
" Pharmacist (community pharmacists) 
# Other 
Interventions " INTERVENTION: mailed guidelines + educational outreach visits (two 10-
minutes visits) 
" INTERVENTION: mailed guidelines 
" CONTROL: not intervention 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: change in the volume prescription (DDD) of ibuprofen, 
diclofenac and naproxen (= recommended NSAIDs) as a percentage of total NSAID 
prescribing 
" Economic outcomes: cost-benefit analysis 
# Other: 
 
" Positive on: the proportion of prescribing of the five most frequently used 
drugs. 
" Negative on: a net increase in costs with both interventions 
" No effect on: prescription of ibuprofen, diclofenac and naproxen 
 
Conclusion: no impact on prescribing behaviour was noted  
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Weller D, May F, Rowett D, Esterman A, Pinnock C, Nicholson S, et al. 
Promoting better use of the PSA test in general practice: randomized 
controlled trial of educational strategies based on outreach visits and 
mailout. Fam Pract. 2003;20(6):655-61. 
Quality appraisal score " 13/14 
Country # Europe 
# US 
# Canada 
" Australia (South Adelaide) 
# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  
" To compare the effectiveness of educational outreach visits and mailout 
strategies targeting PSA testing. 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted " Cancer: prostate cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
 
Caregiver targeted " Family physician (= general practitioner): 145 (46 AD; 47: mail; 52 control) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prostate-specific antigen testing (PSA) 
Who does academic detailing # Nurse 
# Physician 
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" Pharmacist (trained in social marketing techniques) 
# Other 
Interventions " INTERVENTION: AD + educational materials + feedback 
" INTERVENTION: educational materials by mail 
" CONTROL: no intervention 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: PSA testing rates  
# Economic outcomes 
" Other: GP knowledge 
 
" Positive on: correct responses to questions about prostate cancer treatment 
effectiveness and endorsement of PSA testing for prostate cancer by professional 
bodies. 
# Negative on:  
" No effect on: PSA testing rate lower in AD group compared to mail group and 
control group. 
 
Conclusion: Mixed results from intervention targeting PSA screening. 
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Williams PT, Eckert G, Epstein A, Mourad L, Helmick F. In-office cancer-
screening education of primary care physicians. Journal of Cancer 
Education. 1994;9(2):90-5. 
Quality appraisal score " 8/14 
Country # Europe 
" US (Ohio) 
# Canada 
# Australia: 
# Asia (specify) 
 
Initiator " Not specified 
Design # RCT 
# Controlled study (prospective/retrospective): 
" Before-after 
# Time series: 
 
Objectives " To evaluate the effectiveness of academic detailing on cancer preventive and 
screening actions in family physicians + increase knowledge of physicians about and 
use of educational and patient service resources of local, state and national units of 
the American Cancer Society (ACS) + evaluating if physicians employ the 
prevention and screening recommendations of the ACS and whether they have 
developed ways to deal with barriers to implementation of these recommendations 





Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted " Cancer: breast, colon-rectum and prostate cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
 
Caregiver targeted " Family physician (= general practitioner): 22 physicians + staff members 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Screening and preventive actions on breast, colon-rectum and prostate cancer. 
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Interventions " INTERVENTION: AD (one/two face-to-face visit) + follow-up phone calls + 
educational materials for physicians and patients + guidelines + action list for office 
management 
# CONTROL:  
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: activities in compliance with cancer prevention guidelines 
# Economic outcomes 
# Other: 
 
" Positive on: compliance rates + increased awareness of resources of ACS and in 
prompting physicians to adopt cancer prevention and screening procedures, but 
least effective in making office changes. 
# Negative on:  
# No effect on: 
 
Conclusion: AD effective on cancer screening and prevention action in physicians. 
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Witt K, Knudsen E, Ditlevsen S, Hollnagel H. Academic detailing has no effect 
on prescribing of asthma medication in Danish general practice: a 3-year 
randomized controlled trial with 12-monthly follow-ups. Fam Pract. 
2004;21(3):248-53. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (cluster randomized trial) 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To examine the effect of academic detailing as a method of implementing a 
clinical guideline in general practice and to improve GPs prescribing in accordance 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
" Respiratory diseases: asthma (children < 16 years of age) 
 
Caregiver targeted " Family physician (= general practitioner) 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescription of asthma medication (to change medication in children to more 
inhaled steroids and less B2-aginists, and to increase the GPs use of peak-flow 
meters and spirometry). 
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Who does academic detailing # Nurse 
# Physician 
# Pharmacist 
" Other: researchers 
Interventions " INTERVENTION: AD (15-20 minute visit) + guideline + feedback (prescription 
profile)  
" CONTROL: guideline by post + feedback 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: number of asthma medication prescribed (DDD of steroids 
and B2-agonists expressed as sales of asthma medication by pharmacies). 
# Economic outcomes 
# Other: 
 
# Positive on: 
# Negative on:  
" No effect on: prescription of asthma medication 
 
Conclusion: No effect of AD on prescribing of asthma medication. 
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Wong RY, Lee PE. Teaching physicians geriatric principles: a randomized 
control trial on academic detailing plus printed materials versus printed 
materials only. J Gerontol A Biol Sci Med Sci. 2004;59(10):1036-40. 
Quality appraisal score " 12/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " Promotion of geriatric knowledge to physicians 
 
 
Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Elderly 
 
Caregiver targeted " Family physician (= general practitioner): 31 (intervention: 16; intervention 2: 
15) 
# Specialist 
# Type of physician not specified 
" Postgraduate trainees + staff physicians 
 
Behavior targeted " Geriatric knowledge on cognitive impairment, competency, urinary 
incontinence, malnutrition, and stroke. 
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Who does academic detailing # Nurse 
# Physician 
# Pharmacist 
" Other: specialist in geriatric medicine 
Interventions " INTERVENTION: AD (15 minute session) + printed educational materials 
" CONTROL: printed materials only 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
# Process outcomes 
# Economic outcomes 
" Other: Knowledge score on geriatric knowledge 
 
" Positive on: improvements in geriatric knowledge scores 
# Negative on:  
# No effect on: 
 
Conclusion: Intervention effective on geriatric knowledge retention. 
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Young JM, D'Este C, Ward JE. Improving family physicians' use of evidence-
based smoking cessation strategies: a cluster randomization trial. Prev 
Med. 2002;35(6):572-83. 
Quality appraisal score " 13/14 




# Asia (specify) 
 
Initiator " Not specified 
Design " RCT (cluster randomized trial): 2 X 2 balanced incomplete block design 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives  





Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients who smoke (age 18-70 years) 
 
Caregiver targeted " Family physician (= general practitioner): 60 from 39 practices 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Smoking cassation advice 
Who does academic detailing # Nurse 




" Other: not specified 
Interventions " INTERVENTION: AD (Three visits) + audit + feedback + skills training video 
and workbook package + clinical guidelines + prompt sheet to assist with smokers’ 
excuses and self-exemptions + patient-mediated prompts + reminders for medical 
records + patient brochures and free starter packs of nicotine replacement gum. 
" CONTROL: same intensity program, but on cervical screening 
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: recall of GPs advice about nicotine replacement patches 
and gum, patient recall of assessment of smoking status and GP use of ‘quit dates’, 
behavioural advice and provision of written materials 
# Economic outcomes 
# Other: 
 
" Positive on: recall of GPs advice about nicotine replacement patches and gum 
# Negative on:  
" No effect on: Positive increases but not significant for: patient recall of 
assessment of smoking status and GP use of ‘quit dates’, behavioural advice and 
provision of written materials 
 
 
Conclusion: Multifaceted intervention effective on promotion of use of nicotine replacement 
therapy in GPs. 
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Zwar NA, Wolk J, Gordon JJ, Sanson-Fisher RW. Benzodiazepine prescribing 
by GP registrars. A trial of educational outreach. Aust Fam Physician. 
2000;29(11):1104-7. 
Quality appraisal score " 12/14 
Country # Europe 
# US 
# Canada 
" Australia (New South Wales) 
# Asia (specify) 
 
Initiator " Not specified 
Design " RCT 
# Controlled study (prospective/retrospective): 
# Before-after: 
# Time series: 
 
Objectives " To evaluate the effectiveness of an educational academic detailing program 




Setting  " Physician’s office 
# Primary care clinic 
# Other (specify):  
 
Population targeted # Cancer 
# Heart failure 
# Neurodegenerative diseases 
# Respiratory diseases 
" Patients (long term users of ) benzodiazepines 
 
Caregiver targeted " Family physician (= general practitioner): 157: 79 intervention; 78 control 
# Specialist 
# Type of physician not specified 
 
Behavior targeted " Prescription of benzodiazepines 
Who does academic detailing # Nurse 





Interventions " INTERVENTION: AD (20 minute appointment) + guidelines on anxiety and 
insomnia + leaflets for patients on relaxation techniques + a patient held aid to 
managing the benzodiazepine withdrawal process 
# CONTROL:  
 
Multifaceted intervention? " YES 
Outcomes # Biological outcomes 
# Psycho-social outcomes 
" Process outcomes: rate of benzodiazepine prescribing for all indications, for 
anxiety and sleep disorders. 
# Economic outcomes 
# Other: 
 
" Positive on: Overall benzodiazepine prescribing (in continuing rather than 
initial prescriptions), but no difference between groups 
# Negative on:  
# No effect on: 
 
Conclusion: A marked decrease in benzodiazepine prescribing was seen in both intervention 
and control groups but no differential effect due to the educational outreach visit 
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2 APPENDICES QUALITATIVE PART 
2.1 APPENDIX A: PHONE SCRIPT (FRENCH) 
« Bonjour, [X], du laboratoire SPIRAL, département de Science Politique de l’Université 
de Liège. Êtes-vous bien le Docteur [Y] ? Je vous contacte dans le cadre de l’étude KCE 
[si question sur la signification de KCE : « Il s’agit du Centre Fédéral d’Expertise des Soins de 
Santé, qui dépend du SPF Santé Publique »] sur l’évaluation de la visite du délégué médical 
indépendant sur la pratique des médecins généralistes. 
Comme vous aviez marqué votre accord pour participer à cette enquête, vous avez 
reçu un courrier cette semaine à ce sujet. Donc, je vous contacte pour fixer un rendez-
vous pour un entretien qui durera une vingtaine de minutes. Je suis dans votre région le 
[JJ] et le [JJ]/[MM]. Une de ces dates vous convient-elle ? » 
(…) 
« L’entretien sera enregistré, mais votre identité restera confidentielle : seul un groupe 
de chercheurs du SPIRAL connaîtra votre identité, qui n’apparaîtra nulle par sur les 
documents que nous produirons. » 
2.2 APPENDIX B: MAIN FIVE QUESTIONS, USED AS A GUIDE 
FOR THE FIRST INTERVIEWS (FRENCH)  
Ces questions ont été pré-testées le 21 août chez un médecin généraliste. Il s’agit de questions 
définies comme incontournables, de guidelines, qui seront complétées lors des passations selon 
la grille disponible en Annexe C. Elles serviront essentiellement à amorcer et à cadrer 
l’entretien. 
! Que pensez-vous des différents types d’information sur les médicaments 
en Belgique ? [Le but est ici de voir si les généralistes parlent spontanément de 
Farmaka.] 
! Au sujet des informations qui vous ont été fournies par Farmaka, quelque 
chose a-t-il changé pour vous ces dernières années ? 
! Que pensez-vous du niveau de formation des visiteurs indépendants ? 
Quelle est leur légitimité, leur crédibilité ? 
! Recevez-vous des délégués médicaux privés, à quelle fréquence ? [Cette 
question, qui semble redondante par rapport à une étude KCE précédente, nous 
renseigne en fait sur les habitudes du médecin interrogé – elle permet aussi de 
voir quelle est la légitimité du délégué médical privé aux yeux du médecin.] 
! Avez-vous autre chose à ajouter ? 
En plus de ces questions, des informations seront récoltées systématiquement, comme : 
! L’âge précis et le sexe du médecin ; 
! L’interviewer notera si le médecin dispose d’un ordinateur sur son 
bureau ; 
! Les caractéristiques de la patientèle (observation, question) ; 
! Les caractéristiques géographiques (milieu urbain, rural) ; 
! La méthodologie de travail du médecin (seul, en association). 
Il est à noter que la plupart de ces informations peuvent être observées et que seules 
quelques-unes d’entre elles feront l’objet de questions, dans les cas où l’observation 
(quartier du cabinet, salle d’attente) ne donnera pas de résultats suffisants. 
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2.3 APPENDIX C: CHARACTERISTICS OF FACE-TO-FACE 
INTERVIEWEES 







Namur M 34 Medical centre Few 17’ 
Namur M 59 Associated None 40’ 
Namur M 56 Alone Average 8’ 
Liège M 34 
Medical House + 
Hospital None 31’ 
Liège M 61 Alone A lot 35’ 
Bruxelles F 53 Alone Few 16’ 
Brabant 
Wallon F 49 Alone None 17’ 
Brabant 
Wallon M 56 Associated None 15’ 
Brabant 
Wallon F 36 Alone Very few 26’ 
Brabant 
Wallon M 35 
Medical House + 
Social work Very few 16’ 
Brabant 
Wallon F 59 Medical House Very few 31’ 
Hainaut F 34 
Medical House + 
Social work Few 15’ 
Hainaut F 33 Medical House Few 26’ 
Oost-
Vlaanderen M 52 Alone None 16’ 
Oost-
Vlaanderen M 56 Alone Very few 30’ 
Oost-
Vlaanderen M 58 Alone Very few 33’ 
Limburg F 58 Alone None 30’ 
West-
Vlaanderen M 54 Associated Few 8’ 
West-
Vlaanderen M 64 Associated Average 20’ 
West-
Vlaanderen M 61 Alone N/A 30’ 
West-
Vlaanderen M 48 Alone Average 23’ 
West-
Vlaanderen M 55 Alone A lot 15’ 
West-
Vlaanderen M 54 Alone N/A 19’ 
West-
Vlaanderen M 51 Alone Very few 30’ 
Antwerpen M 54 Associated A lot 25’ 
Antwerpen F 35 Associated None 16’ 
Antwerpen M 35 Associated Few 27’ 
Antwerpen M 58 Alone N/A 15’ 
Antwerpen M 54 Associated Very few 19’ 
Antwerpen M 51 Alone Very few 13’ 
Antwerpen M 58 Alone Average 21’ 
Antwerpen M 58 Alone N/A 30’ 
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Antwerpen M 48 Alone Few 13’ 
Oost-
Vlaanderen M 73 Alone Average 8’ 
Oost-
Vlaanderen F 55 Alone Very few 20’ 
Oost-
Vlaanderen M 71 Alone Average 11’ 
Vlaams 
Brabant F 37 Work Medicine N/A 13’ 
Vlaams 
Brabant M 50 Alone N/A 17’ 
Antwerpen M 56 Associated Few 20’ 
Antwerpen M 38 Associated None 20’ 
Caption for the “Number of pharmaceutical delegates” column: 
None: does not see any pharmaceutical delegate 
Very few: sees less than 15 pharmaceutical delegates a year 
Few: sees less than 30 pharmaceutical delegates a year 
Average: sees 1 or 2 delegates a week 
A lot: sees 6+ delegates a week 
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2.4 APPENDIX D. MAIN TOPICS TO BE INVESTIGATED, IN A 
GRID (FRENCH) 
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2.5 APPENDIX E: INVITATION MAIL TEXTS  
2.5.1 Version in French  
 
Docteur, 
Dans le cadre d’une étude portant sur votre perception du projet « évaluation de 
l’impact de la visite des délégués médicaux indépendants », de son utilité, de son 
influence, de son adéquation aux besoins des médecins, etc., le Centre fédéral 
d’expertise des soins de santé (KCE) a chargé le SPIRAL, centre de recherche de 
l’Université de Liège, de procéder à des entretiens individuels ainsi qu’à la mise en 
œuvre d’un questionnaire en ligne. 
Vous avez accepté de participer à cette étude nous vous en remercions. Votre avis est 
important pour notre recherche. Dans ce cadre, je me permets de prendre contact 
avec vous afin de vous inviter à participer à ce questionnaire en ligne. 
Le processus est confidentiel. En un simple clic sur ce lien 
<http://www.mesydel.com/?language=french>, vous aurez accès à l’outil informatique 
Mesydel qui servira de support à ce questionnaire. Vos identifiant et mot de passe sont : 
Identifiant : xxxxxx 
Mot de passe : yyyyyy 
Je vous serais très reconnaissante de bien vouloir compléter le questionnaire avant le 
dimanche 4 octobre prochain inclus. N’hésitez pas à me contacter – ou un autre 
membre de l’équipe – à tout moment ; nous sommes à votre disposition pour répondre 
à vos questions.  
D’avance, je vous remercie pour votre précieuse collaboration et vous prie de croire, 
Docteur, en l’assurance de mes sentiments les meilleurs. 
Stéphanie Vanhaeren 
Chargée de recherche 
Département de Science Politique de l’Université de Liège 
Laboratoire de recherche SPIRAL 
Téléphone : +32 (0) 4 366 46 97 
E-mail : S.Vanhaeren@ulg.ac.be 
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2.5.2 Version in Dutch 
 
Beste Doktor, 
In het kader van een lopende studie om de impact van zelfstandig medisch 
afgevaardigden op het voorschrijfgedrag van huisartsen te evalueren, heeft het Federaal 
Kenniscentrum voor de Gezondheidszorg (KCE) het SPIRAL (een kenniscentrum van de 
ULg) opdracht gegeven om face-to-face gesprekken en een online vragenlijst te boeken. 
U heeft aanvaard om aan deze studie deel te nemen, waarvoor wij u danken. 
Uw mening is belangrijk voor ons onderzoek. In dit kader neem ik contact met u op om 
u vriendelijk uit te nodigen deel te nemen aan deze online vragenlijst. 
Het proces is vertrouwelijk. Met een eenvoudige klik op de link 
http://www.mesydel.com/?language=dutch krijgt u toegang tot het informatienetwerk 




Aarzel niet om mij (of een ander lid van ons team) te contacteren. Wij staan steeds tot 
uw beschikking om al uw vragen te beantwoorden. 
Ik dank u voor uw waardevolle medewerking. 
Met de meeste hoogachting, 
Nick Geukens 
Onderzoeker 
Departement Politieke Wetenschappen – Universiteit van Luik 
SPIRAL kenniscentrum 
Telefoon: +32 (0) 4 366 46 97 
E-mail: Nick.Geukens@ulg.ac.be 
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2.6 APPENDIX F: WEB WELCOME (LOGGED-IN) TEXT  
2.6.1 Version in French 
 
Docteur, 
Vous avez donné votre accord pour participer au Mesydel du projet « évaluation de 
l’impact de la visite des délégués médicaux indépendants ». Ce dernier est organisé par 
le Centre fédéral d’expertise des soins de santé. La partie enquête est mise en œuvre 
par le centre de recherche SPIRAL de l’Université de Liège. 
La date limite pour répondre au questionnaire est le dimanche 4 octobre 2009. D’ici-là, 
vous aurez la possibilité d’enrichir à tout moment vos réponses via cette interface. 
Le processus est tout à fait anonyme et la seule contrainte à respecter pour remplir le 
questionnaire est d’argumenter vos réponses. Le temps pour répondre aux neuf 
questions est estimé à une demi-heure au maximum. 
Au nom de l’équipe du SPIRAL, je vous remercie pour votre précieuse participation. Si 
vous êtes intéressé par les résultats de cette étude, laissez-nous votre adresse mail. 
Nous nous ferons un plaisir de vous contacter lors de sa publication. N’hésitez pas à me 
contacter – ou un autre membre de l’équipe – à tout moment ; nous sommes à votre 
disposition pour répondre à vos questions. 
 
Stéphanie Vanhaeren 
Chargée de recherche 
Département de Science Politique de l’Université de Liège 
Laboratoire de recherche SPIRAL 
Téléphone : +32 (0) 4 366 46 97 
E-mail : S.Vanhaeren@ulg.ac.be 
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2.6.2 Version in Dutch 
 
Beste Doktor, 
U hebt geaccepteerd om deel te nemen aan de studie over de evaluatie van zelfstandig 
medisch aanvaardigden. Het KCE is verantwoordelijk voor deze studie. Een deel ervan 
wordt aan het SPIRAL – een kenniscentrum van de ULg - toevertrouwd. 
De deadline om de vragenlijst in te vullen is 4 oktober 2009. Het proces is 
vertrouwelijk en duurt ongeveer een half uur. U kunt uw vragen tot de deadline op 
ieder ogenblik blijven aanpassen en aanvullen. 
In naam van SPIRAL dank ik u voor uw deelname. Indien u geïnteresseerd bent in de 
resultaten van ons onderzoek, gelieve dan uw e-mail adres te geven. Het zal ons plezier 
doen u van de publicatie op de hoogte te stellen. Aarzel niet om mij (of een ander 
teamlid) te contacteren. Wij staan steeds tot uw beschikking om al uw vragen te 
beantwoorden. 
Ik dank u voor uw waardevolle medewerking. 
Met de meeste hoogachting, 
Nick Geukens 
Onderzoeker 
Departement Politieke Wetenschappen – Universiteit van Luik 
SPIRAL kenniscentrum 
Telefoon: +32 (0) 4 366 46 97 
E-mail: Nick.Geukens@ulg.ac.be 
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2.7 APPENDIX G: MESYDEL PARTICIPANTS 
2.7.1 Contacted GPs for the Mesydel session: response rates 
Round 1 
All GPs who accepted to participate by letter (297 GPs) received a voucher. By sending 
back this voucher to KCE, they gave Spiral their e-mail address and agreed to 
participate to the study.  
At the end of the first round (October 5th), 152 GPs sent their voucher back to KCE 
with their e-mail address, therefore accepting to participate to the Mesydel. 
Figure 4. Attrition table for the first round of the Mesydel 
 
A few of them did provide an incorrect e-mail address. We were able to fix most of 
them by phoning the GPs and therefore to encode and invite 147 of the 152 GPs (26 
French-speaking and 121 Dutch-speaking). By not having the e-mail address of all the 
GPs and having recourse to the voucher system, we lost half of the sample for the 
Mesydel (50,5%). The KCE original listing based on the original Farmaka sample appears 
greyed in Figure 4. 
As of October 5th, 18 (on 26, i.e. 69,2%) French-speaking GPs and 93 (on 121, i.e. 
76,9%) Dutch-speaking GPs answered the Mesydel (a total of 111 GPs, i.e. 75,6% of the 
GPs who sent their voucher back to KCE). 
B. Round 2 
At the end of the Mesydel session, 154 GPs had send their voucher back to KCE with 
their e-mail addresses, therefore accepting to participate to the Mesydel. 
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Figure 5. Attrition table for the second round of the Mesydel 
 
After fixing a few more e-mail addresses, we invited 152 of the 154 GPs (28 French-
speaking and 124 Dutch-speaking).  
At the end of the second round, 21 (on 28, i.e. 75%) French-speaking GPs and 87 (on 
124, i.e. 70,1%) Dutch-speaking GPs answered the Mesydel (a total of 108 GPs, i.e. 71% 
of the GPs who sent their voucher back to KCE). 
2.7.2 Characteristics of the Mesydel participants 





Round 1 Round 2 
Antwerp M 50 Alone A lot X X 
Antwerp M 58 Alone Few X X 
Antwerp M 58 Alone A lot X X 
Antwerp M 55 Alone A lot X X 
Antwerp F 43 Alone Very few X  
Antwerp M 60 Alone N/A X X 
Antwerp F 37 Alone A lot X X 
Antwerp M 50  Alone A lot X X 
Antwerp M 38 Alone Few X X 
Antwerp M 53 Alone A lot X X 
Antwerp M 54 Alone A lot X X 
Antwerp M 32 Associated Few X X 
Antwerp M 35 Associated Few X X 
Antwerp F 46 Associated Average X X 
Antwerp M 50 Associated Few X X 
Antwerp M 44 Associated Few X  
Antwerp  M N/A Associated Few X X 
Antwerp M 65 Associated Very few X X 
Antwerp M 32 Associated Few X X 
Antwerp F 37 Associated Very few X X 
Antwerp M 50 Associated None X  
Antwerp M N/A N/A N/A  X 
Antwerp M N/A N/A N/A  X 
Antwerp M N/A N/A N/A  X 
Antwerp M N/A N/A N/A  X 
Antwerp M N/A N/A N/A  X 
Antwerp F N/A N/A N/A  X 
Antwerpen M 67 Alone Very few X X 
Antwerpen M 51 Alone Few X X 
Antwerpen M 53 Alone N/A X  
Antwerpen M 62 Associated None X X 
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Brabant Wallon F 49 Alone None X X 
Brabant Wallon M 49 Alone A lot X X 
Brabant Wallon F 51 Associated Average X X 
Brabant Wallon M 57 Associated Very few X  
Brabant Wallon M 34 Associated Few X X 
Brabant Wallon M 36 Medical 
House 
Few X X 
Brabant Wallon M N/A N/A N/A  X 
Brabant Wallon F N/A N/A N/A  X 
Hainaut M 60  Alone None X X 
Hainaut F 33 Associated Average X X 
Hainaut M 53 Associated None X X 
Hainaut M 48 Medical 
House 
None X X 
Hainaut M 61 Medical 
House 
None X X 
Hainaut F 47 Medical 
House 
Few X X 
Hainaut F 54 Medical 
House 
Very few X X 
Hainaut F 35 Medical 
House 
Few X X 
Hainaut F N/A N/A N/A X X 
Liège M 36 Medical 
House + 
Hospital 
None X X 
Limburg M 60 Alone Few X X 
Limburg F 41 Alone Few X X 
Limburg M 45 Alone A lot X X 
Limburg M 58 Alone A lot X  
Limburg F 58 Alone None X  
Limburg M 61 Associated Very few X X 
Limburg M 55 Associated Few X X 
Limburg M N/A N/A N/A X  
Namur M  51 Alone Average X X 
Namur M 35 Associated A lot X X 
Namur M N/A N/A N/A  X 
Namur M N/A N/A N/A  X 
Oost-Vlaanderen M 46 Alone A lot X X 
Oost-Vlaanderen M  65 Alone  Few X X 
Oost-Vlaanderen M 51 Alone A lot X X 
Oost-Vlaanderen F 55 Alone Very few X X 
Oost-Vlaanderen M 59 Alone Few X X 
Oost-Vlaanderen M 56 Alone A lot X X 
Oost-Vlaanderen M 42 Alone Few X X 
Oost-Vlaanderen M 63  Alone Few X X 
Oost-Vlaanderen F 30  Alone A lot X X 
Oost-Vlaanderen M 47 Alone N/A X X 
Oost-Vlaanderen M 56  Alone Few X X 
Oost-Vlaanderen M 52 Alone None X X 
Oost-Vlaanderen M 53 Alone A lot X X 
Oost-Vlaanderen M 48 Alone Few X X 
Oost-Vlaanderen F 56 Alone Few X X 
Oost-Vlaanderen M 71 Alone A lot X X 
Oost-Vlaanderen M 64 Alone Very few X  
Oost-Vlaanderen M 72 Associated Average X X 
Oost-Vlaanderen M 51 Associated Average X X 
Oost-Vlaanderen M 33 Associated None X X 
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Oost-Vlaanderen M 61 Associated A lot X X 
Oost-Vlaanderen M 56 Associated Few X  
Oost-Vlaanderen F 37 Associated Few X  
Oost-Vlaanderen M 57 Associated Very few X X 
Oost-Vlaanderen M 59 Associated Few X X 
Oost-Vlaanderen M 53 Associated A lot X X 
Oost-Vlaanderen M 43 Associated Few X X 
Oost-Vlaanderen M 55 Associated Few X X 
Oost-Vlaanderen M 52 Associated A lot X X 
Oost-Vlaanderen M 59  Associated Few X X 
Oost-Vlaanderen M 50  Associated Few X  
Oost-Vlaanderen M N/A N/A N/A X X 
Oost-Vlaanderen M N/A N/A N/A  X 
Vlaams Brabant M 56  Alone Very few X X 
Vlaams Brabant M 50 Alone A lot X  
Vlaams Brabant F 37 Associated Average X X 
Vlaams Brabant F 64 Associated None X X 
Vlaams Brabant M 40  Associated A lot X X 
Vlaams Brabant F 49 Associated A lot X X 
Vlaams Brabant M N/A N/A N/A  X 
West-Vlaanderen M 65 Alone Average X X 
West-Vlaanderen M 59 Alone None X X 
West-Vlaanderen F 49 Alone Few X X 
West-Vlaanderen M 49  Alone N/A X X 
West-Vlaanderen M 51 Alone Very few X X 
West-Vlaanderen M 61 Alone A lot X X 
West-Vlaanderen M 57 Alone Few X X 
West-Vlaanderen M 49  Alone A lot X X 
West-Vlaanderen M 57 Alone Few X  
West-Vlaanderen M 57 Alone A lot X  
West-Vlaanderen M 55  Alone A lot X  
West-Vlaanderen M 48 Alone Few X X 
West-Vlaanderen M 58  Alone Few X  
West-Vlaanderen M 54 Alone + 
Social work 
A lot X X 
West-Vlaanderen F 34 Associated Average X X 
West-Vlaanderen M 55 Associated Average X X 
West-Vlaanderen M 53 Associated None X X 
West-Vlaanderen F 35 Associated Few X X 
West-Vlaanderen M 38 Associated None X X 
West-Vlaanderen F 31 Associated Very few X X 
West-Vlaanderen M N/A N/A N/A X X 
West-Vlaanderen M N/A N/A N/A  X 
West-Vlaanderen M N/A N/A N/A  X 
West-Vlaanderen M N/A N/A N/A  X 
West-Vlaanderen M N/A N/A N/A X  
Caption for the “Number of pharmaceutical delegates” column: 
None: does not see any pharmaceutical delegate 
Very few: sees less than 15 pharmaceutical delegates a year 
Few: sees less than 30 pharmaceutical delegates a year 
Average: sees 1 or 2 delegates a week 
A lot: sees 6+ delegates a week 
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2.8 APPENDIX H: QUESTIONS FOR THE FIRST MESYDEL 
ROUND  
2.8.1 Version in French 
1. L’information fournie par les délégué(e)s Farmaka est-elle applicable dans 
votre pratique ? 
2. L’information fournie par les délégué(e)s Farmaka est-elle utile à votre 
pratique ? 
3. Selon vous, les délégué(e)s Farmaka ont-ils une formation adéquate ? 
4. Quelle serait la formation minimale requise pour être délégué(e) Farmaka ? 
5. Est-ce que les délégué(e)s Farmaka ont changé votre pratique 
professionnelle? 
6. Quel est ou quels sont les sujets qui vous a ou ont été présenté(s) par le ou 
la délégué(e) Farmaka?  
7. Vous sentiez-vous concerné par ces sujets? 
8. Dans quelle mesure compareriez-vous les visites de délégués médicaux 
indépendants à celles des représentants commerciaux? 
9. Quelle est votre opinion sur le rôle des firmes pharmaceutiques dans le 
processus d’information médicale? 
10. Quel rôle devrait jouer à vos yeux l’État dans le processus d’information 
médicale? 
11. Pouvez-vous nous préciser (en quelques mots si nécessaire) : 
a. Combien d’heures vous travaillez par semaine ; 
b. L’organisation de votre cabinet (vous travaillez seul, en collaboration avec 
d’autres médecins, en maison médicale, etc.) ; 
c. Votre type de patientèle (âgée, précaire, faible niveau d’instruction, etc.); 
d. Le nombre de représentants commerciaux que vous recevez par semaine 
ou par mois ; 
e. Votre âge. 
2.8.2 Version in Dutch 
1. Geven de artsenbezoekers van Faramaka informatie die u in uw praktijk kan 
toepassen? 
2. Verschaffen de artsenbezoekers van Farmaka nuttige informatie voor uw 
praktijk? 
3. Hebben de artsenbezoekers van Farmaka volgens u een adequate vorming 
genoten? 
4. Wat zou volgens u het minimum niveau moeten zijn om arstenbezoeker te 
kunnen worden? 
5. Hebben de arstenbezoekers van Farmaka uw professionele praktijk gewijzigd? 
6. Welke thema(s) werde(n) u door de artsenbezoekers van Farmaka 
voorgesteld? 
7. Gaan deze thema’s u aan? 
8. In welke mate kunt u de bezoeken van de onafhankelijke artsenbezoekers 
vergelijken met die van de vertegenwoordigers van de medische firma’s? 
9. Wat denkt u over de rol van de farmaceutische firma’s in de verstrekking van 
medische informatie? 
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10. Welke rol zou de Staat volgens u moeten spelen in de verstrekking van 
medische informatie? 
11. Kunt u verduidelijken of uitleggen (in enkele woorden): 
a. Hoeveel uur werkt u gemiddeld per week?; 
12. De organisatie van uw medisch kabinet (groeps-praktijk of solo); 
13. Uw patiënten (leeftijd, sociaal niveau,…); 
14. Het aantal medisch afgevaardigden dat u per week of per maand ontvangt; 
15. Uw leeftijd. 
2.9 APPENDIX I. QUESTIONS FOR THE SECOND MESYDEL 
ROUND 
2.9.1 Version in French 
1. Le rôle de l’État sur les habitudes de prescription des médecins a suscité des 
polémiques lors du premier tour de ce questionnaire. : 
Nous avons pu lire : 
! « Avec les visiteurs médicaux indépendants, on a le sentiment d’être dans 
un processus de formation, un peu comme à un recyclage (formation 
continue), mais sur un sujet qui m’intéresse. Ça devrait peut-être compter 
pour l’accréditation. » 
! « L’État ne devrait avoir aucun rôle [dans nos habitudes de prescription]. 
J’ai un regard très soupçonneux par rapport à l’État. Ils nous poussent à 
prescrire toujours moins cher. » 
Pourriez-vous vous situer quant à ces deux positions ? 
Seriez-vous disposé(e) à modifier vos habitudes de prescription ? Si oui, pensez-vous 
qu’une contrepartie soit nécessaire ? 
2. Lors du premier tour de ce questionnaire, nous avons pu lire : 
! « [Le visiteur Farmaka est] un scientifique concerné par la santé des 
patients et soucieux d’améliorer la qualité de la médecine sur base de 
critères validés internationalement. » 
! « [Les visiteurs Farmaka] sont politiquement teintés. Je n’ai pas besoin 
qu’un vienne m’apprendre la science sous un couverture idéologique – 
c’est un peu ce qu’ils font. » 
Avez-vous le sentiment que le visiteur Farmaka a un discours plutôt scientifique ou 
plutôt politique ? 
3. Lors du premier tour de ce questionnaire, nous avons pu lire : 
! « [Nous devrions avoir accès à une] information la plus objective possible 
comme déjà avec le CBIP. Pourquoi pas offrir aussi une sorte de hotline ? 
» 
! « Ils devraient nous donner accès à la bibliothèque Cochrane. Là, on 
aurait tout ce qu’il nous faut ! » 
! « Si Farmaka s’adressait aussi aux patients, ça faciliterait mon travail, parce 
qu’il y a plein d’infos que je ne devrais plus donner. » 
Pensez-vous que Farmaka devrait étendre ses services (via une ligne téléphonique, la 
fourniture d’accès à des bibliothèques en ligne, ou même donner une information 
directe aux patients) ? 
Si oui, quel(s) service(s) vous paraîtraient les plus adéquats ? 
4. Lors de nos entretiens, nous avons entendu : 
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! « Je sais que mes confrères pensent différemment, mais j’ai une très haute 
opinion de Farmaka ! » 
! « Sans Farmaka (et le CBIP ou encore les folia) nous serions manipulés 
dans tous les sens. » 
Comment vous situez-vous par rapport à ces citations ? 
5. Lors de nos entretiens, nous avons entendu : 
« Vous savez, un de mes rôles, moi, c’est d’informer mon patient pour qu’il soit juge de 
sa maladie. Mais je ne pense pas que la majorité de mes confrères partage ma vision. » 
! Êtes-vous d’accord avec cette affirmation ? 
! Vous-même, vous sentez-vous représentatif des médecins généralistes 
belges ? Quelle(s) serai(en)t votre/vos particularités par rapport à vos 
confrères ? 
6. Dans votre pratique, trouvez-vous plus facile de gérer une incertitude liée à 
un traitement 
! selon que l’information vous est communiquée via un spécialiste faisant 
autorité ; 
! selon des études basées sur des preuves scientifiques. 
7. Pensez-vous que le service rendu par Farmaka devrait s’étendre à tous les 
médecins généralistes de Belgique ? 
Pour quelle(s) raison(s) ? 
8. Ceci conclut les deux tours de notre enquête en ligne. 
Avez-vous des suggestions, des sujets, des idées qui n’ont pas été abordées et que vous 
trouvez essentielles quant aux visiteurs indépendants ? 
2.9.2 Version in Dutch 
1. De rol van de overheid op het voorschrijfgedrag van huisartsen heeft 
controverse opgewekt in de eerste ronde van de vragenlijst. 
Uit de eerste ronde van de vragenlijst konden we afleiden: 
! "Bij de onafhankelijke artsenbezoekers hadden we het gevoel dat we ons 
in een soort bijscholing bevonden, een beetje een opfrissing (continue 
navorming), maar dan van een onderwerp dat me interesseert. Misschien 
zou het voor accreditering in aanmerking moeten komen." 
! "De overheid zou geen rol mogen spelen [in ons voorschrijfgedrag]. Ik kijk 
zeer wantrouwig naar de overheid. Ze pushen ons altijd om goedkoper 
voor te schrijven." 
Hoe situeert u zichzelf ten aanzien van deze twee visies? 
Bent u bereid uw voorschrijfgedrag aan te passen? Indien ja, vindt u dan dat daar iets 
zou moeten tegenover staan? 
2. Uit de eerste ronde van de vragenlijst konden we afleiden: 
! "[De artsenbezoeker van Farmaka is] een wetenschapper, begaan met de 
gezondheid van patiënten en gericht op de kwaliteitsverbetering van (niet-
)medicamenteuze behandeling, gebaseerd op internationaal gevalideerde 
criteria." 
! "[De artsenbezoekers van Farmaka zijn] politiek gekleurd. Ik heb niemand 
nodig om me wetenschap te komen aanleren onder een ideologische 
paraplu, en dat doet het KCE een beetje." 
Heeft u het gevoel dat de artsenbezoeker van Farmaka een meer wetenschappelijk of 
een meer politiek discours volgt? 
3. Uit de eerste ronde van de vragenlijst konden we afleiden: 
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! "[We zouden toegang moeten hebben tot] de meest neutrale informatie 
mogelijk, zoals we nu al hebben met het BCFI. Waarom bieden ze ook 
niet een soort hotline aan?" 
! "Ze zouden ons toegang moeten geven tot de Cochrane Library. Daar 
zouden we alles vinden wat we nodig hebben!" 
! "Als Farmaka ook met patiënten zou praten, zou dit mijn eigen werk 
vergemakkelijken, omdat er veel informatie zou zijn die ik zelf niet meer 
zou moeten geven." 
Denkt u dat Farmaka zijn diensten zou moeten uitbreiden (telefonisch, door toegang te 
verschaffen tot online bibliotheken, of zelfs door rechtstreeks informatie te verschaffen 
aan de patiënten zelf)? 
Indien ja, welke dienst(en) zou u als de meest afdoende beschouwen? 
4. Tijdens de interviews hoorden we: 
! "Ik weet dat mijn collega’s er anders over denken, maar ik sta erg positief 
tegenover Farmaka!" 
! "Zonder Farmaka (en het BCFI en de Folia) zouden we gemanipuleerd 
worden langs alle kanten." 
Hoe situeert u zichzelf ten aanzien van deze twee visies? 
5. Tijdens de interviews hoorden we: 
"Weet u, één van mijn rollen, voor mij althans, is mijn patiënten te informeren zodat 
hij/zij in staat is om zelf te oordelen over zijn/haar ziekte. Maar ik denk niet dat de 
meerderheid van mijn collega’s mijn visie deelt." 
! Bent u het met dit statement eens? 
! Beschouwt u zichzelf als een vertegenwoordiger van de Belgische 
huisartsen? Wat zou u zelf als uw (eventuele) specifieke kenmerken 
beschouwen in vergelijking met uw collega’s? 
6. Vindt u het gemakkelijker om een onzekerheid ten aanzien van een bepaalde 
behandeling aan te pakken: 
! overeenkomstig de visie van een specialist, een autoriteit in zijn/haar 
domein; 
! overeenkomstig studies gebaseerd op wetenschappelijke bewijzen. 
7.  Vindt u dat de diensten aangeboden door Farmaka uitgebreid zouden 
moeten worden tot alle huisartsen in België? 
Om welke reden(en)? 
8. Hiermee besluiten we de tweede ronde van onze online vragenlijst. 
Heeft u suggesties, topics, ideeën die nog niet werden aangesproken en die u essentieel 
acht ten aanzien van de onafhankelijke artsenbezoekers? 
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2.10 APPENDIX J: DISCUSSION OF THE MESYDEL QUESTIONS 
2.10.1 Round 1 
The questions for the first round of the Mesydel were exploratory questions and 
modelled against the behaviour change theory. We analysed them in a classical way (by 
reading them and analysing answers sequentially). We were not able to apply a 
methodology based on the grounded theory, both because they were written with 
another framework in mind and because it would not have made much sense for 
exploratory questions (see appendix H for the questions in French and in Dutch.). 
2.10.2 Round 2 
The questions for the second round of the Mesydel were the final ones. They were 
written so that the answers could be analyzed with a methodology based on the 
grounded theory. In this section, we briefly illustrate the method of the tag clouds 
(questions are in English in this appendix, see appendix I the original versions). 
Question 1 
The role of the State on the prescribing behaviour of GP’s has generated a lot of 
controversy in the first round of the questionnaire. 
In the first round of the questionnaire, we read: 
! "With the independent medical visitors, we have the feeling of being in a 
process of training, just as a refresher (continuing education), but on a 
subject that interests me. Perhaps it should count for accreditation." 
! "The State should have no role [in our prescribing habits]. I look very 
suspiciously at the State. They push us to always prescribe cheaper." 
How do you stand in relation to these two visions? 
Would you be willing to change your prescribing behaviour? If yes, do you think that a 
return is necessary? 
Figure 3: Tags for the French Mesydel question 1, round 2 
 
Figure 4: Tags for the Dutch Mesydel question 1, round 2 
 
In this question, we searched to: 
! dig further the question of the State perception by GP’s; 
! see how GP’s see the role of the State in their prescribing behaviour; 
! if a return would be welcome or necessary in order for GP’s to accept to 
meet Farmaka visitors. 
Question 2 
In the first round of the questionnaire, we read: 
! "[The Farmaka visitor is] a scientist concerned with the health of patients 
and willing to improve the quality of medicine based on internationally 
validated criteria." 
! "[Farmaka visitors] are politically tainted. I don’t need people to teach me 
science under an ideological umbrella – it’s a bit what they do." 
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Do you feel that the Farmaka visitor has a rather scientific or rather political discourse? 
Figure 5: Tags for the French Mesydel question 2, round 2 
 
Figure 6: Tags for the Dutch Mesydel question 2, round 2 
 
In this question, we searched to see if the Farmaka visitor was seen as being scientific or 
political. A third answer emerged: economical. 
Question 3 
In the first round of the questionnaire, we read: 
! "[We should have access to] the most objective information possible, as 
we already have with the CBIP. Why not also provide some sort of 
hotline?" 
! "They should give us access to the Cochrane Library. There, we would 
have everything we need!" 
! "If Farmaka was aimed at patients too, it would facilitate my work, 
because there would be many details that I would not have to give myself 
anymore." 
Do you think Farmaka should extend its services (through a telephone line, providing 
access to online libraries, or even by providing direct information to patients)? 
If yes, what service(s) do you think would be most appropriate? 
Figure 7: Tags for the French Mesydel question 3, round 2 
 
Figure 8: Tags for the Dutch Mesydel question 3, round 2 
 
In this question, we searched to: 
! test if an online service or a hotline would be of interest to the GP’s and 
how they would like to see it implemented. 
! test if an access to the Cochrane Library (and other publications of the 
same kind) would interest the GP’s; 
! test if Farmaka should extend its services to patients. 
Question 4 
During our interviews, we heard: 
! "I know my colleagues feel differently, but I have a very high opinion of 
Farmaka!" 
! "Without Farmaka (and the CBIP/BCFI and the folia) we would be 
manipulated from all sides." 
How do you stand in relation to these views? 
Figure 9: Tags for the French Mesydel question 4, round 2 
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Figure 10: Tags for the Dutch Mesydel question 4, round 2 
 
In this question, we searched to: 
! test the visibility of Farmaka; 
! test the perception of Farmaka; 
! test if Farmaka was an efficient counterweight to pharmaceutical 
delegates. 
Question 5 
During our interviews, we heard: 
"You know, one of my roles in my opinion is to inform my patients so that they can be a judge 
to their own illness. But I don’t think the majority of my colleagues share my view." 
! Do you agree with this statement? 
! Do you feel yourself a representative of the Belgian GP’s? What would be 
your characteristic features wehn compared to your colleagues? 
Figure 11: Tags for the French Mesydel question 5, round 2 
 
Figure 12: Tags for the Dutch Mesydel question 5, round 2 
 
In this question, we searched to: 
! see if the GP’s have open discussions with their patients or have a more 
paternalistic posture; 
! see if the GP’s feel representative of the “Belgian GP”. 
Question 6 
In your practice do you find it easier to manage uncertainty related to a treatment 
! according to the view of a who has an authority in his/her domain; 
! according to studies based on scientific evidence. 
Figure 13: Tags for the French Mesydel question 6, round 2 
 
Figure 14: Tags for the Dutch Mesydel question 6, round 2 
 
In this question, we searched to: 
! see if uncertainties related to a treatment are solved through EBM or 
ABM (“Authority Based Medicine); 
! test the relation between GP’s and specialists. 
Question 7 
Do you think the services provided by Farmaka should be extended to all GP’s in 
Belgium? 
For what reason(s)? 
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Figure 15: Tags for the French Mesydel question 7, round 2 
 
Figure 16: Tags for the Dutch Mesydel question 7, round 2 
 
In this question, we searched to see if Farmaka should extend its services to all Belgian 
GP’s and to make emerge various opinions about the topic. 
Question 8 
This concludes the two rounds of our online survey. 
Do you have any suggestions, topics, ideas that have not been addressed and that you 
feel are essential when it comes to independent visitors? 
Figure 17: Tags for the French Mesydel question 8, round 2 
 
Figure 18: Tags for the Dutch Mesydel question 8, round 2 
 
This question was essentially there to check if we had not forgotten important topics. 
Nothing new emerged; we can therefore conclude that the two Mesydel rounds 
covered the important parts about the topic. This question also served as information 
for the GP’s that the Mesydel session was now finished for them. 
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3 APPENDICES - ANALYSIS OF IMA DATABASE 
3.1 DIABETES TOPIC 
3.1.1 Descriptive statistics: number of patients by GP – Overall Population 
Statistics Value 
N 156 
Mean (sd) 42 (26) 
Median 41 
Q1 – Q3 25 – 55 
Min – Max 1 – 156 




Mean (sd) 68 (13) 
Median 69 
Q1 – Q3 60 – 77 
Min – Max 18 - 101 
3.1.3 Number (%) of patients by type of therapy given before and after the AD 




Therapy given After the AD visit 
0 1 2 3 4 5 6 7 8 9 Total 
0 0 733 236 0 36 118 47 14 5 4 1193 
0.00 11.13 3.58 0.00 0.55 1.79 0.71 0.21 0.08 0.06 18.12 
1 457 1614 45 35 18 76 60 5 2 4 2316 
6.94 24.51 0.68 0.53 0.27 1.15 0.91 0.08 0.03 0.06 35.18 
2 208 49 818 16 4 140 2 11 2 3 1253 
3.16 0.74 12.42 0.24 0.06 2.13 0.03 0.17 0.03 0.05 19.03 
4 61 17 3 7 161 3 39 12 0 7 310 
0.93 0.26 0.05 0.11 2.45 0.05 0.59 0.18 0.00 0.11 4.71 
5 95 73 135 2 4 492 6 6 11 4 828 
1.44 1.11 2.05 0.03 0.06 7.47 0.09 0.09 0.17 0.06 12.58 
6 49 70 2 60 47 0 207 3 1 11 450 
0.74 1.06 0.03 0.91 0.71 0.00 3.14 0.05 0.02 0.17 6.83 
7 13 2 18 12 14 8 11 42 4 5 129 
0.20 0.03 0.27 0.18 0.21 0.12 0.17 0.64 0.06 0.08 1.96 
8 6 2 2 7 0 7 1 6 11 0 42 
0.09 0.03 0.03 0.11 0.00 0.11 0.02 0.09 0.17 0.00 0.64 
9 5 0 1 4 4 3 5 7 0 34 63 
0.08 0.00 0.02 0.06 0.06 0.05 0.08 0.11 0.00 0.52 0.96 
Total 894 2560 1260 143 288 847 378 106 36 72 6584 
13.58 38.88 19.14 2.17 4.37 12.86 5.74 1.61 0.55 1.09 100.00 
0 = None/ No data available 
1 = Monotherapy – Metformin (Recommended) 
2 = Monotherapy – Sulfonylurea (Recommended) 
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3 = Monotherapy – Insulin 
4 = Monotherapy – Others  
5 = Bitherapy – Metformin & Sulfonylurea (Recommended) 
6 = Bitherapy – Metformin & Others 
7 = Bitherapy – Others 
8 = Tritherapy – Metformin & Sulfonylurea + Insulin (Recommended) 
9 = Others 
3.1.4 Number (%) of Patients by type of therapy given before and after the AD 




Therapy given After the AD visit 
1 2 3 4 5 6 7 8 9 Total 
1 1614 45 35 18 76 60 5 2 4 1859 
35.89 1.00 0.78 0.40 1.69 1.33 0.11 0.04 0.09 41.34 
2 49 818 16 4 140 2 11 2 3 1045 
1.09 18.19 0.36 0.09 3.11 0.04 0.24 0.04 0.07 23.24 
4 17 3 7 161 3 39 12 0 7 249 
0.38 0.07 0.16 3.58 0.07 0.87 0.27 0.00 0.16 5.54 
5 73 135 2 4 492 6 6 11 4 733 
1.62 3.00 0.04 0.09 10.94 0.13 0.13 0.24 0.09 16.30 
6 70 2 60 47 0 207 3 1 11 401 
1.56 0.04 1.33 1.05 0.00 4.60 0.07 0.02 0.24 8.92 
7 2 18 12 14 8 11 42 4 5 116 
0.04 0.40 0.27 0.31 0.18 0.24 0.93 0.09 0.11 2.58 
8 2 2 7 0 7 1 6 11 0 36 
0.04 0.04 0.16 0.00 0.16 0.02 0.13 0.24 0.00 0.80 
9 0 1 4 4 3 5 7 0 34 58 
0.00 0.02 0.09 0.09 0.07 0.11 0.16 0.00 0.76 1.29 
Total 1827 1024 143 252 729 331 92 31 68 4497 
40.63 22.77 3.18 5.60 16.21 7.36 2.05 0.69 1.51 100.00 
1 = Monotherapy – Metformin (Recommended) 
2 = Monotherapy – Sulfonylurea (Recommended) 
3 = Monotherapy – Insulin 
4 = Monotherapy – Others  
5 = Bitherapy – Metformin & Sulfonylurea (Recommended) 
6 = Bitherapy – Metformin & Others 
7 = Bitherapy – Others 
8 = Tritherapy – Metformin & Sulfonylurea + Insulin (Recommended) 
9 = Others 
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3.1.5 Volume (in number of Defined Daily Doses) by Group of Medications, Population and Semesters – Diabetes 
 
Volume in number of DDDs 
N Mean Std Median Q1 Q3 Min Max 
Medication Group population semestre 
80 341.31 402.86 158.67 74.67 494.67 18.67 1829.34 Glitazones Visited GPs 2006-S1 
2006-S2 76 347.48 376.85 205.34 93.34 541.33 18.67 1642.67 
2007-S1 82 355.01 373.27 214.67 112.00 448.01 14.00 1810.66 
2007-S2 77 378.79 412.29 224.00 112.00 485.34 14.00 2183.99 
2008-S1 75 398.72 433.09 224.00 112.00 504.00 18.67 2165.32 
2008-S2 73 359.40 402.90 224.00 93.34 466.67 18.67 1829.32 
Overall GPs 2006-S1 6432 258.04 312.87 149.34 70.00 336.00 0.00 4242.02 
2006-S2 6609 259.79 316.88 149.33 74.67 336.00 0.00 4624.70 
2007-S1 6710 279.60 335.31 168.00 74.67 354.67 14.00 4703.98 
2007-S2 6724 272.37 325.21 168.00 74.67 354.67 0.00 4741.30 
2008-S1 6403 292.04 350.56 186.67 74.67 373.34 0.00 5058.65 
2008-S2 6128 302.83 367.24 186.67 74.67 392.00 14.00 5319.97 
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Volume in number of DDDs 
N Mean Std Median Q1 Q3 Min Max 
Metformin Visited GPs 2006-S1 148 2290.27 1732.81 1992.25 1066.75 3261.25 15.00 10207.50 
2006-S2 149 2315.58 1722.86 2072.00 1081.00 2977.50 42.50 9395.00 
2007-S1 149 2540.19 1847.33 2219.00 1170.00 3490.00 30.00 11068.50 
2007-S2 153 2600.99 1890.20 2377.00 1198.00 3450.00 15.00 10967.50 
2008-S1 155 2872.65 2098.09 2519.50 1186.00 4121.00 75.00 11862.00 
2008-S2 155 3018.93 2132.44 2675.00 1329.50 4254.50 57.50 11053.50 
Overall GPs 2006-S1 17094 1504.20 1848.73 915.00 127.50 2266.50 15.00 41077.50 
2006-S2 17258 1503.96 1834.01 907.50 127.50 2287.50 15.00 41766.00 
2007-S1 17229 1627.86 1998.23 987.50 136.00 2468.50 0.00 38453.50 
2007-S2 17525 1639.94 1998.89 970.50 127.50 2533.50 15.00 40278.00 
2008-S1 17925 1833.11 2298.22 1053.50 127.50 2822.00 0.00 43457.00 
2008-S2 17993 1870.97 2306.01 1064.50 127.50 2920.00 0.00 41649.50 
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Volume in number of DDDs 
N Mean Std Median Q1 Q3 Min Max 
Metformin & derivates of 
Sulfonylurea 
Visited GPs 2006-S1 64 598.13 687.44 420.00 240.00 750.00 60.00 3780.00 
2006-S2 72 485.83 532.97 300.00 150.00 690.00 60.00 2940.00 
2007-S1 73 527.67 621.69 300.00 180.00 660.00 60.00 3540.00 
2007-S2 77 472.21 551.57 240.00 180.00 600.00 60.00 2640.00 
2008-S1 79 535.44 661.17 240.00 180.00 660.00 60.00 3480.00 
2008-S2 80 495.00 670.21 240.00 120.00 600.00 60.00 4200.00 
Overall GPs 2006-S1 5189 491.16 701.33 240.00 120.00 600.00 0.00 15660.00 
2006-S2 5357 464.27 626.66 240.00 120.00 540.00 60.00 10260.00 
2007-S1 5309 493.84 715.63 240.00 120.00 600.00 60.00 18720.00 
2007-S2 5272 469.56 616.12 240.00 120.00 540.00 60.00 10500.00 
2008-S1 5396 508.90 749.19 240.00 120.00 600.00 60.00 14400.00 
2008-S2 5357 479.46 664.10 240.00 120.00 540.00 60.00 9240.00 
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Volume in number of DDDs 
N Mean Std Median Q1 Q3 Min Max 
Others (Diabetes), including the 
medications in Metformin & 
Rosiglitazone 
Visited GPs 2006-S1 101 578.01 670.07 315.00 180.00 690.00 15.00 3270.00 
2006-S2 103 586.39 665.97 330.00 135.00 810.00 15.00 3540.00 
2007-S1 108 644.21 783.76 360.00 150.00 682.50 15.00 3765.00 
2007-S2 110 655.95 823.95 378.50 150.00 810.00 15.00 3825.00 
2008-S1 116 782.53 968.22 390.00 180.00 979.00 15.00 4868.00 
2008-S2 127 735.58 917.31 435.00 135.00 908.00 0.67 4948.67 
Overall GPs 2006-S1 9921 509.99 689.23 255.00 75.00 660.00 15.00 10395.00 
2006-S2 10089 502.65 671.67 255.00 75.00 645.00 15.00 9375.00 
2007-S1 10299 533.86 717.43 270.00 90.00 690.00 0.00 11460.00 
2007-S2 10430 540.39 718.05 270.00 90.00 705.00 15.00 9885.00 
2008-S1 10921 607.69 822.62 300.00 90.00 795.00 0.00 14911.00 
2008-S2 11189 635.94 831.26 330.00 98.00 840.00 0.00 11498.67 
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Volume in number of DDDs 
N Mean Std Median Q1 Q3 Min Max 
Sulfonylurea Visited GPs 2006-S1 144 1894.38 1699.95 1422.75 757.25 2526.25 30.00 10153.00 
2006-S2 146 1846.28 1697.22 1313.75 691.50 2520.00 60.00 10882.00 
2007-S1 146 1845.26 1680.90 1362.75 710.00 2388.00 90.00 9883.00 
2007-S2 149 1792.90 1620.30 1320.00 650.50 2351.50 10.50 8979.00 
2008-S1 150 1828.70 1673.14 1304.00 716.50 2460.00 15.00 9744.00 
2008-S2 150 1817.72 1715.19 1301.75 768.50 2231.50 10.50 10352.00 
Overall GPs 2006-S1 15648 1284.70 1615.47 732.00 140.00 1861.50 10.00 36151.50 
2006-S2 15686 1237.61 1535.89 717.25 132.00 1790.00 10.00 31069.50 
2007-S1 15620 1246.81 1570.77 722.00 132.00 1788.00 10.00 36933.50 
2007-S2 15610 1205.62 1527.25 690.00 140.00 1726.00 10.00 43247.50 
2008-S1 15724 1250.06 1621.65 707.50 132.00 1781.75 0.00 48238.00 
2008-S2 15721 1206.05 1558.79 686.50 126.00 1734.00 0.00 44794.50 
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3.1.6 Proportion (in %) of the Medications prescriptions by Group of Medications, Population and Semesters – Diabetes 
 
Proportion (in%) of prescriptions 
N Mean Std Median Q1 Q3 Min Max 
Group of Medications population semestre 
80 5.33 4.51 3.51 1.62 7.89 0.28 17.57 Glitazones Visited GPs 2006-S1 
2006-S2 76 5.34 4.38 3.55 1.95 8.46 0.44 18.05 
2007-S1 82 6.71 11.36 3.99 2.04 8.03 0.32 100.00 
2007-S2 77 5.89 5.06 3.64 2.09 9.58 0.24 21.21 
2008-S1 75 5.94 5.20 3.61 1.95 9.03 0.16 21.52 
2008-S2 73 4.62 4.12 2.83 1.62 7.06 0.12 18.51 
Overall GPs 2006-S1 6432 7.10 10.80 4.14 1.97 8.20 0.00 100.00 
2006-S2 6609 7.18 11.02 4.27 2.04 8.15 0.00 100.00 
2007-S1 6710 6.90 9.75 4.21 2.06 8.40 0.06 100.00 
2007-S2 6724 7.12 10.92 4.19 2.04 8.18 0.00 100.00 
2008-S1 6403 6.63 9.86 4.08 1.95 7.83 0.00 100.00 
2008-S2 6128 6.79 10.40 3.96 1.96 7.79 0.07 100.00 
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Proportion (in%) of prescriptions 
N Mean Std Median Q1 Q3 Min Max 
Metformin Visited GPs 2006-S1 148 48.83 15.82 47.49 37.87 57.62 14.49 100.00 
2006-S2 149 49.34 15.22 48.27 38.02 58.94 13.40 100.00 
2007-S1 149 50.28 15.23 48.94 39.54 59.06 17.06 100.00 
2007-S2 153 51.98 15.48 50.72 42.07 61.32 4.16 100.00 
2008-S1 155 53.83 16.73 51.33 43.34 63.56 13.72 100.00 
2008-S2 155 55.22 15.37 53.32 44.76 64.24 26.57 100.00 
Overall GPs 2006-S1 17094 55.48 23.19 50.97 39.29 67.15 1.05 100.00 
2006-S2 17258 56.38 22.98 51.94 40.41 68.04 1.75 100.00 
2007-S1 17229 57.40 22.60 53.32 41.58 69.08 0.00 100.00 
2007-S2 17525 58.58 22.69 54.60 42.88 70.88 1.48 100.00 
2008-S1 17925 60.27 22.49 56.50 44.74 73.00 0.00 100.00 
2008-S2 17993 61.26 22.33 57.70 45.80 74.13 0.00 100.00 
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Proportion (in%) of prescriptions 
N Mean Std Median Q1 Q3 Min Max 
Metformin & derivates of Sulfonylurea Visited GPs 2006-S1 64 11.40 9.46 9.79 4.56 14.38 0.73 45.99 
2006-S2 72 10.19 9.31 7.83 2.50 14.40 0.64 43.06 
2007-S1 73 10.00 8.68 7.61 3.23 14.29 0.84 42.02 
2007-S2 77 9.14 8.90 5.59 2.90 13.22 0.71 41.46 
2008-S1 79 9.10 10.20 5.33 2.48 11.80 0.72 57.74 
2008-S2 80 7.99 8.46 4.96 2.08 10.78 0.25 40.75 
Overall GPs 2006-S1 5189 13.12 16.78 7.42 3.35 16.01 0.00 100.00 
2006-S2 5357 12.63 16.01 7.17 3.25 15.53 0.22 100.00 
2007-S1 5309 13.04 16.87 7.36 3.25 15.95 0.15 100.00 
2007-S2 5272 12.52 16.32 7.04 3.22 14.92 0.14 100.00 
2008-S1 5396 12.16 16.62 6.56 2.86 14.31 0.17 100.00 
2008-S2 5357 11.44 15.85 6.09 2.80 13.20 0.11 100.00 
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Proportion (in%) of prescriptions 
N Mean Std Median Q1 Q3 Min Max 
Others (Diabetes), including the 
medications in Metformin & 
Rosiglitazone 
Visited GPs 2006-S1 101 11.21 10.32 7.40 3.24 14.78 0.26 44.24 
2006-S2 103 11.22 10.27 8.58 3.50 16.75 0.29 48.64 
2007-S1 108 11.67 11.17 8.26 2.62 16.35 0.14 49.87 
2007-S2 110 11.77 11.10 8.67 3.17 17.07 0.27 50.39 
2008-S1 116 12.23 10.64 8.88 4.16 18.72 0.23 41.47 
2008-S2 127 11.55 10.05 8.67 3.26 18.16 0.03 43.47 
Overall GPs 2006-S1 9921 16.22 18.61 10.50 4.40 20.64 0.10 100.00 
2006-S2 10089 15.87 18.02 10.33 4.44 20.45 0.07 100.00 
2007-S1 10299 16.16 18.43 10.52 4.57 20.54 0.00 100.00 
2007-S2 10430 16.22 18.27 10.64 4.64 20.69 0.10 100.00 
2008-S1 10921 16.17 18.08 10.73 4.76 20.63 0.00 100.00 
2008-S2 11189 16.42 17.87 11.27 5.21 20.83 0.00 100.00 
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Proportion (in%) of prescriptions 
N Mean Std Median Q1 Q3 Min Max 
Sulfonylurea Visited GPs 2006-S1 144 36.70 15.07 36.80 24.71 46.24 8.65 80.00 
2006-S2 146 36.67 15.83 36.51 25.29 46.61 4.91 100.00 
2007-S1 146 34.02 15.09 34.53 22.38 45.14 3.81 75.00 
2007-S2 149 32.86 15.33 33.35 20.60 43.09 3.25 80.33 
2008-S1 150 31.15 14.94 29.72 18.60 42.28 4.31 100.00 
2008-S2 150 29.98 14.46 28.86 19.35 38.93 1.28 69.12 
Overall GPs 2006-S1 15648 41.82 23.28 38.13 25.71 52.49 0.06 100.00 
2006-S2 15686 40.87 23.10 37.04 24.90 50.87 0.05 100.00 
2007-S1 15620 39.31 23.10 35.28 23.28 49.04 0.31 100.00 
2007-S2 15610 38.12 22.99 34.04 22.17 47.66 0.12 100.00 
2008-S1 15724 36.73 23.14 32.23 20.58 45.57 0.00 100.00 
2008-S2 15721 35.48 23.15 30.64 19.80 43.96 0.00 100.00 
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3.2 DEMENTIA TOPIC 
3.2.1 Descriptive statistics of the number of patients by GP – Overall Population 
Statistics Value 
N 117 
Mean (sd) 5 (3) 
Median 4 
Q1 – Q3 2 – 6 
Min – Max 1 - 23 
3.2.2 Age distribution of the Patients analyzed for Dementia – Overall Population 
Statistics Value 
N 543 
Mean (sd) 82 (7) 
Median 82 
Q1 – Q3 78 – 93 
Min – Max 54 - 101 
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Total 0 1 2 3 4 5 6 7 8 9 10 11 
0 0 42 3 20 2 0 12 2 2 2 0 0 85 
0.00 7.73 0.55 3.68 0.37 0.00 2.21 0.37 0.37 0.37 0.00 0.00 15.65 
1 
26 102 0 0 1 0 28 0 0 0 0 8 165 
4.79 18.78 0.00 0.00 0.18 0.00 5.16 0.00 0.00 0.00 0.00 1.47 30.39 
2 
7 0 21 0 0 0 0 2 0 0 0 0 30 
1.29 0.00 3.87 0.00 0.00 0.00 0.00 0.37 0.00 0.00 0.00 0.00 5.52 
3 
10 2 0 33 1 0 0 0 2 0 0 3 51 
1.84 0.37 0.00 6.08 0.18 0.00 0.00 0.00 0.37 0.00 0.00 0.55 9.39 
4 
6 0 0 0 16 0 0 0 0 8 0 2 32 
1.10 0.00 0.00 0.00 2.95 0.00 0.00 0.00 0.00 1.47 0.00 0.37 5.89 
5 
2 0 0 0 0 1 0 0 0 0 0 0 3 
0.37 0.00 0.00 0.00 0.00 0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.55 
6 
7 15 0 0 0 0 40 0 0 0 0 9 71 
1.29 2.76 0.00 0.00 0.00 0.00 7.37 0.00 0.00 0.00 0.00 1.66 13.08 
7 
1 0 6 0 0 0 0 9 0 0 0 3 19 
0.18 0.00 1.10 0.00 0.00 0.00 0.00 1.66 0.00 0.00 0.00 0.55 3.50 
8 
3 0 0 6 0 0 0 0 12 0 0 5 26 
0.55 0.00 0.00 1.10 0.00 0.00 0.00 0.00 2.21 0.00 0.00 0.92 4.79 






Visit Therapy after the AD Visit Total 
0 1 2 3 4 5 6 7 8 9 10 11  
9 
3 0 0 0 1 0 0 0 0 10 0 2 16 
0.55 0.00 0.00 0.00 0.18 0.00 0.00 0.00 0.00 1.84 0.00 0.37 2.95 
10 
0 0 0 0 0 0 0 0 0 0 3 0 3 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.55 0.00 0.55 
11 
0 11 4 7 1 1 8 4 4 1 1 0 42 
0.00 2.03 0.74 1.29 0.18 0.18 1.47 0.74 0.74 0.18 0.18 0.00 7.73 
Total 65 172 34 66 22 2 88 17 20 21 4 32 543 
11.97 31.68 6.26 12.15 4.05 0.37 16.21 3.13 3.68 3.87 0.74 5.89 100.00 
0 = None/ data not available 
1 = Donepezil 
2 = Rivastigmine 
3 = Galantamine 
4 = Memantine 
5 = Ginkgo Biloba 
6 = Donepezil in association with Other(s) 
7 = Rivastigmine in association with Other(s) 
8 = Galantamine in association with Other(s) 
9 = Memantine in association with Other(s) 
10 = Ginkgo Biloba in association with Other(s) 
11 = Other(s) 
 
KCE Reports 125 Academic Detailing – Supplement 275 
 
3.2.4 Volume (in number of Defined Daily Doses) by Group of Medications, Population and Semesters – Dementia 
 
Volume in number of DDDs 
N Mean Std Median Q1 Q3 Min Max 
Group of medications population semestre 
112 481.92 434.47 401.33 186.67 616.00 37.33 3047.32 Inhibitors of Cholinesterase Visited GPs 2006-S1 
2006-S2 113 506.15 518.11 373.34 186.67 606.67 18.67 4130.00 
2007-S1 111 555.00 465.65 448.00 242.67 756.00 18.67 3094.00 
2007-S2 109 573.15 421.76 522.67 261.33 714.00 18.67 2193.34 
2008-S1 115 592.95 488.56 466.67 242.67 886.67 18.67 3103.34 
2008-S2 117 640.49 502.14 541.34 266.00 858.67 18.67 2781.34 
Overall GPs 2006-S1 9205 402.71 470.54 270.67 121.33 532.00 9.33 11438.01 
2006-S2 9412 422.95 499.62 294.00 126.00 560.00 9.33 11545.35 
2007-S1 9431 455.41 532.86 308.00 149.33 606.66 9.33 11718.02 
2007-S2 9774 466.50 545.56 308.00 149.33 625.33 9.33 12166.01 
2008-S1 9906 511.78 612.92 350.00 149.33 681.33 9.33 16443.07 
2008-S2 10039 535.51 655.05 364.00 149.33 714.00 9.33 19427.49 
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Volume in number of DDDs 
N Mean Std Median Q1 Q3 Min Max 
Memantine & Ginkgo Biloba Visited GPs 2006-S1 40 144.97 70.26 140.00 103.33 168.00 28.00 336.00 
2006-S2 45 132.85 113.09 84.00 56.00 168.00 28.00 569.33 
2007-S1 37 155.77 90.16 140.00 84.00 224.00 28.00 364.00 
2007-S2 38 150.32 109.67 140.00 56.00 168.00 28.00 448.00 
2008-S1 38 153.65 91.17 140.00 84.00 196.00 28.00 392.00 
2008-S2 44 147.27 101.58 126.00 84.00 196.00 25.00 448.00 
Overall GPs 2006-S1 2938 132.51 104.34 112.00 56.00 168.00 25.00 917.33 
2006-S2 3086 132.94 106.72 112.00 56.00 168.00 0.00 1092.00 
2007-S1 3140 138.64 112.30 112.00 56.00 178.00 0.00 1129.00 
2007-S2 3298 135.66 111.36 112.00 56.00 168.00 25.00 1533.33 
2008-S1 3417 140.28 121.72 112.00 56.00 178.67 0.00 1967.67 
2008-S2 3543 143.16 120.24 112.00 56.00 196.00 25.00 1799.67 
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